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Hepatitis B core protein (HBc) virus-like particle (VLP) is a self-assembled nanoparticle that 
resembles the native conformation of a virus without viral genome. HBc has been widely 
applied as a vaccine production platform to present foreign antigens.  
Escherichia coli is recognised as an industrial microbial factory that offers high yield of 
products and economics of process. However, poor protein folding attributes to the 
accumulation of newly synthesised recombinant protein in inclusion bodies (IB). Complicated 
purification process, low yield and high cost are the consequence of IB expression from 
fermentation. Therefore, the soluble intracellular protein expression with correct conformation 
of HBc-VLP is desirable in fermentation process.  
As biological processes involve many factors and reactions concomitantly, a conventional 
approach of one-factor-at-a-time is not suitable. However a statistical approach, also known 
as design-of-experiment, offers an improved means to determine the effects of multiple factors 
to achieve the most advantageous setting. 
A research program was therefore undertaken with the aim to apply statistical approach 
to investigate the fermentation process factors impact soluble expression of chimeric HBc 
VLP when they carry foreign epitope in E. coli fermentation. Additionally, findings 
extrapolated from a careful statistical approach are necessary for optimised cultivation at 
fermenter scale. 
A logical and stepwise approach was implemented as a research strategy. This is the first 
time that design of experiment is used to boost the soluble expression of HBc VLP. 
Two (2) VLP protein models includes HBc carrying Hepatitis C virus and HBc carrying 
Epstein–Barr virus nuclear antigen which are listed as EBNA1-HBc and HCV-HBc. 
Fractional factorial design (FFD) was applied to study the effects process factors on the 
soluble expression of chimeric HCV-HBc in shake-flask fermentation. The greatest yields 
achieved were 89.7 mg g-1 dry cell weight (DCW) and 84.4 mg from one (1) L of culture 
media. The important process factors were ranked as 1) cell density at induction,  
2) post-induction rotation speed of shaker, and 3) post-induction temperature. 
Similar to HCV-HBc case, the significant factors for the soluble expression of 
EBNA1-HBc were determined from FFD. These process factors, particularly cell density at 
induction, post-induction rotation speed of shaker, and post-induction temperature and were 
optimised by response surface methodology (RSM). The highest volumetric yield and the 
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cellular yield achieved were 272.0 mg L-1 of culture media and 210.5 mg g-1 DCW, 
respectively.  
It was found that using Terrific Broth (TB) as culture media provided optimal conditions 
for EBNA1-HBc production at an induction time of six (6) h. The production of EBNA1-HBc 
was scaled up to 5 L fermenter cultivation using the optimal setting achieved from RSM and 
TB media. Results in fermenter-scale agreed with findings in shake-flask, showing that the 
soluble yields decreased as the culture was induced at greater cell density.  
It was hypothesised that the nutrient in the media is depleted when culture reaches to 
higher cell density, limiting the protein synthesis. Two (2) feeding strategies were applied in 
fed-batch mode, namely, 1) constant feeding and 2) dissolved-oxygen (DO) stat feeding. 
Results showed that both feeding strategies improved productivity of EBNA1-HBc in case of 
induction of OD600 of 20. Constant feeding is significantly improved over DO-stat-based 
feeding. The greatest yield achieved from constant feeding was 1800 mg L-1, which is greater 
than from DO-stat-based feeding of 2.57 x times. By using constant feeding strategy, EBNA1-
HBc cost per media therefore decreases by a significant 10 %, compared with batch-mode. 
Additionally, it was found that the thermal stability of ENBA1-HBc is beneficial to couple 
with SEC to quantify the EBNA1-HBc capsid in clarified crude lysate. 
Results from this research confirm that the newly applied statistical approach is a practical 
tool to determine the impact of process factors on fermentation and to provide robust data 
optimise conditions. Process factors, media composition, induction time and feeding strategy 
contribute to the soluble expression of chimeric HBc-VLP and need to be optimised to boost 
productivity. However there are present limitations of this research that need to be determined 
in future work, namely 1) quantitative variation of complex media between batches, 2) an 
explanation of why this is the optimal combination of factors, and; 3) the reason why carbon 
limitation from DO-stat-feeding limits the production. 
The justification for this is that these findings will aid a detailed understanding of process 
factors that contribute to soluble expression of chimeric HBc VLP. Not only navigate the 
design space, but this application of statistical approach is also a general framework for 
process development and scaling up.  
This research is original and not incremental work. Findings will be of direct interest and 
benefit to recombinant protein production in E. coli in general and HBc platform in particular, 
and the wider biopharmaceutical industries. 
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Hepatitis B virus (HBc) is reckoned one of the most versatile platforms to present 
heterologous antigen. It can be expressed in different expression hosts, both prokaryotic 
(Sominskaya et al., 2010) and eukaryotic (Freivalds et al., 2011).  
Escherichia coli provides a beneficial means because of inexpensive production and 
high yield (Middelberg et al., 2011). However, the lack of post-modification machinery in 
E. coli is a major drawback. Expressing significant amounts of recombinant protein can 
overwhelm the cellular metabolism of E. coli, impacting protein synthesis and protein 
folding (Rosano and Ceccarelli, 2014). Formation of misfolded protein often occurs, and 
results in low levels of soluble production. Recombinant proteins need to be expressed as 
native form to maintain high bioactivity. 
This acknowledged accumulation of insoluble aggregates is a controversial subject of 
recombinant protein expression in E. coli (Markossian and Kurganov, 2004). It is feasible 
to recover the target protein from inclusion bodies via solubilisation and refolding, but these 
extra stages require substantial cost and, place financial pressure on process economics. 
Moreover, it is not guaranteed that purification from inclusion bodies is able to maintain 
the biological activity of the recombinant protein. 
Inclusion bodies accumulation is common in chimeric HBc-VLP expressed in E. coli.  
To boost soluble production of HBc-based VLP in E. coli process parameters need to be 
optimised to minimise the physiological stress to the cell and for conditions to target protein 
synthesis (Kaur et al., 2018). In conventional experiment, process factors are optimised 
sequentially, one-factor-at-a-time. This approach limits the possibility to determine the 
most advantageous combination of factors because the interactions between factors are lost. 
Therefore, to understand quantitatively the effects of fermentation process variables on 
soluble production of HBc-based VLP, statistical approach such as factorial design and 
response surface methodology should be employed. 
 Additionally, findings extrapolated from a careful statistical approach are useful to 
optimise the production at both shake-flask and fermenter scale to improve the process 
efficiency and process economics. 
A research program was therefore undertaken to apply statistical approaches, including 
fractional factorial design (FFD) and response surface methodology (RSM) to determine 
the effects of fermentation process factors on soluble production of two (2) chimeric  
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HBc-VLPs, EBNA1-HBc and HCV-HBc in microbial system in small-scale. The optimal 
combination of factors was then applied for larger, fermenter scale cultivation.  
 
1.2 Research aim and objectives 
 
Despite HBc-based VLPs having been intensively studied as a practical vaccine platform, 
the effects of process factors and their interaction on high yield of soluble expression in  
E. coli remain largely illusive.  
The overarching aim is to apply the statistical approach to determine the effects of 
process factors in order to boost the soluble production of chimeric HBc-VLP in the 
microbial system. To gain technical insights for chimeric HBc-VLP soluble production, the 
overarching objectives of this research are to: 
1. Use fractional factorial design to quantify the impact of process parameters on 
production of soluble of HBc-VLP carrying epitope HCV  
2. Determine of the impact of process parameters and enhance the soluble production of 
HBc-VLP carrying epitope EBNA1, using fractional factorial design and response 
surface methodology 
3. Optimise the batch cultivation and fed-batch cultivation based on the findings in small-
scale to boost soluble production of HBc-based VLP in fermenter-scale. 
 
A justification for this research is that it will aid greater understanding of factors that 
contribute to the production of HBc VLP in E. coli in terms of vaccine carrier. A better 
understanding will lead to reliable process development for recombinant protein production 
and increase chances of commercialisation. 
A stepwise and logical approach is adopted, as is presented in Fig 1.1. The research 
starts with screening experiment of two (2) chimeric HBc-VLPs to navigate the design 
space in Task 1 and Task 2A. Optimisation experiment is used to obtain the optimal process 
performance in small-scale cultivation in Task 2B. Scaling up fermentation experiment is 




Fig. 1-1: Outline of research. 
 
1.3 Thesis outline 
 
Chapter 1 presents the background, aim and objectives, and thesis outline.  
Chapter 2 provides a critical review of HBc-VLP and relevant literature for soluble 
intracellular protein production in microbial systems, plus potential problems and 
application of statistical approaches. It is proposed here that statistical approach is able to 
boost the expression level of recombinant protein expressed by E. coli in shake-flask 
fermentation by optimisation of cultivation process factors. 
In Chapter 3 the impact of fermentation process factors on soluble production of  
HBc-VLP carrying epitope HCV using fractional factorial design is presented. Although 
key post-induction process factors are identified, namely, 1) the cell density of induction, 
2) temperature, and 3) rotation speed of shake, a drawback soon acknowledged is that FFD 
only investigates two-level of each factor so further optimisation experiment is necessary. 
In Chapter 4 the optimisation of soluble production of HBc-VLP carrying epitope 
EBNA1 in E. coli using two steps of statistical approach is presented. The key fermentation 
process factors were identified from FFD, including the cell density of induction, 
expression temperature, and shake-flask rotation speed. These factors were further 
optimised by response surface methodology (RSM) to improve the fermentation process 
performance. 
In Chapter 5 based on the significant fermentation process factors screened by  
shake-flask fermentation in Chapter 4. The production of soluble EBNA-HBc was further 
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implemented and optimised in 5 L working volume of 14 L laboratory-bench scale 
fermenter with automatic control system. This is undertaken because of the differences in 
cell density at induction between large and small scale. The impact of cell density at 
induction point and the importance of feeding strategy were further investigated. It is found 
that fed-batch with constant feeding achieved gram-per-litre scale of volumetric 
productivity. Furthermore, a brief media cost analysis is made to determine process 
economics.  
The findings and conclusions from this research in promoting soluble production of 
HBc-based VLP are given in Chapter 6.  
Results from this original research will provide technical insights for HBc VLP 
production in E. coli. Navigating the design space of the fermentation process factors in a 
systematic way is crucial to develop a practical production strategy from shake-flask to 
fermenter-scale, and; more widely, to researchers interested in improving knowledge of 
recombinant protein bioprocessing. 
A definition of some important terms used in this research is presented in Appendix A. 
Details of related buffer composition are presented in Appendix B. A set of supporting data 
















Globalization has increased the speed of transportation. Despite economic advantages, 
there are accompanying risks of infectious disease spreading, especially human-to-human. 
Current COVID-19 global pandemic is urging world-leading research activities, especially 
in safe and efficient vaccine development.  
Vaccination is an effective means to prevent infectious disease. Since it was 
introduced, vaccination has improved the quality of public health highly significantly. 
However conventional vaccines, both live-attenuated and inactivated, have drawbacks 
(Greenwood, 2014). These include the efficiency in controlling multiple strains of 
infectious pathogen, risk of infection and side effects, plus stability during transportation, 
and manufacturing cost. Therefore, there is a need to create a vaccine that is rapid to 
produce, safe, stable, highly immunogenic, cost-effective, and with life-long immunity 
from a single dose.  
Virus-like particle (VLP) is a new generation of vaccine that is potentially safer than 
conventional vaccines. This is because of the lack of viral genetic materials (Roldao et al., 
2010). Amongst various VLP platform, Hepatitis B core (HBc) protein is one of the most 
promising due to its flexibility to present heterologous antigen on the capsid surface (Roose 
et al., 2013). A significant feature of VLPs is that they can be expressed in many expression 
systems, both eukaryotic and prokaryotic.  
Expression of a large quantity, soluble, functional, and properly folded recombinant 
protein is essential because of the requirements in biochemical characterisation and 
production process. Even with good pre-clinical results, a vaccine candidate will face 
significant difficulties to reach a commercial market if it is unable to be produced in large 
quantity.  
Escherichia coli has been used intensively to produce recombinant protein. It possesses 
a high-level of expression, low cost and scale-up ability (Chuan et al., 2014). High level of 
expression introduces physiological stress on E. coli, however affecting the protein 
synthesis and protein folding. This eventually leads to expression as an insoluble form 
(Fahnert et al., 2004). Because of lacking post-translation modification mechanism, 
expression of recombinant protein in E. coli as soluble with native conformation is highly 
regarded. Not only maintaining the specific immunogenicity, but soluble expression also 
simplifies the recovery and purification process, ultimately reducing production cost. 
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In this chapter, a detailed review of HBc VLP as vaccine carrier advantages, recent 
developments, applications, benefits and limitations, in comparison with conventional 
vaccines is presented. Additionally, two (2) epitopes HCV core and EBNA1 are critically 
reviewed. 
E. coli is reviewed as microbial factory for protein production. This includes metabolic 
aspects, protein production processes, potential problems, and solutions. The significance 
of target protein folding state is highlighted and the process factors that influence the 
soluble intracellular protein are presented. As biological processes involve interconnection 
between factors and reactions, statistical approaches are reviewed. 
To conclude this chapter, a statistical approach consisting of screening experiment and 
optimisation experiment is selected for soluble production of chimeric. The effects of 
process factors are investigated for each chimeric HBc VLP in shake-flask cultivation 
before cultivating in fermenter scale. 
 
2.2 Conventional vaccines versus virus-like particle vaccine 
 
The first successful conventional vaccine was the smallpox vaccine, introduced by Edward 
Jenner in 1796 (Riedel, 2005). It is noteworthy that conventional vaccines provide 
protection against rubella, polio, tetanus, etc., and resulted in the complete eradication of 
smallpox in 1980 (Fenner et al., 1988) and, rinderpest in 2011 (Horzinek, 2011). 
There are two types of conventional vaccine, live-attenuated and inactivated vaccine. 
Live-attenuated vaccines consist of viable bacterial cells or viral particles, which have been 
reduced in virulence but still provoke an immune response. For example, pathogens can be 
attenuated by culturing the pathogen in less optimal conditions, forcing them to replicate 
repeatedly in tissue culture. Another approach is introducing them into different hosts, 
where the capacity of replication is limited (Mak and Saunder, 2006). 
Inactivated vaccines are non-infectious because the infectivity of the pathogen has 
been destroyed by chemicals or heat. Immunogenicity is retained, but a significant amount 
needs to be injected in comparison to live-attenuated vaccines (Hoft et al., 2017).  
Conventional vaccines have drawbacks, including: 1) limited protection of a certain 
disease that has various strains or subtype of pathogens (Wong and Webby, 2013), 2) slow-
production (Tree et al., 2001), 3) limited shelf-life and storage conditions (Amorij et al., 
2008), 4) need for multiple doses and addition of adjuvants to enhance immune response 
for inactivated vaccine (Handley et al., 2007), and; 5) a risk of side effects. 
9 
Production of conventional vaccines is usually based on the propagation of 
embryonated chicken eggs, yielding one embryonated egg per dose (Tree et al., 2001). 
Therefore large-scale production is limited. The transportation for conventional vaccines 
requires a cold-chain refrigerator to maintain the quality of vaccine (Amorij et al., 2008). 
This raises the barrier for logistics. The side-effects with conventional vaccines have been 
reported, particularly, Crohn's disease (Afzal and Minor, 2002) and people with a 
compromised immune system (Nuttall and Eley, 2011). Moreover, it is reported that 
conventional smallpox vaccine may induce serious side-effects, not only skin rashes at the 
vaccination site, but also a chance of getting lymphadenopathy, life-threatening illnesses, 
cardiovascular disease, or death (Lederman et al., 2012). 
Amongst various non-conventional vaccine platforms, Virus-like particles (VLPs) are 
designed to resemble closely the native virus conformation without viral genetic material 
(Buonaguro et al., 2011; Fuenmayor et al., 2017). VLPs can be derived from a number of 
sources including, Hepatitis B virus (HBV) (Roose et al., 2013), Human papilloma virus 
(HPV) (Tumban et al., 2013), Tobacco mosaic virus (TMV) (Smith et al., 2006), and; 
Cowpea mosaic virus (CPMV) (Montague et al., 2011). Notably, there are VLPs that have 
been commercially produced, particularly against Hepatitis B virus and Human 
Papillomavirus. They are VLP-based human vaccines, Cervarix™ and Gardasil™ for 
cervical cancer; Engerix™ and Recombivax HB™ for hepatitis B viral infection.  
VLP are non-pathogenic and unable to replicate, which makes VLP safer compared 
with live-attenuated vaccine (Wheeler et al., 2008). Classification of VLPs can be based on 
1) origin viral taxonomy (hepadnavirus, papillomavirus, polyomavirus, etc.), 2) particulate 
structures, and; 3) expression systems. VLP has been produced in a variety of enveloped 
and non-enveloped viruses. Fig. 2-1 presents example structures of VLPs, including a 
single, double, and triple, capsid proteins. They are categorized as VLP with single or 
multiple capsid proteins, with or without the lipid membrane.  
The structure of VLP confirms either the conformation, or the size of either parental 
antigenic epitopes or foreign antigens. Naked VLPs are suitable to present simple structure 
and short peptide. These can be genetically fused into viral capsid protein to form chimeric 
VLP, for example, Hepatitis B core protein as a carrier for B cell/ T cell epitope (Pumpens 
and Grens, 2001). Non-enveloped VLP are easier to produce and purify. Alternatively, 
enveloped VLPs are able to carry full-length monomeric or multimeric conformational 
proteins, for example, influenza VLP producing from plant-based expression (D’Aoust et 
al., 2008). The structure of VLP depends on the expression system. For example, it is 
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reported that prokaryotic host, particular microbial system, can only express naked VLPs, 




Fig. 2-1: Structure of naked and enveloped VLPs  
(adapted from Tagliamonte et al., 2017). 
 
The immunogenicity of VLPs is notable. VLPs present a high-density display of 
antigen in a highly organized and repetitive structure. Their immunogenicity can trigger 
the innate and adaptive immune system because of the similarity of pathogen associated 
molecular patterns (PAMPs) (Bachmann and Jennings, 2010). VLPs can be processed 
either as 1) exogenous antigens, or 2) endogenous antigens (Grgacic and Anderson, 2006). 
Buonaguro et al. (2011) reported that B cell activation and high production of antibody are 
impacted by the quantities of epitope and conformation of VLPs. With these beneficial 
immunogenic properties, VLPs induce the immune response effectively. 
Not only are they safer and more immunogenically effective, VLPs have a shorter 
production time, compared with embryonated chicken eggs as is presented in Fig. 2-2. As 
an attractive alternative influenza vaccine can be produced in VLP platform using insect 
cells, Flublok© has been developed to prevent seasonal influenza and is approved in US in 





Fig. 2-2: Comparison of conventional vaccine (A) and VLPs (B) manufacturing process 
(adapted from Naskalska and Pyre, 2015). 
 
Amongst VLP platforms Hepatitis B core protein has been intensively studied since its 
discovery by Clarke et al. (1987). Since then Hepatitis B core protein has been used to 
develop vaccine candidates for HCV (Sominskaya et al., 2010), human papilloma virus 
(HPV) (Chu et al., 2016), meningococcal meningitis and sepsis (Aston-Deaville et al., 
2020), and influenza (Ravin et al., 2015). The molecular characteristics, structural feature 
and application of HBc is reviewed in the next section. 
 
2.3 Chimeric Hepatitis B core virus-like particle as potential vaccine candidate 
 
Hepatitis B core virus-like particle is one of the best known VLPs vaccine carrier.  
HBc monomeric protein consists of 183 – 185 amino acid residues in length for the ayw 
and adw subtypes (Pumpens et al., 2008).  
 
2.3.1 Molecular information of HBc-VLP 
 
Fig. 2-3 presents the domain organisation of HBV core protein. The viral self-assembly 
(SA) domain is from aa 1 to aa 140 and arginine-rich at C-terminal domain (CTD) for 
nucleic acid binding is from aa 150 to aa 183 (Birnbaum and Nassal, 1990). These two 
domains are linked by protease-sensitive hinge peptide 141-STLPETTVV-149 involved in 




Fig. 2-3: Portrait of Hepatitis B core protein (adapted from Pumpens and Grens, 1999). 
 
In addition, this peptide linker manipulates the ratio between the two HBc isomorphs 
upon recombinant expression (Zlotnick et al., 1996). The SA domain is responsible for 
immunological B-cell epitopes. The linking peptide and CTD do not appear to possess any 
immunological importance (Pumpens and Grens, 1999; Chain and Myers, 2005). 
The HBc∆ variants and truncated HBc protein are HBV core protein without CTD, 
they still however possess self-assembly characteristic but are unable to encapsulate RNA 
from host cell (Borisova et al., 1988). Although the CTD enhances the encapsulation of 
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nucleic acid (between 100 to 3,000 nucleotides depended on the length of CTD), the 
interactions between protein-nucleic acid contribute to capsid stability (Birnbaum and 
Nassal, 1990).  
HBc monomer protein is formed by five α-helices. In order to form a central helical 
bundle (tip of the spike), the helix-3 and helix-4 of HBc monomer fold themselves into 
“hairpin” structure and dimerize with a second monomer (Wynne et al., 1999). This 
ultimately creates the building blocks for capsid formation. At position of aa 61, cysteine 
residues from each monomer create a disulfide bridge.  
Protein dimer is the basic structure of HBc protein. Fig. 2-4 presents the structure of 
HBc protein. The icosahedral HBc particles are assembled into two isomorphs, T = 3 (90 
dimeric units) and T = 4 (120 dimeric units) according to the triangulation number. Mature 




Fig. 2-4: Structure of Hepatitis B core VLP; TEM image presenting T=3 and T=4 
symmetry (A) and Cryo-electron microscopy picture of HBc particles (B) 
(adapted from Roose et al., 2013). 
 
The morphology and antigenicity of Hepatitis B core VLP expressed in E. coli are 
similar to the viral cores that are seen in HBV-infected human or infected chimpanzee 
(Cohen and Richmond, 1982). Due to this unique feature E. coli-derived HBc VLP has 
been exploited as an experimental vaccine carrier. Table 2-1 summarises the current HBc-
based VLP vaccine candidates. These vary by the degree of epitope size and insertion 
location, including, 1) major immunogenic region (MIR) (aa residues 74-93 of HBc 
protein), 2) N-terminus and 3) C-terminus.  
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tau protein (aa residues 
294-305) 
MIR (between aa 78 
and aa 79) of the 




Yield: not available 




Envelope domain III 
(EDIII) 
MIR (replacing aa 
residues 76–80) of 
the truncated HBc 
gene (lacking aa 166 




7 mg L-1 





SP70 (sequence of 15 
aa) 
MIR (aa 78 and aa 
79) of the truncated 
HBc gene (aa 1-144) 
Lac operon 
Soluble expression 
Yield: not available 
Pu et al. 
(2018) 
Foot and mouth 
disease virus 
(FMDV) 
Amino acids 142-160 
of virus protein VPl, 
N-terminus of HBc Expression yield 
and promoter are 
not available 







(eGFP) (238 aa) 
 
MIR (between aa 78 
and 80) of the 
truncated HBc gene 
(aa 1–149) 
His-tag C-Terminal 
Lac operon  
Soluble & Insoluble 
Soluble yield: 
1 to 32.5 mg L-1  
Vogel et al. 
(2005) 
Hantavirus 120 amino-terminal aa 
of N protein from 
DOBV, HTNV & 
PUUV 
MIR at aa 78 of the 




Yield: not available 
Geldmacher 
et al. (2004) 
Hepatitis B virus 
(HBV) 
HBV Pre-S1; pure (aa 
31-35); extended (aa 
20-47); PreS1-phil (aa 
16-60 and aa 89-119) 
C-terminal and 
modification of aa 
144-183 of full-
length HBc gene 




Yield: not available 
Dishlers et 
al. (2015) 
Hepatitis B virus 
(HBV) 
HBV Pre-S1-
hydrophilic (aa 12-60 
and aa 89-119) 
MIR (between aa 78 
and aa 79) of the 
truncated HBc gene 
(aa 1-144) and full-









HCV core (aa 1-98, aa 
1-173, aa 1-151); 
HCV NS3 (aa 327-482, 
aa 202-326) 
MIR at aa 78 or at aa 
144 of the truncated 
HBc gene (aa 1-144) 
Tryptophan operon 
Soluble expression 
Yield: not available 
Mihailova 
et al. (2006) 
Hepatitis C virus 
(HCV) 
HCV core (aa 1-60); 
HBV Pre-S1 (aa 20 -
47) 
MIR at aa 78 or C-
terminal at aa 144 of 
the truncated HBc 
gene (aa 1-144) 
Tryptophan operon 
Soluble expression 
Yield: not available 
Sominskaya 
et al. (2010) 
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(aa 158–166) and 
AFP2 (aa 542–550) 
C-terminal (aa 149) 
with GA linker of the 
truncated HBc gene 
(aa 1-149) 
Lac operon  
Insoluble expression 








epitope E7 (aa 49-
57) 
MIR (between aa 78 
and aa 79) of the 
truncated HBc gene 
(aa 1-149) 
Lac operon  
Soluble expression 
Yield: not available 





5EPIS epitope (78 
aa)  
MIR (between aa 79 
and aa 80) of the full-




Yield: not available 
Wang et al. 
(2012) 
Influenza virus 1, 2 or 4 copies of 
trans membrane 
protein M2e (aa 2-
24) of human and 
avian strain 
MIR (replacing 78-81 
aa) of the truncated 





Yield: not available 
Ravin et al. 
(2015) 
Influenza virus Long alpha helix 
(LAH) from HA2 
(aa 76–130) 
MIR (replacing 75–
85 aa) of the HBc 




Yield: not available 
Chen et al. 
(2015) 
Influenza virus Multiple M2e 
epitopes 
N-terminal and MIR 
(78-81 aa) of the 
truncated HBc (aa 1-
149) and N-terminal 






Yield: not available 
Sun et al. 
(2015) 
Melanoma MAGE-3 (aa 168–
176); MAGE-3 (aa 
163–181) 
MIR (replacing 76-
84aa) and C terminal 
of aa 161, 168, 176 of 











Linker of glycine 
and serine; FHbp 
ORF (aa 157-274); 
NadA ORF (aa 26-
309) 
MIR (replacing aa 
78-81) and aa 148 of 
the HBc gene (aa 1-
148) 
Strep-tag C-Terminal 
Lac operon  
Soluble expression 









epitope tag (8 aa) 
N-terminal of the 





Yield: 75 mg L-1 














PEDV linear B-cell 
epitopes (aa 748-755, 
aa 764-771, aa 1368-
1374, aa 195-200) 
MIR (replacing aa 
78-82), MIR (aa 
79), and C-terminal 
(aa 149) of the HBc 










PUU N Vranica 
epitope (aa 1-45); 
PUU N CG18-20 (aa 
1-45; aa 75-119) 
N-terminal, MIR 
(aa 78) and C-
terminal of the 











G protein (aa residues 
144-204); M2 protein 
(aa residues 82-90) 
MIR (between aa78 
and aa79) and C-
terminal of the 





Yield: not available 
 
Qiao et al. 
(2016) 
Rubella virus E1 glycoprotein (aa 
214-285, aa 214-240, 
aa 245-285) 
MIR (aa 78 and aa 









A comparison of potential insertion sites suggests MIR is more effective in inducing 
antigen-specific antibodies. This can be explained by the structure of HBc dimer because 
MIR allows maximum exposure of the inserted protein on the tip of the spike (Schodel et 
al., 1992). Although the insertion capacity at MIR is not fully studied, Geldmacher et al. 
(2004) successfully expressed HBc-VLP bearing two copies of 120 aa hantavirus 
nucleocapsid protein, and Vogel et al. (2005) employed HBc-VLP to present full-length 
238 aa of green fluorescent protein.  
Insertion at N-terminal guarantees the outer exposure of epitopes on the capsid surface, 
which was demonstrated in the first HBc-VLP vaccine candidate carrying FMDV epitope 
by Clarke et al. (1987). To support the argument, an analysis in crystallization and X-ray 
of T=4 particle of hepatitis B capsid protein, conducted by Tan et al. (2007), confirmed that 
fused peptides at N-terminal insertion was exposed on the exterior of HBc capsid. However, 
it is reported that the assembly of the capsid is influenced by the peptide fused to the N-
terminus, unless there is a flexible linker included prior to the 
N-terminus of HBc (Murray and Shiau, 1999). 
However to the contrary, insertion at C-terminal of HBc protein does not guarantee 
outside exposure of foreign epitope since C-terminus of HBc is located interiorly of the 
capsid (Zlotnick et al., 1997). Usually, the attached protein of interest is buried within the 
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HBc capsid, leading to poor immunogenicity. Therefore, the use of N-terminal fusion HBc 
in the development of other HBc vaccine candidates is limited. To overcome this 
disadvantage a modified HBc protein was developed by fully or partially replacing the 
arginine residues of the CTD with glycine residue, namely HBcG vector (Dishlers et al., 
2015). This modification allowed the outer surface exposure of C-terminally inserted 
epitope and improved immunogenicity.  
Although full-length HBc protein has the advantage of capsid stability, the 
C-terminally truncated HBc∆ protein, consisting of HBc aa 1-144 or HBc aa 1-149, are 
adequate to be used as vaccine scaffolds (Sominskaya et al., 2013; Roseman et al., 2012). 
As a versatile vaccine-carrier platform, the potential of using HBc-derived VLPs in 
vaccine production is great. HBc-derived VLPs can be modified in various means, 
including alteration of the length of antigen epitopes, the choice of insertion site in the 
protein, and the adjustment in C-terminal sequence or MIR region. Although these means 
sound promising in creating an effective recombinant HBc-based VLPs, there is no 
guarantee that the designated recombinant protein will be expressed as soluble, native-
folded, and particulate structure. It is necessary to explore how molecular design, regarding 
the length of inserting epitope at either N or C-terminal insertion site, and environmental 
conditions influence the expression of soluble chimeric HBc-VLP in order to establish a 
cost-effective production. 
It is stated that there is no difference in structure between HBc particles from liver of 
infected patients and recombinant HBc particles that derived from E. coli (Kenny et al., 
1995). Recombinant HBc protein forms a dimer then self-assemble into two (2) forms of 
icosahedral particles (Roseman et al., 2005), it is in agreement with the vaccine candidates 
listed in Table 2-1, recombinant HBc protein were expressed as HBc monomer then self-
assembled into VLP in E. coli. Based on the product folding state and nature of the 
recombinant protein, different purification pathways have been developed, which will be 
reviewed in the next section. 
An additional advantage of full-length Hepatitis B core protein is high thermal 
stability. For example in the study by Naito et al. (1997) Hepatitis B core antigen (HBcAg) 
was heated to temperatures of 60, 65 and 70, oC for 60 min. Only the sample heated at  
70 oC decreased in quantity. This finding suggests HBcAg in the crude lysate had thermal 
resistance up to 65 oC. This feature was confirmed by Ng et al. (2006) where HBcAg 
retained its structure and antigenicity when heated at 80 oC for 45 min.  
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The thermal stability of chimeric HBc VLP has also been utilised to remove host cell 
protein in order to obtain a less complicated feed for chromatography (Li et al., 2018). In 
addition, the size of assembled VLP is considered large, compared with other host protein. 
Size exclusion chromatography has been used to monitor the expression of HBc VLP (Yang 
et al., 2015). These two features can be use in sample treatment before the determination 
of assembly expression level. It is expected that insertion of foreign epitope may influence 
the stability and assembly of HBcAg (Karpenko et al., 2000). Therefore, the condition in 
sample treatment should be considered. 
 
2.3.2 Potential epitopes for new vaccine development  
 
2.3.2.1 VLPs based vaccine against Epstein-Barr virus (EBV) infection  
 
Epstein-Barr virus (EBV) is one of the most widely distributed pathogens since the primary 
spreading pathway is via saliva. EBV-infection impacts significantly on public health and 
world economics since EBV infection often develops to infectious mononucleosis (IM) and 
patients with IM exhibit symptoms such as fever, sore throat, swollen lymph node, severe 
fatigue, immune dysfunction and these patients have higher chance to EBV-associated 
malignancies (Cohen et al., 2011). These malignancies include lymphoma (Burkitt’s 
lymphoma, Hodgkin’s disease, natural killer cell and T cell lymphomas) and carcinoma 
(nasopharyngeal carcinoma and gastric carcinoma), which contributes to about 1.5 % of all 
cases of human cancer worldwide (Farrell, 2019). 
It is reported that although chemotherapy is an effective approach to battle against  
EBV-associated malignancy, chemotherapy-associated complications, disease relapse or 
secondary malignancies have been putting an end to 50 % of survivors of all forms Hodgkin 
lymphoma (Cohen et al., 2011). EBV-associated lymphoma is the second most common 
malignancy, which occur in bone marrow and organ transplant recipients (Cohen et al., 
2011).  
Since the first vaccine proposal was developed by Epstein (1976), most of the EBV 
prophylactic vaccine trials was focused on EBV membrane glycoprotein gp350 as the 
monomeric EBV gp350 reduced the incidence of infectious mononucleosis (Cohen, 2018; 
Sokal et al., 2007). Besides of glycoprotein gp350, EBNA1, a crucial protein that meditates 
EBV genome synthesis and partitioning to daughter cells, and regulates viral gene 
transcription (Altmann et al., 2006; Smith and Sugden, 2013), has been utilised to boost 
humoral response and trigger cell-mediated immunity (Perez et al., 2017). A full-length 
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EBNA1 consists of 641 amino-acids (EBV strain B95-8), and two of this polypeptide 
compose together to form dimeric protein (Lindner and Sugden, 2007). Although EBV 
nuclear antigen (EBNA1) has been successfully expressed in E. coli, because of the 
composition of the rare codon, the yield of EBNA1 in E. coli was low, approximately  
2 mg L-1 (Mayer et al., 2012). 
For development of effective EBV vaccine against virus-associated cancers, the 
vaccine candidate must be able to induce a strong T cell-mediated immune response and 
fewer side effects. It is challenging to fuse the full-length EBNA1 to any vaccine carrier, 
therefore, using EBNA1-derived epitope HPVGEADYFEY as an alternative approach has 
high potential. HPVGEADYFEY is a linear epitope from the EBNA1 primary sequence 
(aa 407–417). Effectors that recognize and kill infected target cells are generated by the 
contribution form CD8+ cytotoxic T lymphocyte (CTL) response. It is reported that EBNA1 
epitopes (aa 407–417) can induce CD8+ T cell responses in vivo through uptake of the 
exogenous protein (Blake et al., 1997; 2000). Another approach is using VLP platform to 
generate EBV VLP vaccine candidate, this EBV-derived VLP was expressed in 
mammalian expression system and demonstrated highly immunogenic in terms of humoral 
and strong CD8+ and CD4+ T cell responses in vitro and in vivo (Ruiss et al., 2011), 
however, expression in mammalian system is not an economical process.  
Therefore, construction of E coli-derived HBc VLP carrying EBNA1 epitope is 
promising for developing an effective vaccine candidate. Even though there are progress in 
vaccine development against EBV-infection, there is no therapeutic or prophylactic 
vaccination available at present.  
 
2.3.2.2 VLPs based vaccine against Hepatitis C virus (HCV) infection  
 
Hepatitis C virus is a single-stranded RNA (ssRNA) enveloped virus, classified in the genus 
Hepacivirus in the Flaviviridae family (Choo et al., 1989). HCV is a blood-borne virus, 
including blood exposure, drug use, sexual transmission, mother-to-baby and sharing 
hygiene items if infected blood present. HCV infects approximately 3 % of the world 
population with a breakdown of an estimated 100 million people are serologically positive 
and at least 71 million people are diagnosed as persistent infection (Soriano et al., 2018). It 
is reported that HCV-associated end-stage liver disease and its complication cause nearly 
476,000 deaths per year globally (Calvaruso et al., 2018). In Australia, HCV infection 
occurs at a rate of 10,000 new case annually (Holmes et al., 2013).  
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In past decade treatment of HCV primarily is focused on the combination of 
PEGinterferon alfa-2a and ribavirin. This treatment is administered for 24 or 48 weeks. 
However the high percentage (up to 60 %) of treated subjects cannot eliminate the virus 
completely (Fried et al., 2002), eventually making this treatment less ideal. Therefore, the 
preventative vaccine is a priority to fight against HCV infection. 
It is a challenging and rewarding progress to develop an effective HCV vaccine 
candidate because there are multiple genotypes of HCV with complex nature of 
immunological response to HCV and limited availability of animal model (Stoll-Keller et 
al., 2009). To provide a proper virus clearance, it is requires that vaccine candidates possess 
neutralizing antibody (NAb) responses with strong and broadly cross-reactive CD4+, CD8+ 
(Alvarez-Lajonchere and Duenas-Carrera, 2012). For this reason, HCV vaccine often 
combines HCV NS3, core, NS4, NS5 protein or their epitope to induce strong cellular 
response meanwhile E1 and E2 focus on Nab (Bellier and Klatzmann, 2013). Particularly, 
HCV core, E1 and E2 are structural protein, which demonstrate significant protective 
immune responses compared with BS3, NS4, NS5 as they are non-structural protein 
(Dahari et al., 2010). Moreover, a study of Boulant et al. (2005) stated that HCV core 
protein structure is a dimeric α-helical. To induce antigen-specific board NAbs, 
conformational epitopes need to be presented as their correct 3D structure. 
Virus-like particle is a promising platform to fulfil all the criteria for HCV vaccine, 
especially HBV core-based VLP. At first, for serological diagnosis purpose, HCV core (aa 
1-98) was fused with HBc in compliance with preS1 and preS2 to form 
HBcPreS1PreS2HCc (1-98). In terms of anti-HCc induction, this synthesised protein 
possessed higher immunogenic property than HCc (1-98) (Wu et al., 1999). Later 
Sominskaya et al. (2010) has constructed multivalent HBc VLP carrying HBC (PreS) and 
HCV core epitope as vaccine candidate. Moreover, chimeric HBc VLP carrying HCV 
epitopes (HCV core 98 aa and HCV NS3 155 aa) was also produced by Mihailova et al. 
(2006). Although both chimeric HBc VLP were able to be constructed and expressed in E. 
coli, the antibody and T-cell proliferative responses to HCV epitopes were low. One 
important factor about these chimeric HBc VLP is the insertion site of the epitopes,  
C-terminally fusion directes the epitopes to be buried inside the capsids, leading to poor 
antibody responses (Schodel et al., 1992).  
Since there is no therapeutic or preventative vaccination available for HCV infection 
yet, it is a promising approach to fuse HCV core (aa 10-53), also known as c22p, to HBc 
VLP at N-terminus to develop new vaccine candidates. HCV core consists of aa 10-53 was 
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used as novel Hepatitis C virus major epitope for diagnosis of HCV infection (Chien et al., 
1999; Sominskaya et al., 2010). 
To summary the review of HBc VLP, six (6) key aspects are: 
1. Hepatitis B core VLP is a promising platform for vaccine development and it is 
expressed in both prokaryotic and eukaryotic expression system 
2. The immunogenicity of chimeric HBc-VLP depends on the location of epitope. 
There are three (3) insertion sites: 1) N-terminus, 2) C-terminus, 3) MIR.  
They determine the location of epitope, either displayed on exterior surface or 
interior of the viral capsid 
3. Full-length HBc protein has the advantage in capsid stability 
4. Although many molecular design approaches have been conducted, including 
insertion site, with tag or without tag, choice of promoter, etc., it is not guarantee 
that chimeric HBc VLP is expressed as soluble intracellular protein 
5. The thermal stability and size of HBc is beneficial for purification process. 
However, the inserted epitope may alter these properties  
6. Although HBc VLPs tolerate the structural modification, the influence of structure 
and size of the inserted epitope on the formation of VLP is not well-studied. It is 
expected that the soluble expression of HBc protein carrying complex structure 
epitope is less than the HBc protein and HBc protein carrying simple structure 
epitope.  
7. HCV core protein has α-helical structure, in comparison with EBNA1 protein, 
which is a linear epitope, HCV vaccine and EBV vaccine are potential innovative 
vaccines against HCV and EBV infectious disease. 
 
The nature and flexibility of HBc platform has been reviewed and summarised. The 
next section presents the microbial expression system, particularly process factors that 
influence the soluble recombinant protein expression. 
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2.4 Escherichia coli as microbial expression system 
 
Escherichia coli has been used intensively as microbial expression system for producing 
biopharmaceutical products from both prokaryotic and eukaryotic origins, i.e. the human 
insulin (Goeddel et al., 1979) and human protein somatostatin (Itakura et al., 1977). The 
benefits of short doubling time (~20 min) and ability to culture in expensive media makes 
E. coli as one of the most popular means to produce recombinant pharmaceutical, 
particularly virus-like particle. The followings are some examples of commercialised 
vaccine or vaccine candidates in the pipeline produced by Escherichia coli. 
Hepatitis E Virus (HEV 239) vaccine has been approved in China, under the name of 
Hecolin©. It was reported as the first E. coli-derived VLP-based vaccine (Proffitt, 2012). 
Moreover, expression of murine polyomavirus VLP, carrying M2e epitope from influenza, 
in E. coli has potential to produce a safe and effective vaccine (Middelberg et al., 2011). 
There are several vaccine candidates, in which epitope is fused into Hepatitis B core 
(HBcAg) or Hepatitis B surface antigen (HBsAg), have been in clinical trials, including:  
1. ACAM-FLU-A© (Phase I), Hepatitis B core antigen (HBcAg) bearing M2e epitope 
(Ibanez et al., 2013) 
2. MalariVax© (ICC-1132) (Phase I) - HBcAg bearing Plasmodium falciparum 
circumsporozoite protein (Gregson et al., 2008) 
3. HBV ABX203 (HeberNasvac©) (Licensed) - HBsAg/HBcAg as vaccine antigens 
(Lobaina et al., 2015). 
 
These are strong evidence that E. coli is feasible to generate new HBc-based vaccine 
candidate. In the following sections, the recombinant protein production process, 
production folding state associated with purification process are discussed. Moreover, the 




2.4.1 Recombinant protein production process by E. coli 
 
Because of advances in genetic engineering, E. coli has become the first choice for 
laboratory study and initial development for large-scale production. Bacterial system offers 
easily scale-up and economical production process (Chuan et al. 2014). 
The key components of recombinant protein production process are presented in  
Fig. 2-5. They include the 1) design of expression vector, 2) selection of host strain and 





Fig. 2-5: Outline of recombinant protein production in Escherichia coli  
Abbreviation: MCS, multiple cloning site (adapted from Overton, 2014). 
 
It is common that the during protein production in bacteria, potential problems that 
come from cell viability, plasmid loss or protein folding occurred (Overton, 2014). Cell 
viability problems are described as extensive cell death during growth phase or at the time 
of inducer introduction. Plasmid loss is another common problem, since production of 
recombinant protein put cells in metabolic pressure, the energy demand for maintenance 
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and replication of plasmid vectors is significant (Silva et al., 2012). The next issue is protein 
folding, which is also the main focus of this research project. 
In general, the overexpression of heterologous recombinant protein leads to metabolic 
burden in host cell (Glick, 1995). Cells start to overconsume the metabolic precursors such 
as adenine triphosphate (ATP), ribosomal ribonucleic acid (rRNA) and amino acids to 
support the protein synthesis (Ramchuran et al., 2005). Expression of recombinant protein 
in E. coli remains a major challenge. Because of lacking post-translation modification, the 
protein folding which is crucial for protein solubility, stability, biological activity, 
immunogenicity and purification strategy (Walsh and Jefferis, 2006). It is proposed by 
Peternel and Komel (2011) that various transitional folding states of target protein are 
presented during the expression, not just only the correct folded protein. Fig. 2-6 
demonstrates the mechanism of protein folding and aggregation. The aim of protein folding 
is to fold the newly synthesized protein into correct folding, however, if the folding 
intermediates fails to achieve the native folding, they will be degraded or form into small 
proto-aggregates (soluble aggregates) (Schrodel, and de Marco, 2005). A significant note 
is protein folding is assisted with cell quality control machinery, including chaperone, heat-
shock protein and proteases. This network establishes the kinetic equilibrium between 
soluble and aggregates form of protein (reviewed by Peternel and Komel, 2011). Therefore, 
soluble fraction of crude cell lysates includes both protein with native conformation and 
proto-aggregates. In addition, proto-aggregations accumulate themselves, promoting the 




Fig. 2-6: A potential mechanism of protein folding and aggregation in E. coli 
(adapted from Peternel and Komel, 2011). 
 
In some cases, protein from inclusion bodies can be recovered by solubilisation and 
refolding, however, there is uncertainty that protein will gain back their native function 
fully (Ventura and Villaverde, 2006). Proper folding not only enhances the solubility of the 
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protein but also maintain the specific structure for clinical assessment, particularly for HBc-
based VLP, where the epitope of interest was displayed on the surface of the capsid in 
repetitive manner. 
Table 2-2 illustrates the typical downstream process for each upstream product folding 
state. A generic purification process of soluble recombinant protein includes protein 
extraction, clarification, bioburden reduction, purification chromatography and polishing 
chromatography (Kazaks et al., 2008; Vicente et al., 2011), meanwhile, the downstream 
processing of inclusion bodies includes the solubilisation of inclusion bodies, refolding, 
purification and assembly (Suffian et al., 2017; Zhang et al., 2020; Jevsevar et al., 2005). 
Moreover, the chance that host cell proteins or DNA are encapsulated in recombinant 
inclusion bodies is high, eventually affecting the refolding yield negatively  
(Maachupalli‐Reddyet al., 1997).  
In comparison, the purification of soluble protein is less complicated and more 
productive, both in time and cost, than the recovery of bioactive material from inclusion 
bodies. The complexity of downstream processes increases significantly when recombinant 
protein is purified from inclusion body protein. Therefore, maximizing the expression of 
HBc-based VLP as soluble form is highly regarded. It is found that adjusting the process 
factors during induction phase increases the soluble expression of recombinant protein in 
E. coli because they influence both folding state and yield of the target product (Tripathi et 
al., 2009; Papaneophytou and Kontopidis, 2014). These are discussed in the following 
section. 
 
Table 2-2: Product folding state determines the purification strategy. 
 
 
Product folding state 
Soluble intracellular proteina  Inclusion body proteinb 
Steps 
Cell harvest Cell harvest 
Cell disruption Cell disruption 
Clarification Clarification 
Heat and salt precipitation Denaturing/Solubilisation 
Solubilisation of precipitate Purification in monomer form 
Diafiltration Assembly in step-wise reduction 
Size-exclusion chromatography Diafiltration 
(a) Kazaks et al., 2008; (b) Suffian et al., 2017 
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2.4.2 Genetic factors and host strain 
 
In expression vector design, there are some variables to be taken into consideration, 
including the selection of promoters, the insertion of target gene into multiple cloning site, 
the origin of replication and optional tags. The selection and development of promoter, 
based on the characteristic of each protein, are important because it should be tuneable to 
achieve high yield of the target protein able to and minimise the leaky expression 
 (Rosano and Ceccarelli, 2014). 
There are several promoters that are widely used in protein production, such as 
Arabinose, hybrid (trc, tac) and T7. Although they are considered as strong promoters, they 
also exhibit their own drawbacks (Jia and Jeon, 2016). For example, arabinose promoters 
possess the lowest basal transcriptional activity among promoters because they rely on 
positive control (Siegele and Hu, 1997). However they depend on gene-regulation of the 
recombinant protein, and the minimal basal transcriptional activity does not always 
guarantee to reach zero (Guzman et al., 1995). Moreover, hybrid promoters demonstrate 
leaky expression, affecting plasmid stability and eventually decreasing the yield of the 
target protein (De Boer et al., 1983; Tegel et al., 2011). 
It is undeniable that lac promoter, key opponent of lac operon, is extremely popular 
for protein expression. The lac operon is responsible for the transport and metabolism of 
lactose in E. coli. Lactose or its non-hydrolysable analog Isopropyl β-D-1-
thiogalactopyranoside (IPTG) are two common inducer that can induce Lac operon. 
However, lac operon is only a moderate promoter, in the presence of glucose, it is difficult 
for lac operon to be completely activated. For a complete activation of lac operon, the cyclic 
adenosine monophosphate (cAMP) is necessary, which is produced when glucose has been 
utilized (Kimata et al., 1997). It is suggested that lac promoter and its derivatives are rather 
weak (Deuschle et al., 1986). 
The T7 RNA polymerase (RNAP) system, also known as pET system, which is 
developed based on the T7 bacteriophage (Studier and Moffatt, 1986; Studier, 1991) to 
overcome the dependence on the cAMP and increase the strength of the promoter. The gene 
of the T7 RNA polymerase is chromosomally integrated under the influence of a lac 
promoter derivate, the lac-UV5, less sensitive to the presence of glucose (Grossman et al., 
1998). With this hybrid fusion, the T7lac system allows strong induction and high level of 
target gene expression. To produce the recombinant protein, IPTG or lactose is required for 
pET system. The connection between T7 promoter, lac operon and IPTG are well-studied 
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by Studier and Moffatt (1986). In the absence of IPTG, the transcription of T7 RNAP is 
prevented due to the binding between lac promoter and Lac represseor LacI. When the 
IPTG is added, LacI binds to the IPTG molecules and releases lac-UV5, therefore, E. coli 
RNAP is able to transcribe T7 RNAP, which activates the promoter on expression vector 
to produce the target gene. Another crucial point is the native E. coli RNAP cannot activate 
T7 promoter on the pET expression plasmid. This activation is significantly dependent on 
the presence of inducer (Overton, 2014). Regarding metabolic pathway, inducers should be 
able to enter the cell via active transport system or passive diffusion through cell membrane. 
For example, the uptake of natural inducer (lactose) in E. coli depends on the lactose 
permease LacY (Guan and Kaback. 2006) and the uptake of synthetic inducer (IPTG) is 
mediated by both passive diffusion and lactose permease LacY active transport  
(Fernandez-Castane et al., 2012). 
The choice of host strain is also a major factor to determine the efficiency of the protein 
production process. In principle, the requirements of the plasmid expression system 
determines which host strain should be used. Regarding pET expression system, the 
chromosomally encoded T7 RNA polymerase is required. Because of this reason, the 
choice of host strain limits into two (2) strain: K-12 and BL21 (Overton, 2014). The E. coli 
BL21 (DE3) strain is preferred for the expression of protein that are cloned under the 
control of T7 promoter (Studier and Moffatt, 1986) Moreover, in comparison to E. coli K-
12, E. coli BL21 demonstrates a higher biomass yield and lower acetate production 
(Waegeman et al., 2013). 
 
2.4.3 Cultivation factors effecting soluble expression of recombinant protein  
 
As is presented in Fig. 2-5 the scale of bacteria culture varies from screening to commercial 
production, particularly from 10 mL to larger than 10000L. The expression screening 
studies can be done using conventional shake-flask cultivation (Li et al., 2015) or microtiter 
plate-based cultivation system (Rohe et al., 2012). After determined the growth condition 
from the initial batch culture, the production is often tested in stirred-tank reactor (STR) on 
batch and fed-batch regime, in which the condition of culture are well-controlled and 
monitored, in comparison to shake-flask cultivation. At this point, the growth and 
expression condition decide the success of the production process.  
In ideal recombinant protein production, a strong promoter supports a high soluble 
protein-production with native conformation. A strong promoter often has these properties: 
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1) it must be tightly regulated to ensure the growth and survival of cell by preventing the 
product toxicity when the recombinant gene is overexpressed, and 2) it allows the 
accumulation of protein-based products up to 50 % of the total cell protein (Studier and 
Moffatt, 1986). 
As significant transcription rate occurs, the destruction of ribosome and cell death 
remain as disadvantages (Studier, 1991). Expression of a foreign recombinant gene creates 
stress on the expression host. The metabolic burden, either energy or nutrients, will 
interfere the cell metabolism and cell growth. The resources will be utilized for cell 
maintenance and expression of target gene. The foreign recombinant protein may have 
different properties from the microenvironment of E. coli. The differences in pH, redox 
potential, osmolarity and folding mechanism as well as high concentration of hydrophobic 
stretches in the newly synthesized protein lead to the formation of inclusion bodies 
 (Carrio and Villaverde, 2002). 
 As is presented in Table 2-1, most of HBc-based VLPs is expressed as inclusion 
bodies under lac promoter, including vaccine candidate of porcine epidemic diarrhea virus 
(Gillam and Zhang, 2018), influenza virus (Chen et al., 2015; Sun et al., 2015), 
hepatocellular carcinomas (Zhang et al., 2007), infectious bursal disease virus (Wang et al., 
2012). To obtain maximum soluble yield of target products with T7lac, an optimal 
induction strategy is required.  
The environmental expression conditions contribute to the yield and ratio 
soluble/insoluble protein (Papaneophytou and Kontopidis, 2014). The influence from 
protein synthesis rate and protein folding rate are important for the expression of chimeric 
HBc in E. coli in order to maintain its structure and immunogenicity. In general, expression 
conditions are optimised in shake-flask or microlitre cultivation prior to fermenter because 
of process economics. In terms of induction in batch mode, no feeding is required. 
However, regarding fed-batch mode, feeding strategy and feeding rate have strong 
influence on protein production (Wechselberger et al., 2012).  
Therefore, optimisation of process parameters during induction phase is necessary to 




2.4.3.1 Media composition  
 
Theoretically, complex media contains yeast hydrolysates, it offers a rapid growth for 
bacterial culture and a great reservoir of amino acids for recombinant protein production. 
Organic nitrogenous source, such as yeast extract, provides precursors for cellular building 
blocks synthesis and reduces the inhibitory effects of acetate in the culture. These benefits 
improve the specific cellular yield of the target protein (Tripathi et al., 2008; Lim et al., 
2000). For example, Luria-Bertani (LB) media is a classic media for production of 
recombinant protein in E. coli, which provides basic nutrient content and suitable 
osmolarity for E. coli growth at early log phase (Sezonov et al., 2007). However limited 
quantity of divalent cations and carbon source in LB cannot support the culture to reach 
high cell density (Sezonov et al., 2007).  
The supplement of divalent cations, i.e. MgSO4, enhances the cell growth by extending 
the exponential phase (Studier, 2005). Magnesium has also been reported to enhance the 
cell growth in multiple strains of E. coli and decrease acetylation based on the ratio between 
carbon and magnesium (Christensen et al., 2017). Moreover, lack of Mg2+ in peptide media 
may lead to ribosome degradation (Nierhaus, 2014; McCarthy, 1962). It is reported that in 
the presence of magnesium (0.1 mM), gloshedobin, snake venom enzyme, had 50 % 
increase in solubility when expressed at 25 oC (Yang et al., 2003). With these arguments, 
addition of Mg2+ is predicted to boost the production rate.  
Because of the lack of carbon source in LB, other advanced complex media such as 
Terrific Broth has been used. The carbon source in these complex media comes from the 
addition of glucose or glycerol. E. coli can be cultivated aerobically or anaerobically. In 
case of aerobic cultivation, E. coli consumes glucose for respiration. Carbon source enters 
the central carbon metabolism and tricarboxylic acid (TCA) cycle to make adenine 
triphosphate (ATP) in the presence of oxygen (Martinez-Gomez et al., 2012; Hempfling 
and Mainzer, 1975). In case of anaerobic cultivation, E. coli switches the metabolism 
pathway of glucose from respiratory pathway to fermentative pathways to create mixed 
acids, also known as by-products (Clark, 1989). The fermentative pathway is undesirable 
because it promotes acetate accumulation, leading to both lower biomass and energy yields.  
Limitation in carbon source may reduce the yield of biomass and protein production 
but excess nutrient is also a drawback. The excess of glucose in culture media can direct 
the culture to overflow metabolism despite the presence of oxygen. When the glucose 
concentration in the medium exceeds a certain concentration, instead of utilizing glucose 
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as energy source via respiratory pathway to produce ATP, the overflow of glucose flux 
through the TCA cycle leads to acetate generation (Contiero et al., 2000; Eiteman and 
Altman, 2006). Therefore, the initial concentration of carbon source or feeding strategy in 
fed-batch regimens should be considered carefully. 
Another choice of carbon source is glycerol, which is recognized as renewable 
feedstock. The growth rate of E. coli on glycerol is much lower than growth rate on glucose, 
particularly, the growth rate of E. coli JM101 on glucose and glycerol is 0.69 h-1 and  
0.49 h-1, respectively (Martinez-Gomez et al., 2012). Glycerol cannot be readily consumed 
so it does not generate acid as much as glucose. Therefore, substitution glucose with 
glycerol is an attractive approach to reduce the acetate formation as well as overflow 
metabolism (Holms, 1986). Glycerol has been used in auto-induction media (Stuider, 
2005), in which glycerol, glucose and lactose are compromised. It is reported that the yield 
of target protein obtained via auto-induction media is greater than those obtained by 
conventional IPTG induction.  
 
2.4.3.2 Cell density at induction 
 
Cultivation of E. coli is an aerobic process. This operation is conducted in stirred and 
aerated fermenter in various scales. It is reported that productivity of E. coli can reach 
higher than 15 g L-1 for protein as inclusion bodies, 5 g L-1 for simple monomeric protein 
and 0.5 g L-1 for complex protein (Sagmeister et al., 2014). To achieve these productivity 
scale, one of the most common approach is expression of the target product in high cell 
density culture by employing two-step cultivation, including accumulation of biomass step 
and induction step (Faulkner et al., 2006; Lee, 1996; Choi et al., 2006) 
The cell density at induction is a crucial factor for soluble protein synthesis, which is 
monitored by optical density at wavelength 600 nm (OD600). In the study of Liew et al. 
(2010) the effects of cell density at induction for murine polyomavirus (MPV) VLP 
production was determined.  The volumetric yield was recorded at 4.38 g L-1 (culture 
media) of MPV VLP with solubility of 60.4 % when the induced at OD600 of 60 using  
fed-batch culture. Induction at OD600 of 100 decreased the solubility and volumetric yield. 
Chua et al. (2008) also investigated the effects of cell density at induction on the production 
of core streptavidin to find out that induction at OD600 of 100 achieved the highest 
volumetric yield. 
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Other examples of the effects of cell density at induction on the expression are studies 
of Chuan et al. (2008) and Ladd Effio et al. (2016). These studies evaluated the significance 
of induction at early exponential phase and late exponential phase (OD600 of 0.5 and 4.0) 
in small-scale cultivation to point out the negative impact when culture was induced at late 
exponential phase in the production of MPV VLP. 
As is mentioned in Table 2-1, most of the HBc VLP expressed under the control of lac 
operon was induced with IPTG at early exponential phase (OD600 of 0.6 to 0.8) in shake-
flask fermentation. In fermenter-scale, cell density at induction is varied from 20 to 100 of 
OD600. However, only a few of expressions are expressed in soluble fraction. In terms of 
batch cultivation, at higher cell density, the activity of cells decreases due to the decline in 
nutrient concentration, the availability of dissolved oxygen, acetate accumulation and the 
rise of carbon dioxide in the culture. Eventually, these factors negatively impact the gene 
expression (Miao and Kompala, 1992). 
Not only affects the protein production, the cell density at induction also has impacts 
on the activity of the protein of interest. Study of Olaofe et al. (2010) for amidase 
production demonstrates the volumetric amidase activity enhanced 70-fold when culture 
was induced at early exponential phase. 
These studies suggest that optimisation of cell density at induction is essential for 
soluble intracellular protein expression. 
 
2.4.3.3 Inducer concentration 
 
Lactose and IPTG are two common inducers that are used to induce protein expression in 
lac promoter. The inducer concentration determines the rate of protein synthesis. The 
excess of inducer has negative impacts on both cell growth and protein expression, 
meanwhile, low concentration of inducer may lead to insufficient induction, especially in 
high cell density culture (Baneyx and Mujacic, 2004). It is reported that IPTG concentration 
will not affect the specific growth rate and biomass when the culture is induced with the 
concentration between 0-1 mM (Ramirez et al., 1994; Olaofe et al., 2010).  
High concentration of inducer in the culture media may lead to aggressive expression 
of target protein in vivo, which increases the intracellular protein concentration and 
overwhelms the folding machinery of E. coli. This results in the formation of inclusion 
bodies (Fahnert et al., 2004). IPTG concentration in range of 0.5-1.0 mM has been used in 
expression of HBc-based VLP, listed in Table 2-1. Another approach for minimizing the 
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toxic effects of IPTG on culture is multiple times of induction (Hu et al., 2015). Not only 
increases the Pfu DNA polymerase activity, but this strategy also avoids overaccumulation 
of IPTG and reduces the cost of production. The nature of each recombinant protein is 
different, it is hard to use one IPTG concentration as standard. It must be characterized for 
specific strain/ vector/ protein to achieve soluble expression. 
 
2.4.2.4 Post-induction temperature 
 
The optimal temperature for E. coli growth is 37 oC. This temperature may cause plasmid 
loss and stimulate the hydrophobic interactions that are responsible for aggregation reaction 
(Hunke and Betton, 2003; Strandberg and Enfors, 1991). It is possible to interfere the 
accumulation of protein aggregates by partially controlling the factors that influenced the 
aggregation reaction. One of the common practices is to reduce the protein synthesis rate. 
The post-induction temperature is adjusted to lower than 37 oC.  
This approach offers the newly expressed protein time to fold properly and overcome 
the overcrowded intracellular protein in cytoplasm (Schein, 1989; Vera et al., 2007). 
Furthermore, in the scenario in which the target protein is expressed as insoluble form, the 
protein quality in the inclusion bodies is influenced by temperature. For instance, the 
activity Aβ42 Alzheimer peptide in the aggregates inversely correlates with the temperature 
(De Groot and Ventura, 2006). 
Regarding HBc-based VLP expression in E. coli, the study of Ravin et al., 2015 
demonstrates the success of soluble expression of M2e-HBc VLP, vaccine candidate 
against influenza. The culture was induced with 0.5 mM of IPTG and was cultivated at  
20-30 oC for 16-18 h. Meanwhile, the vaccine candidate for PEDV was expressed as 
inclusion bodies when the culture was induced at 28 oC with 1 mM of IPTG  
(Gilliam and Zhang, 2018). 
The effect of temperature on the solubility of His-tag HBcAg has been investigated by 
Yap et al. (2009). The culture was induced with IPTG of 0.5 mM and incubated for 16-18 
h at temperature of 27, 30, and 37 oC. The greatest soluble yield was recorded at 75 mg L-
1 (culture media) with the solubility of 95 % when the culture was incubated at 30 oC. It is 
reported that low temperature incubation (30 oC) also enhanced the activity and expression 
of E. coli chaperones (Mogk et al., 2002). Moreover, low expression temperature (28 oC) 
and co-expression of Trigger Factors (TF) and E. coli chaperones GroEL–GroES improved 
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the soluble production of GST–VAS (vasostatin 120–180) by 6-fold in comparison to the 
yield at 37 oC (Sun et al., 2005). 
Although expression at low temperature enhances the soluble yield, low temperature 
may inhibit the cell growth, resulting in a decline of biomass. These arguments should be 
taken into consideration when evaluating the operating range.  
 
2.4.3.5  Dissolved oxygen level 
 
Bacterial metabolism depends on the availability of oxygen level in the culture, particularly 
the demand of oxygen for cellular respiratory when the culture reaches high cell density 
(Whiffin et al., 2004). It is essential to maintain the aerobic condition for supporting high 
cell growth and providing oxidising environment for protein synthesis (Phue and Shiloach 
2005).  
Oxygen limitation is classified as a stress for culture. E coli will adjust their own 
metabolic capacity to fit their energy generation and availability of oxygen  
(Bettenbrock et al., 2014). In aerobic metabolism, in electron transport chain, oxygen is 
served as terminal electron acceptor (Anraku, 1988). Molecular oxygen directly influences 
the generation of adenosine triphosphate (ATP), an energy currency that involves in various 
biological activities in cell, including metabolic changes, protein oxidation, DNA 
oxidation, protein synthesis and plasmid replication (Konz et al., 1998; Henkel et al., 2014). 
Therefore, a fluctuation in oxygen supply can cause intracellular oxidative stress, affecting 
the quality of the final product. 
Kim et al. (2012) demonstrates that high intracellular levels of ATP enhanced the 
production of green fluorescence protein in E. coli. In agreement with the findings,  
Kim et al. (2013) discovered that ATP hydrolysis is required for folding of non-native 
protein, for example, the GroEL-GroES and DnaK systems requires ATP for functioning. 
ATP has been proved to be involved in Human Immunodeficiency virus (HIV) VLP 
assembly (Tritel and Resh, 2001).  
It is reported that even a short exposure to anaerobic condition, pre-proinsulin 
productivity can be substantially reduced by intermittent switching between aerobic and 
mixed acid fermentation (Sandoval-Basurto et al., 2005). The formation of by-products, 
such as acetate, lactate, and succinate causes the loss in the biomass and protein yields.  
There are several approaches to maintain dissolved oxygen level in a bioprocess 
culture. They include 1) changing the agitation speed of the impeller (Shin et al., 1996),  
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2) increasing fermenter pressure (Ma et al., 2010), 3) supplying oxygen-enriched air (Ma 
et al., 2010); and 4) using oxygen vector to enhance the solubility of oxygen in culture 
medium (Pilarek et al., 2011).  
Significant increase in agitation speed or aeration may lead to foam formation and 
enormous power consumption, which has negative impact on the cost of production. 
Addition of hydrophobic liquids organic solvents with higher affinity for oxygen, such as, 
immiscible oxygenated oils (Sklodowska and Jakiela 2017), alkanes (Zhang et al., 2018; 
Li et al., 2012), paraffin oil (Narta et al., 2011), oleic acid (Liu et al., 2016), and perfluoro-
chemicals (Westbrook et al., 2018), is able to reduce the surface tension of water and retain 
oxygen molecules in the two-phase system (Rols et al., 1990; Nielsen et al., 2003), 
eventually increase the oxygen transfer rate in the reactor. 
 
2.4.3.6 Batch and fed-batch in fermenter scale cultivation 
 
All the mentioned fermentation process factors in previous section apply to both shake-
flask and fermenter-scale. In fermenter-scale cultivation, as the high cell density and large 
culture volume, the consumption of nutrient is enormous. Consequently, guarantee of an 
adequate supply of nutrients is of great importance. 
Initially, in batch cultivation, the availability of nutrients is defined, the cultivation 
ends when culture medium is depleted. This provides an overflow of nutrient for  
non-limiting growth for E. coli at the start of cultivation and possibility of nutrient shortage 
at the end. These could result in the formation of unwanted metabolites, such as acetate, 
formate (Szenk et al., 2017), leading to the inhibition of cell growth and decrease of the 
production yield of target recombinant protein (Lee, 1996). Despite of the availability of 
nutrient, the maximum growth rate is also temperature-dependant (Kovarova et al., 1996). 
Therefore, the initial carbon source concentration and temperature should be determined 
with caution regarding the technical or physical constraints.  
Following the batch phase, fed-batch is initiated by addition of the supplementary 
media when the culture shows the sign of the nutrient limitation. A sudden rise in pH or 
dissolved oxygen level indicates the growth limiting substrate (carbon source) is depleted.  
There are several types of feeding regimes to control the growth rate of the culture and 
avoid the overflow of nutrient (Lee, 1996). They are classified into two main categories: 
1) feeding strategies without feedback control (linear or exponential) and 2) with feedback 
control (DO-stat or pH-stat) feeding strategies (Mears et al., 2017). Since there is no 
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“one size fits all” in protein production, each recombinant protein has favoured expression 
condition. The efficiency of each feeding strategy should be investigated. 
In fed-batch cultivations, feeding strategies without feedback control (feed forward) 
are mainly based on the cell growth rate which is strongly influenced by feeding rate. This 
feeding rate is determined by the initial biomass concentration of the fed-batch phase, the 
current working volume of the culture, the biomass yield coefficient, the concentration of 
feed solution, and the desired specific growth rate (Kim et al., 2004). Meanwhile, in 
feedback control feeding strategies, the feeding solution is supplied under the control of 
DO or pH level of the cell culture.  
DO-stat feeding based on the concept of DO rises because of the reduction of 
respiration (oxygen consumption by cell) as the nutrient is limited. During the cultivation, 
the configuration of fermenter such as agitation speed and aeration rate are fixed, the DO-
stat maintains the culture at constant DO set point by controlling the nutrient feed rate in 
relation to DO level. Nutrient is supplied when DO rises higher than the set point and 
nutrient feeding rate is stopped or reduced when DO drops below the setpoint. 
In pH-stat feeding, the pH of the culture increases as the carbon source is depleted. 
Similar to DO-stat mechanism, pH of the culture is maintained at constant level by nutrient 
feeding. Nutrient is supplied when pH rises higher than the set point and nutrient feeding 
rate is stopped or reduced when pH drops below the set point. During the cultivation, the 
DO level of the culture is usually controlled in cascade mode. Auto-adjustment of agitation 
speed and aeration is performed by proportional–integral–derivative controller (PID) 
controller of the fermenter. 
Therefore, not only nutrient is important, but the availability of oxygen throughout the 
cultivation is also a growth limiting factor (Farrell et al. 2015). In general, the oxygen 
uptake rate (OUR) of the cell has to be smaller than oxygen transfer rate (OTR) to ensure 
the physiological condition of the working cell. In fed-batch cultivation, culture will reach 
to a cell density where OUR larger than OTR in which the reactor is unable to adjust its 
impeller agitation and gas aeration velocities to cover the demand of oxygen in cascade 
control, leading to oxygen limitation. This limitation switches the metabolism pathway of 
E. coli, from respiratory to fermentative metabolism (Spiro and Guest, 1991).  
Farrell et al. (2012) conducted pH-stat fed-batch cultivation to produce 41 kDa 
recombinant protein vaccine candidate. The study demonstrates the constraint of 
maintaining the DO level in 200-L bio-reactor when using pH-stat. Large bio-reactor has 
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its agitation speed limit (approximately 500 rpm), which narrows down the maximum 
volumetric oxygen mass transfer coefficient (kLa) to 0.06 (s
-1).  
For a consistent process performance between reactor scales, DO-stat has more 
advantages since the method use the feeding rate to maintain the dissolved oxygen level at 
a designated set-point to avoid the oxygen limitation (Farrell et al., 2015).  
 
As a result of using E. coli as expression host, following six (6) key aspects were 
discussed. They are: 
1. General recombinant protein production process includes 1) design of expression 
vector, 2) selection of host strain and transformation, 3) growth of bacteria and 
protein production, 4) protein recovery and purification 
2. Potential problems in fermentation process include cell viability, plasmid loss, and 
protein folding. High expression rate of recombinant protein with poor protein 
folding rate leads to accumulation of inclusion bodies 
3. Protein folding state determines the bioactivity of the protein. The bioactivity of the 
target protein recovered from inclusion bodies is not guaranteed. It is feasible to 
control the protein synthesis rate via process factors to improve solubility of the 
expression 
4. Expression vectors and choice of promoter determine the host strain 
5. Process factors that influence the soluble production of recombinant protein include 
post-induction temperature, the cell density and pH level at induction, inducer 
concentration, metal ions, and dissolved oxygen level in both shake-flask and 
fermenter-scale 
6. Feeding strategy in fed-batch cultivation is a crucial factor. 
 
The recombinant protein production process, potential problems and process factors 
contributed to soluble production of target protein in E. coli have been reviewed and 
summarised. Because of the interactions between process factors, to extrapolate the insights 




2.5  Statistical approach – Design of Experiment (DoE) 
 
As is discussed in section 2.4, there are many variables that influence the soluble production 
of HBc-based VLP in E. coli. Besides of genetic modification, fermentation process factors 
are also crucial to soluble production of chimeric HBc-based VLP. 
One-factor-at-a-time (OFAT) approach is described as the method of changing one 
independent variable and while the other factors remains unchanged (Frey et al., 2003). 
Experiment continues with the determination of the next factor based on the optimal 
condition of previous factor. It has been applied for several decades to improve the 
performance of biopharmaceutical fermentation process. 
The statistical approach, also known as design of experiment (DoE), offers a controlled 
model to screen and optimise the process factors to achieve single or multiple optimal 
responses by exploring the relationship between variables and experimental responses 
(Myers et al., 2016).  
Table 2-3 demonstrates the comparison between conventional and statistical 
approaches, i.e. factorial design and response surface design. In general, although OFAT is 
simple, it requires intensive labour work and is time-consuming. In addition, the interactive 
effects among the variables studied are lost, leading to an incomplete understanding of 
system behavior and the approach. Ultimately, OFAT fails to identify the true optimum of 
process settings (Abou-Taleb and Galal, 2018). Not only beneficial in time and cost of 
experiment, the amount of information extrapolated from the statistical design is 
significantly greater than those from OFAT with fewer experiment runs. This approach 
provides a mean to navigate the design space. In recombinant protein expression, from the 
review by Papaneophytou and Kontopidis (2014), all of the process factors during the 
expression are interconnected, it is feasible that the interaction between factors has higher 
influence than the effect of single factor (Noguere et al. 2012). 
Another key advantage of DoE is the sequential experiment. A typical DoE workflow 
includes the planning, screening and optimisation. Screening experiment is completed in 
factorial design (first-order models) and optimisation is achieved using response surface 
methodology (polynomial equation) (Bezerra et al., 2008; Uhoraningoga et al., 2018; 
Snedecor and Cochran, 1989). Because of these arguments, statistical approaches offer 
ideal means for optimisation of soluble production of HBc-based VLP. 
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Table 2-3: Comparison between conventional and statistical approaches. 
 
Conventional approach Statistical approaches 
Design - Factorial Response surface 
Popular 
design model 
One-factor-at-a-time i.   Two-level full factorial  
ii.  Fractional factorial  
iii. Placket -Burman  
i.  Central composite  
ii. Box-Behnken  
Aim Optimisation Screening/Optimisation Optimisation 
Assessment Linear equation with 
one variable 
Linear equation of multiple 
variables and their two-
factor interaction 
Quadratic equation with 
multiple variables and their 
two-factor interaction 
Advantages i.  Both continuous 
and categorical 
factors 
ii. Simple and 
straightforward  
 
i.   Both continuous and 
categorical variables 
ii.  Knowledge of main 
effects and interaction 
between factors 
iii. The number of 
experiment runs can be 
reduced using fractional 
factorial design  
iv. Prediction in design 
range 
v.  Non-bias  
vi. Computer-aid 
i.   Graphical or numerical 
option for point optimisation 
ii.  Extensive information on 
experimental factor effects 
and interaction between 
factors  
iii. Less number of factors but 
greater number of levels for 
each factor. 
iv. Prediction in design space 
v.  Non-bias 
vi. Computer-aid 
Disadvantages i.   Large number of 
experiments runs 
ii.  Time consumption 
iii. Expensive 
iv. Loss of interaction 
between factors 
v.  Lack of predictive 
ability. 
i.   Only investigated the 
high (+) and low (-) level of 
each factor 
ii.  Approach become 
expensive in relation to the 
numbers of factors 
iii. The number of 
experiments determines the 
amount of information 
extrapolate from the design  
iv. Possibility of sequential 
experimentation 
i.   Continuous variables only 
ii.  Requirement of screening 
experiment or knowledge to 
design the experimental 
matrix 
iii. The investigated range of 
design factors should be 
carefully determined to 
achieve curvature 
iv.  Sometimes optimal 
combination of factors does 





2.5.1  Screening experiments by full/fractional factorial design 
 
Screening experiment focuses mainly on media composition and culture conditions 
(Swalley et al., 2006; Marini et al., 2014). To evaluate all the variables that influence the 
soluble production of HBc-based VLP in microbial expression system, a wide range of 
factors should be included in experimental screening to narrow down the significant factors 
(Mandenius and Brundin, 2008; Box et al., 2005).  
The classical designs for screening purpose include full factorial design, fractional 
factorial design and Plackett-Burman designs. The choice of design depends on the 
screening purpose. In terms of effects achieved by the model, full factorial design provides 
information regarding the main effect and two-factor interactions in exactly the same way; 
fractional factorial design offers either only the main effect or both main effects and two-
factor interactions based on the resolution of the design; and Plackett-Burman design offers 
main effect only (Montgomery, 2012).  
Although the protein expression condition has been intensively studied, the selection 
of variables and their levels should be appropriate, following the pre-knowledge to avoid 
experimental bias and bad judgement (Mandenius and Brundin, 2008). 
In case of lacking pre-knowledge of expression of protein of interest, it is 
recommended to conduct a screening experiment to examine as many factors as possible. 
A full factorial design, 2k, is an ideal experimental design. The controlled model includes 
two coded levels for each factor, lower (-) and (+) higher value, and k is number of factors, 
which is larger than two (2). The drawback of full factorial design is the number of 
experiments increases in exponential manner if the number of factors is large. 
Full factorial design of experiment has been used to optimise the soluble expression of 
VP1 of murine polyomavirus VLP in the study of Chuan et al. (2008) and Ladd-Effio et al. 
(2016). These studies suggest that strategical modification of host cell and optimal 
induction strategy are better alternatives to boost the soluble expression of recombinant 
protein rather than codon optimisation. 
 In comparison, fractional factorial design is recommended when factors number is 
larger than five (5), this design offers less experimentation but come with the cost of losing 
some information about potential interactions (Papaneophytou and Kontopidis, 2014). The 
design is described as 2 (k−p)
R
, in which 2 is the number of levels, k is the number of factors, 
p extra columns required, and R is the resolution of the design. Resolution is determined as 
how much the effects in a fractional factorial design are aliased with other effects. 
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A significant feature of full or fractional factorial design is the evaluation for both 
continuous factors (temperature, induction time, IPTG conc., etc.) and categorical factors 
(cell line, expression vector, fusion tag, culture media, etc.) (Papaneophytou and 
Kontopidis, 2014). For example, to boost the soluble expression of pneumolysin  
(250 mg L-1), Marini et al. (2014) studied the effects of induction time, IPTG conc., 
expression temperature and media composition using fractional factorial design. 
To rank the effects from design factors, the half-normal probability plot coupled with 
Lenth’s method (Lenth, 1989) is an established statistical technique (Taylor, 1994). The 
absolute value of the effect estimates is plotted against their cumulative normal 
probabilities. Significant effects of design factor will be shown as outliers from the straight 
line that passing through the origin and close to the fiftieth percentile data value. Analysis 
of variance and residual plot are integral part of regression model building. 
After completing the observation from experimental design, a quantitative relationship 
(equation) between the response and important design factors is established. In general, a 
low-order polynomial model is appropriate for screening or characterisation purpose. 
Equation 2-1 presents a common model includes main effects and interaction between two-
factors: 
 
y = β0 + β1X1 + β2X2 + β12X1X2 + … + ε (Eq. 2-1) 
 
where y is the response, β is the unknown parameter that is estimated from the data in 
the experiment, the X is the design factors, the cross-product term X1X2 is the two-factor 
interaction between the design factors and ε is the experimental error in the system 
(Montgomery, 2012) 
The limitation of these designs is they can only generate first-order equation, which is 
inadequate to demonstrate the curvature of the process. The importance of each factor 
influencing protein production is estimated using statistical software such as Minitab™ 




2.5.2  Optimisation experiment by response surface methodology 
 
After identifying the significant process factors, simultaneous optimisation of the greater 
number of levels of the investigated variables is necessary to achieve the best system 
performance, which can be done by response surface methodology (RSM). The optimal 
objective can be a single or a set of responses, for example, biomass, volumetric yield and 
solubility of expressed protein (Papaneophytou and Kontopidis, 2012; Muntari et al., 2012; 
Puente-Massaguer et al., 2020).  
The RSM uses a collection of statistical and mathematical techniques to achieve the 
fitting of the experimental data to the quadratic equation (second-order equation) 
(Montgomery, 2012), increasing the precision of the model, compared to fractional 
factorial design. Equation 2-2 demonstrates the relationship between design factors and 
response is similar to Eq. 2-1 with the extension of higher order of interaction (βii(Xii)
2): 
 
y = β0 + β1X1 + β2X2 + β12X1X2 + β11(X11)
2 + β22(X22)
2 + … + ε (Eq. 2-2) 
 
Usually, before applying the RSM methodology, it is essential to have pre-knowledge 
about the expression of the protein of interest or perform screening experiment to choose 
the optimal plasmid vector and strain (Papaneophytou and Kontopidis 2014). Experimental 
designs for response surface methodology include Box–Behnken (BBD), central composite 
designs (CCD), and full three-level factorial designs (Bezerra et al., 2008). Both CCD and 
BBD are widely used in optimisation of protein expression. For example, Balderas et al. 
(2008) utilised the BBD to enhance the production of human interferon gamma by 13-fold. 
The expression of extracellular Zinc-Metalloprotease (SVP2) protein was enhanced by 15-
fold using CCD (Beigi et al., 2012).  
Central composite design, first presented by Box and Wilson (1951), consists of three 
components: 1) a full or fractional factorial, 2) an axial point (star design) and 3) central 
points. An optimisation study involves four (4) variables will generates a matrix of 30 
experiments, covering five (5) levels of each factors (-2, -1, 0, 1, 2). Replication of centre 
point provides the measurement of reproducibility and model lack of fit (Ferreira et al., 
2007). Based on three-level incomplete factorial design, BBD is composed of the middle 
points of the edges and centre point from a cube, leading to a spherical, rotatable second-
order design (Box and Behnken, 1960). With 4 variables, BBD only need twenty-seven 
(27) experiments. Although the smaller number of run benefits the time and cost, the lower 
number of experiments leads to smaller degrees of freedom.  
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Fig. 2-7 demonstrates the examples of a 3-factor CCD and a 3-factor BBD. The number 
of experiments in 3-factor BBD is less than the number of experiments in 3-factor CCD. 
However, because of the difference in localisation of experimental points, the predictive 
ability of the model to calculate the response of the new experimental point, particularly 
the extreme combinations, is affected. CCD contains the extreme factor combinations, 
whereas BBD does not examine borderline region. Therefore, CCD has better prediction 




Fig. 2-7: Example of a 3-factor central composite design (left) and a 3-factor  
Box-Behnken design (right) (adapted from Ockuly et al., 2017) 
 
In case of optimising of serval responses, changing the level of a factor can have 
positive effect on a specific response and negative effects on the others. It is common that 
all surfaces found do not provide the optimal condition for the data set. There are two main 
approaches to find the optimum regions, visual inspection and Derringer function, also 
known as desirability function (Murphy et al., 2005; Derringer and Suich, 1980).  
The design of experiment with their special properties compared with conventional 
approach (OFAT) has shown their advances in boosting the soluble expression of 
recombinant protein in E. coli, particularly VLP vaccine candidate. Therefore, it is wise to 
employ statistical approach to optimise the expression of HBc VLP as soluble form and 




2.6 Chapter summary and conclusions 
 
Based on a critical review of the literature, the following important factors emerge: 
 
1. Hepatitis B core virus-like particle is a promising platform for vaccine development. 
Compared with conventional vaccines, it is more advanced because it is potentially 
safer and has the flexibility to carry epitope of interest at three different insertion sites 
to induce the immune response. Two epitope models, EBNA1 and HCV core have 
been reviewed in terms of structure and immunogenicity aspects. HBc VLP is a 
thermal stable protein that is beneficial for protein purification.  
 
2. E. coli has advantages in recombinant protein expression. These include, high yield of 
product, the availability of well-studied hosts and vectors, short cultivation time and, 
process economics. However, solubility of the expression is a potential challenge. This 
is because mis-folding protein accumulates insoluble protein into inclusion bodies. The 
expression of chimeric HBc-based VLP tends to be in inclusion bodies. The soluble 
expression of chimeric HBc-based VLP is highly preferred so the fermentation process 
factors, including media composition, the concentration of inducer, cell density at 
induction, post-induction temperature, dissolved oxygen level during the expression 
and feeding strategy, need to be optimised. 
 
3. One-variable-at-a time is not a good approach because multiple factors and biological 
reactions occur at the same time in biological process. Statistical approaches provide 
a platform to identify the most influence factors and interaction for a specific response. 
In general, statistical approach consists of 1) fractional factorial design (FFD) and 2) 
response surface methodology (RSM). FFD can be used to rank the effects of design 
factors and RSM provides the optimal setting and prediction with higher precision. 
 
In the next chapter, Chapter 3, the expression of HBc VLP carrying HCV core peptide 
is investigated in shake-flask fermentation. Fractional factorial design is employed with six 
(6) factors and two (2) levels. The protein is characterized with size-exclusion 
chromatography and transmission electron microscopy. The impacts of factors on 
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A review of the literature (Chapter 2) showed that the microbial expression system is able 
to express HBc VLP, particularly inducible expression system.  
E. coli has been used widely as an exceptional host because it is well-characterized and 
is readily available in a range of commercial strains. As is mentioned in Chapter 2, chimeric 
Hepatitis B core (HBc) virus-like particle (VLP) features intracellular self-assembly 
properties. Although it is reported that E. coli-derived VLP can only be expressed as naked 
VLP (Pushko et al., 2013), the size of naked VLP is considerably large to E. coli folding 
machinery. Moreover, T7 expression system triggers strong and rapid over-expression of 
recombinant protein when exposures to IPTG, putting the host cell into metabolic burden 
(Glick, 1995). Gasser et al. (2008) reviewed the protein folding and conformational stress 
in microbial cell, suggesting that when the rates of protein synthesis overwhelm  
post‐translational modifications such as folding machinery, the incorrectly folded 
intermediates often accumulate.  
Therefore, soluble expression of recombinant protein from E. coli is limited and it is 
not beneficial if the product is expressed as inclusion bodies. Inclusion bodies complicate 
the purification process and refolding solubilized inclusion bodies to a bioactive form is a 
challenging task and protein dependent (Burgess et al., 2009). Besides of strain and 
plasmid, many fermentation process factors are being manipulated to reduce inclusion 
bodies formation and enhance soluble expression of recombinant protein, typically  
post-induction temperature, IPTG concentration, pH level at induction, the cell density at 
induction time (Chen, 2012; Papaneophytou and Kontopidis, 2014).  
It is not known how the inserted epitope and process factors influence the soluble 
expression in a systematic way. Evidence from the literature is strong nevertheless that 
most of study is focused on synthesis new vaccine candidate and their immunogenicity, not 
many studies are focused on improving the soluble production of HBc-based VLP. Because 
of significant responsive regulatory systems in E. coli, cells rapidly adapt to environmental 
change to secure survival. Therefore utilization of conventional experimental design, and 
trial and error, will be time-consuming and require laborious effort. This is unlikely 
therefore a good method for study (Uhoraningoga et al., 2018).  
A statistical method using the design of experiments can reduce the number of the 
experiments but still extract significant information, including any interactions between 
factors. Fractional factorial methods can include both categorical and continuous variables 
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(Wu and Hamada, 2009). It has been applied to improve the production of VP1 of murine 
polyomavirus VLP in the study of Chuan et al. (2008) and Ladd-Effio et al. (2016). This is 
therefore suitable to this research into enhancing soluble production of recombinant protein 
in E. coli. 
Hepatitis C virus infection is a cause of liver cirrhosis and hepatocellular carcinoma 
(Caselmann and Alt, 1996). The potential of using HBc as carrier for HCV vaccine 
candidate was reported by Mihailova et al. (2006). HBc VLP bearing virus-neutralizing 
HBV pre-S1 epitope and HCV core epitope was also reported by Sominskaya et al. (2010). 
Both demonstrated the flexibility of the HBc protein as a vaccine carrier.  
Aim of this chapter was to boost the soluble production of HBc VLP carrying structural 
epitope in E. coli. A set of 32 experiment was conducted to identify the effect of the main 
fermentation process factors on the soluble expression of HBc-based VLP using fractional 
factorial design in shake-flask fermentation. The structural epitope, HCV, has 44 amino 
acids and is able to form into α-helices structure. Because of this, it is used as model to 
investigate the impact of parameters on soluble production of HCV-HBc VLP.  
It is hoped that insight gained from this chapter could be used to provide needed 
technical insight to navigate the operating range of process parameters in laboratory 
fermenter and methods of up-scaling. 
 
3.2 Material and methods 
 
3.2.1 Expression strain 
 
The epitope of Hepatitis C Virus core protein was inserted at N-terminus of HBc protein to 
form chimeric HCV-HBc (HBc: 183 amino acid). The amino acid sequence of HCV core 
is KTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTS). The plasmid 
pET-30a (+) (Invitrogen ®, USA) was used to form pET-30a (+)/HCV-HBc, carrying the 
gene of HCV-HBc protein under control of T7 promoter with lac operon. 
Via heat-shock transformation the plasmid was transformed into E. coli by using One 
Shot™ BL21 (DE3) chemically competent E. coli (Invitrogen©, USA). Cell were cultured 
on Luria Bertani (LB) agar plate. Cells were stored at minus 20 oC as the working cell.  
HBc protein (the carrier – without epitope) was also transformed into E. coli as control. 
All reagents were analytical grade (AR) unless otherwise stated. 
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3.2.2 Fractional factorial experimental design 
 
Table 3-1 shows a fractional factorial design that was used to boost the soluble expression 
of HCV-HBc. Design included 32 expression condition, made up from six (6) design 
factors with two (2) designated levels as low (-1) and high (+1) level. Process factors were 
presented as coded value. They included (A) post-induction temperature (30 oC and 40 oC), 
(B) post-induction rotation speed of the shaker (120 rpm and 250 rpm), (C) pH level at 
induction (6.2 and 7.2), (D) isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration 
(0.2 mM and 0.8 mM), (E) optical cell density measured at wavelength 600 nm at induction 
(OD600 of 0.8 and OD600 of 2.0), and; the (F) presence of Mg
2+ (0 mM and 10 mM). 
Three (3) responses were recorded, they were: 1) biomass per litre of culture media  
(g L-1), 2) the volumetric yield of target protein per litre of culture media (mg L-1), and 
3) the yield of soluble VLP per dry cell mass (mg g-1), which was set as main response for 
the experimental design. To clearly determine the main effects of process factors and  
two-factor interaction, a 26-1 fractional factorial design consists of 32 experiments was used. 
Data analyses were performed by Design-Expert™ (version 11, Stat-Ease©, Minnesota, 
USA) where the response was kept as normal (no transformation required by the Box-Cox 
method) (Box and Cox, 1964). As is included in Design-Expert, half-normal probability 





Table 3-1: Factors and coded levels of the fractional factorial design for HCV-HBc VLP. 
 















(-1): 30 (-1): 120 (-1): 6.2 (-1): 0.2  (-1): 0.8  (-1): 0  
(+1): 40 (+1): 250 (+1): 7.2 (+1): 0.8 (+1): 2.0 (+1): 10 
oC rpm  mM OD600 mM 
1 -1 -1 +1 -1 -1 +1 
2 -1 -1 +1 +1 -1 -1 
3 +1 +1 -1 -1 -1 -1 
4 -1 -1 -1 -1 +1 +1 
5 +1 +1 +1 -1 +1 -1 
6 +1 +1 +1 +1 -1 -1 
7 +1 +1 +1 -1 -1 +1 
8 -1 +1 +1 +1 -1 +1 
9 -1 +1 +1 +1 +1 -1 
10 +1 -1 +1 +1 -1 +1 
11 -1 -1 +1 -1 +1 -1 
12 +1 +1 -1 +1 +1 -1 
13 +1 +1 -1 +1 -1 +1 
14 -1 +1 -1 +1 +1 +1 
15 -1 +1 -1 -1 -1 +1 
16 +1 -1 -1 -1 +1 -1 
17 -1 +1 +1 -1 -1 -1 
18 +1 -1 -1 -1 -1 +1 
19 -1 -1 +1 +1 +1 +1 
20 +1 +1 -1 -1 +1 +1 
21 -1 +1 -1 +1 -1 -1 
22 +1 -1 -1 +1 +1 +1 
23 +1 -1 +1 +1 +1 -1 
24 -1 -1 -1 +1 -1 +1 
25 +1 -1 +1 -1 -1 -1 
26 -1 -1 -1 +1 -1 -1 
27 -1 +1 -1 -1 -1 -1 
28 -1 +1 +1 -1 +1 +1 
29 +1 +1 +1 +1 +1 +1 
30 +1 -1 +1 -1 +1 +1 
31 -1 -1 -1 -1 -1 -1 
32 +1 -1 -1 +1 -1 -1 
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3.2.3 Expression of HCV-HBc VLP 
 
The E. coli transformed with the pET-30a/HCV-HBc were cultured in 50 mL of sterilised 
Luria-Bertani media (10 g L-1 tryptone (Oxoid, USA), 5 g L-1 yeast extract (Oxoid, USA), 
10g L-1 NaCl (Chem-supply, Australia) in 250-mL Erlenmeyer flask, supplemented with 
50 µg mL-1 kanamycin sulfate (Invitrogen©, USA), at 37 oC and 200 rpm (round per minute) 
for 16 h.  
The overnight culture was added into 200 mL of fresh sterilized LB media volume 
with 50 µg mL-1 kanamycin sulfate, in 500-mL Erlenmeyer flask at a ratio of 1 v/v % 
(seeding/culture volume), and cultivated at 37 oC and 200 rpm. MgCl2 (Chem-supply, 
Australia) was added to the culture following the experiment design, as is listed in  
Table 3-1. The optical density (OD600) was measured by UV-1600PC Spectrometer (VWR 
International©, USA).  
The expression of HCV-HBc was conducted followed fractional factorial design 
matrix, as is presented in Table 3-1. Experiments were conducted in randomised sequence 
to avoid bias. When culture reached to designated value of cell density, the fermentation 
process factors were adjusted according to FFD matrix. K2HPO4 2 M (Chem-supply, 
Australia) and KH2PO4 0.5 M (Chem-supply, Australia) were used to adjust the pH of the 
culture at induction. IPTG (Invitrogen©, USA) was added to the culture to express the target 
protein. Temperature and rotation speed of the shaker were also adjusted. The expression 
was continued for the next six (6) h. 
Before cells were harvested by centrifugation (3700 rpm, 20 oC, 30 min), the final cell 
density was measured to obtain the biomass concentration. The cell pellet was washed with 
deionized water, then stored at minus 20 oC for further analyses.  
Cells were lysed at a ratio of 1 g wet cell weight (WCW) per 10 mL of lysis buffer  
(20 mM of Tris-HCl (Chem-supply, Australia), 0.1 v/v % Triton X-100 (Glentham, United 
Kingdom), 3 mM EDTA (Invitrogen©, USA), pH 8.0) by ultra-sonication (350 W, 10 min) 
on ice-bath (0 oC). Each cycle has a pulse of four (4) s on with six (6) s off. Cell crude 
lysate was clarified by centrifugation (12000 rpm, 4 oC, 30 min) to separate supernatant 
fraction (soluble protein) and insoluble precipitate (inclusion bodies). These fractions were 
further analysed by 12 % reducing SDS-PAGE. 
The supernatant fraction was identified as clarified crude lysate. Protein 
concentration of each fractions was determined by Bradford assay (Bradford, 1976). 
Bovine serum albumin (Sigma-Aldrich, USA) was used as standard. 
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To determine the constant number between dry cell weight (DCW) and optical 
density (OD600), 10 mL of culture media at different optical density was centrifuged. The 
cell pellet was collected and washed with deionized water then dried in oven at 60 oC for 
24 h to remove water. In one (1) L of culture media at OD600 of 1 has 0.4 g DCW. 
It is hypothesised that in the clarified crude lysate, there were: 1) HCV-HBc soluble 
monomer protein, 2) soluble aggregation, and 3) soluble HCV-HBc VLPs. Reducing SDS-
PAGE 12 % (w/v) was used to break down the soluble aggregation and soluble VLPs into 
HCV-HBc protein monomer. The percentage (%) of HCV-HBc protein expressed in 
clarified crude lysate was estimated from the gel densitometry. High-performance 
size-exclusion chromatography (HPSEC) was used to quantify the soluble aggregates.  
The soluble HCV-HBc VLP mass (mg) is calculated, following Equation (3-1), 
where X is the percentage of protein monomer obtained from SDS-PAGE gel densitometry, 
Y is the percentage of soluble aggregates obtained from HPSEC and Z is the total soluble 
protein mass of clarified crude lysate. 
 
Soluble HCV-HBC VLP mass (mg) = [X (%) – Y (%)] × Z (mg) (Eq. 3-1) 
 
The calculated soluble HCV-HBc VLP mass (mg) is converted to volumetric yield 
(mg L-1) of culture media and cellular yield of protein (mg g-1 DCW) over biomass (g). 
 
3.2.4 Gel densitometry of SDS-PAGE  
 
For evaluation of monomer HBc-based VLP expression clarified crude lysate from each 
designed expression condition was separated on SDS-PAGE gel (Polyacrylamide 
12 w/v %) using Mini-Protean Handcast System (Bio-rad©, USA). Sample was mixed with 
5X SDS sample-loading at ratio 4:1 (v/v). Samples were heated on heat block at 100 oC for 
20 min to denature the protein sample. Sample was deposited into the gel and was resolved 
at 100 V for 1.5 h at 25 oC in 1X SDS-PAGE running buffer. The gel then was staining 
with Coomassie Blue (Bio-rad©, USA). After de-staining, gel was captured by Syngene  
G-box (Syngene©, USA). The gel densitometry was analysed by Image J software 
(Schneider et al., 2012). VLPs collected from HPSEC peak was detected by reducing  
SDS-PAGE with silver staining using SilverQuest™ Silver Staining Kit (Invitrogen©, 
USA). The staining procedure was followed SilverQuest™ Silver Staining Kit manual. 
The component of sample loading buffer, running buffer, staining solution and  
de-staining solution was summarized in Appendix B. 
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3.2.5 High-performance size-exclusion chromatography (HPSEC) 
 
HPSEC has been used to analyse the ratio between soluble-aggregates and soluble VLPs 
capsid (Yang et al., 2015). The measurement was performed on the Prominence HPLC 
system (Shimadzu, Japan) equipped with TSK-G5000 GWXL (300 × 7.8 mm, I.D., pore size 
100 nm) (Tosoh Bioscience, Germany) with UV monitoring at wavelength 260 nm and 
280, nm. Prior injection, all clarified crude lysate samples were filtered with 0.2 µm 
membrane and 50 µL of the filtered sample was resolved at flowrate 0.3 mL min-1. The 
mobile phase was phosphate buffer (50 mM, pH 7.4) (Chem-supply, Australia). Peak 
integration was analysed by Lab Solution (Shimadzu, Japan).  
 
3.2.6  Transmission electron microscopy 
 
To confirm VLP structure, a 5 µL semi-purified HCV-HBc VLP from HPSEC fraction, 
was applied on the carbon-coated grid and stained with 5 µL 1 w/v % aqueous uranyl 
acetate. Micrographs were recorded by FEI Tecnai G2 Spirit TEM at 100 kV  
(FEI Company, Japan). Images were captured at 100 nm scale. 
 
3.2.7  Expression of HBc carrier protein 
 
To determine whether HCV epitope has influence on the soluble expression of HBc VLP, 
the E. coli transformed with the pET-30a/HBc were cultured in LB media under the optimal 
expression condition of HBc-VLP. The cultivation, expression and analysis procedure are 
followed as is described in section 3.2.3. The volumetric yield and cellular yield of  





3.3.1  Characteristic of HCV-HBc VLP in E. coli 
 
In the preliminary experiment, it was found that HCV-HBc was expressed in the insoluble 
form of inclusion bodies when culture was incubated at conventional condition (37 oC, 
OD600 of 0.8, IPTG of 1 mM and 200 rpm). Therefore, it is essential to optimise the 
fermentation process factors to achieve soluble expression of HCV-HBc. These factors, 
including:  1) post-induction temperature, 2) post-induction rotation speed of the shaker, 3) 
pH level at induction, 4) IPTG concentration, 5) cell density at induction, and; the 6) 
presence of Mg2+, were investigated to determine their effects on the response, cellular 
yield (mg g-1 DCW). The detail of expression condition is listed in Table 3-2. 
To investigate the expression form (protein folding state) either of soluble or insoluble 
protein, SDS-PAGE is applied. Fig. 3-1 presents the HCV-HBc folding state in two 
different expression conditions, namely, experiment (exp.) no. 28 (30 oC, OD600 of 2.0, 
0.2 mM of IPTG and 250 rpm) as Fig. 3-1A and exp. no. 21 (30 oC, OD600 of 0.8,  
0.8 mM of IPTG, and 250 rpm) as Fig. 3-1B. Cell pellet was lysed and cloudy cell lysate 
(Lane 1) was further centrifuged to obtain clarified crude lysate (Lane 2, soluble protein) 
and crude lysate pellet (Lane 3, insoluble). 
In both of the experimental conditions, lane 1 of both of Fig. 3-1A and Fig. 3-1B shows 
an obvious band at 23 kDa, showing that HCV-HBc was expressed successfully by E. coli 
using IPTG inducible expression system. However, the folding state was different. Most of 
the target protein from exp. no. 28 formed inclusion bodies (Lane 3, Fig. 3-1A) comparing 
with the exp. no. 21 where most of the target protein was expressed in the soluble form 
(Lane 2, Fig. 3-1B). This phenomenon suggests that the expression protein folding state is 
significantly influenced by the process factors, particularly cell induction conditions.  
The compositions of clarified crude lysate from experiment no. 21 was further analysed 
by HPSEC using purified HBc-VLP as reference with the retention time of 23.8 min. Fig. 
3-2 demonstrates the chromatogram of clarified crude lysate when resolved by HPSEC. 
The soluble HBc was separated at retention time of 20 min (peak 20), 23.8 min (peak 23.8) 





Fig. 3-1: Expression of HCV-HBc in different conditions. (A)  Experiment no. 28 and (B) 
Experiment no. 21. Both (A) and (B) Lane 1: crude lysate, Lane 2: clarified of crude 
lysate and pellet of crude lysate Lane 3: inclusion bodies. M: marker.  
 
Two (2) peak fractions were analysed by SDS-PAGE and silver staining to confirm 
the size of monomer, which is 23 kDa (Fig. 3-2B). Then TEM was used to confirm the 
spherical structure of HBc-VLP. From TEM images the soluble HBc-VLP aggregates were 
seen in peak 20 (Fig. 3-2C), a mixture of T=4 and T=3 of fully assembled HCV-HBc VLP 
were seen in peak 23.8 (Fig. 3-2D) and T=3 of HCV-HBc VLP were seen in peak 25.5 
(Fig. 3-2E). It is noticed that there was only a few of particles in shoulder peak 25.5, 
suggesting this is a tailing effects from peak 23.8. Moreover, two (2) peaks at retention 
time of 33 and 38 min were mostly impurities from host cells and no HCV-HBc protein 
monomer were detected (data not shown). 
The percentage of soluble aggregates detected by HPSEC was about 0.5 to 3 % of 
soluble HCV-HBc expression. These estimations were achieved from peak integration 
using LabSolution©. 
Noticeably, the complicated composition of clarified crude lysate makes the 
chromatogram (Fig. 3-2A) become poorly resolved. The VLP percentage is not a precise 
value due to peak overlapping. Therefore, it is unable to directly measure the fully 
assembled HCV-HBc VLP from HPSEC. Because there was no HCV-HBc protein 
monomer were detected in other peaks from chromatogram, it is assumed that all the 
soluble monomer can self-assemble into soluble VLPs or soluble aggregates. To consider 
this, the yield of HCV-HBc VLP was determined by SDS-PAGE densitometry minus 
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percentage of soluble aggregates from HPSEC. This method is more accurate than directly 




Fig. 3-2: Characteristic of HCV-HBc VLP using HPSEC; (A) HPSEC chromatogram of 
clarified crude lysate, resolving in TSK-G5000 GWXL at 0.3 mL min
-1; (B) Peak fractions 
of minute 20, and 23.8 were analysed by SDS-PAGE with silver staining, (C) TEM image 
aggregated soluble VLPs in Peak 20; (D) TEM image of a mixture of VLP in Peak 23.8; 
(E) TEM image of a few VLP in shoulder peak 25.5. 
 
3.3.2  Model analysis and diagnostics for soluble HCV-HBc VLP expression 
 
Table 3-2 lists the process factor, their two levels and responses in 32 different expression 
conditions. The response was set as the soluble yield of HCV-HBc VLP per unit biomass, 
also known as cellular yield (mg g-1 DCW) The biomass yield range of soluble expression 
of HCV-HBc VLP is from 0.7 to 1.2 g L-1 DCW, the volumetric yield range of soluble 
HCV-HBc VLP is 33.4 to 91.1 mg L-1, and the cellular yield range of soluble HCV-HBc 
VLP is 32 to 90 mg g-1 DCW.  
55 















































oC rpm  mM OD600 mM g L
-1 mg L-1 mg g-1 
1 30 110 7.2 0.2 0.8 10 0.8 40.2 48.2 
2 30 110 7.2 0.8 0.8 0 0.8 42.3 52.0 
3 40 250 6.2 0.2 0.8 0 1.0 33.4 33.9 
4 30 110 6.2 0.2 2.0 10 1.2 68.4 41.5 
5 40 250 7.2 0.2 2.0 0 1.2 56.1 49.6 
6 40 250 7.2 0.8 0.8 0 1.0 38.4 37.8 
7 40 250 7.2 0.2 0.8 10 1.0 42.7 42.1 
8 30 250 7.2 0.8 0.8 10 1.0 91.1 87.5 
9 30 250 7.2 0.8 2.0 0 1.1 78.1 54.4 
10 40 110 7.2 0.8 0.8 10 0.8 43.9 58.5 
11 30 110 7.2 0.2 2.0 0 1.2 56.3 38.7 
12 40 250 6.2 0.8 2.0 0 1.1 76.7 56.9 
13 40 250 6.2 0.8 0.8 10 1.0 49.8 50.0 
14 30 250 6.2 0.8 2.0 10 1.1 72.2 52.8 
15 30 250 6.2 0.2 0.8 10 1.0 77.1 76.7 
16 40 110 6.2 0.2 2.0 0 1.1 34.4 27.1 
17 30 250 7.2 0.2 0.8 0 1.0 74.4 72.3 
18 40 110 6.2 0.2 0.8 10 0.7 41.6 55.8 
19 30 110 7.2 0.8 2.0 10 1.1 55.7 42.7 
20 40 250 6.2 0.2 2.0 10 1.2 63.1 41.6 
21 30 250 6.2 0.8 0.8 0 0.9 84.4 89.7 
22 40 110 6.2 0.8 2.0 10 1.1 41.2 38.8 
23 40 110 7.2 0.8 2.0 0 1.1 34.0 32.4 
24 30 110 6.2 0.8 0.8 10 0.8 34.5 41.8 
25 40 110 7.2 0.2 0.8 0 0.7 42.7 60.5 
26 30 110 6.2 0.8 2.0 0 1.1 56.0 43.6 
27 30 250 6.2 0.2 2.0 0 1.1 76.4 49.2 
28 30 250 7.2 0.2 2.0 10 1.1 77.5 53.9 
29 40 250 7.2 0.8 2.0 10 1.1 75.9 53.6 
30 40 110 7.2 0.2 2.0 10 1.0 42.8 42.8 
31 30 110 6.2 0.2 0.8 0 0.9 47.0 54.2 
32 40 110 6.2 0.8 0.8 0 0.7 40.8 55.9 
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Fig. 3-3A shows the half-normal plot, obtained from Design-Expert Software. 
Significant factors and interactions were identified, showing that A (post-induction 
temperature), B (post-induction rotation speed of the shaker) , D (IPTG concentration), E 
(optical cell density at induction OD600), AB (post-induction of temperature - rotation speed 
of the shaker), AE (post-induction of temperature – cell density at induction), ABE (post-
induction of temperature - rotation speed of the shaker - cell density at induction), and ACD 
(post-induction temperature-pH-cell density at induction) are significant model terms as 
their effects were shown as outliers from fiftieth percentile line (red line). The terms, C 
(pH), AC (post-induction temperature – pH), AD (post-induction temperature – IPTG), and 
CD (pH-IPTG) were added to maintain the hierarchy. Fig. 3-3B presents the normal 
probability plot of the external studentised residuals to support the reliability of the model, 
demonstrating the errors are normally distributed and not significant. 
 
 
Fig. 3-3: Design analysis and model diagnosis of HCV-HBc VLP; (A) Half-normal plot of 
standardized effect and (B) the normal probability plot of externally studentised residual 
for the model. 
 
Table 3-3 presents the ANOVA results for cellular yield of soluble HCV-HBc VLP 
production. To examine the reliability of the model, ANOVA was computed. The main 
effects and interaction effects of each design factor having P value less than 0.05 are 
considered as potentially significant, and design factor that has value larger than 0.1 is not 
significant. The F value of 28.93 shown the model is significant, with R² = 0.94, and 
importantly reflects the ability of the model to predict experimental outcome in the 
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investigated range. Also, R² = 0.94 implies that 94 % of the variations in the soluble 
production of HCV-HBc can be explained by the model. Moreover, adjusted R² = 0.89 
agrees reasonably with predicted R² = 0.80 and Adequate Precision = 17.51. This finding 
indicates the model is applicable for navigating the design space and prediction of soluble 
expression of HCV-HBc VLP. 
 








F-value p-value  
Model 6028.07 13 463.70 20.05 < 0.0001 Significant 
A-Temperature 819.11 1 819.11 35.41 < 0.0001 Significant 
B-Rotation speed 876.76 1 876.76 37.91 < 0.0001 Significant 
C-pH level 9.57 1 9.57 0.4138 0.5282 Not significant 
D-IPTG 113.63 1 113.63 4.91 0.0398 Significant 
E-Cell density 1216.48 1 1216.48 52.59 < 0.0001 Significant 
AB 1013.63 1 1013.63 43.82 < 0.0001 Significant 
AC 9.14 1 9.14 0.3951 0.5375 Not significant 
AD 0.0153 1 0.0153 0.0007 0.9798 Not significant 
AE 275.54 1 275.54 11.91 0.0028 Significant 
CD 46.80 1 46.80 2.02 0.1720 Not significant 
ABE 1427.12 1 1427.12 61.70 < 0.0001 Significant 
ACD 166.99 1 166.99 7.22 0.0151 Significant 
Residual 416.33 18 23.13    
Cor Total 6444.40 31     
R2 = 0.94; adjusted R2 = 0.89; predicted R2 = 0.80; Adequate precision = 17.51, df: degree of freedom 
 
Equation (3-2) predicts the yield of HCV-HBc VLP (mg g-1) by fitting the 
eperimental data to first order empirical model (Eq. 2-1), where β is estimated from the 
experiment data, and X is the design factor: 
  
Yield HCV-HBc VLP (mg g
-1) = +51.14 –5.06*A +5.23*B +0.5469*C +1.88*D –6.17*E 
 –5.63*AB +0.5344*AC +0.0219*AD +2.93*AE +1.29*BE 
 –1.21*CD +6.68*ABE –2.28 ACD  (Eq. 3-2) 
 
Regarding the HBc VLP, the expression was conducted followed the condition of 
experiment no. 21 in Table 3-2. The volumetric yield and cellular yield of HBc VLP were 
estimated as 184.3 mg L-1 and 137.5 mg g-1.   
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3.3.3  Influence of process factors on HCV-HBc soluble yield 
 
The greatest expression levels were seen at 30 oC, 250 rpm, 0.8 mM of IPTG, induced at 
OD600 of 0.8, regardless of pH level and the presence of Mg
2+ (cellular yield 87.5 mg g-1 in 
experiments no.8 and 89.1 mg g-1 in experiment no.21). In general, low temperature  
(30 oC) and high shaker speed (250 rpm) and induction at early exponential phase were 
beneficial for the soluble production HCV-HBc. 
Fig. 3-4 and Fig. 3-5 present the percentage of soluble HCV-HBc over total HCV-HBc 
expressed and volumetric yield of soluble HCV-HBc VLP in one (1) litre of culture media. 
Overall, the solubility of HCV-HBc VLP was 25 to 70 % in case of early induction  
(OD600 of 0.8) (Fig. 3-4A) and 20 to 35 % when culture induced at higher cell density 
(OD600 of 2.0) (Fig. 3-4B). Significantly under aerobic conditions low expression 
temperature and early induction, Fig. 3-4A presents the solubility of HCV-HBC VLP vary 
from 62 to 75 % and volumetric yield increased by 2.5-fold in comparison to the induction 
at higher cell density as is presented in Fig. 3-5.  
Fig. 3-6 demonstrates the effect of interactions between AB, CD and AE on soluble 
production of HCV-HBc VLP. At early induction and high rotation speed (250 rpm), the 
influence of temperature on soluble yield was significant, the yield when protein expressed 
at 30 oC was 80 mg g-1, 2 - fold in comparison to protein expressed at 40 oC (40 mg g-1).  
Additionally, under early induction with low rotation speed (120 rpm), the effect of 
temperature did not influence the expression much, the yield was recorded at 50 to 60  
mg g-1 (Fig. 3-6A). Further regarding the expression at mid-exponential phase  
(OD600 of 2.0) the temperature effect was similar in both cases of rotation speed of shaker  
(Fig. 3-6B). Although expression at 40 oC decreased the soluble yield. Noticeably, high 
post-induction rotation speed of shaker gave higher soluble yield. 
Fig. 3-6C and Fig. 3-6D present the effects of interaction between IPTG concentration 
and pH level at induction at 30 OC and 40 O. Both IPTG concentration and pH level did not 
significantly influence soluble expression when protein was expressed at 30 oC  
(55 mg g-1). However when the expression was conducted at 40 oC and pH of 6.2 the 
addition of 0.8 mM IPTG gave greater yield than addition of 0.2 mM IPTG (the difference 
was approximately 10 mg g-1).  
Fig. 3-6E and Fig. 3-6F present the effects of interaction between cell density at 
induction and post-induction temperature when induced with IPTG of 0.8 mM and 0.2 mM. 
The yield had a meaningfully small increase when cell culture was induced with IPTG of 
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0.8 mM. The result highlights the importance of post-induction temperatures, post-
induction rotation speed of shaker, IPTG concentration and cell density at induction time. 
The soluble production can be increased if the cell culture was induced at early exponential 
phase (OD600 of 0.8), low expression temperature (30 
oC), IPTG of 0.8 mM and high 




Fig. 3-4: Percentage of soluble HCV-HBc over the total HCV-HBc protein expressed. 









Fig. 3-6: Interactions between AB, CD, AE on the soluble expression on HCV-HBc VLP; 
(A) and (B) is the effects of interaction between A and B at induction cell density OD600 of 
0.8 and 2.0; (C) and (D) is the effects of C and B at induction temperature of 30 oC and 40 
oC; (E) and (F) is the effects of interaction between A and E level with IPTG of 0.2 mM 





HBc is a promising carrier platform because of its flexibility to carry antigen epitope. The 
size of HBc-based VLP even without epitopes, is highly significant to the capacity of  
E. coli, especially when assembled intracellularly. As an effective promoter for expression 
of recombinant protein in E. coli, T7 promoter can boost the expression level of product to 
50 % of total cell protein (Studier and Moffatt, 1986). However, due to overexpression 
from T7, cell will be overflowed with protein that impacts protein folding velocity and 
promotes formation of inclusion bodies (Kesik-Brodacka et al., 2012). To overcome this 
drawback and continue using the T7 promoter, adjusting fermentation parameters is 
essential to achieve higher soluble production.  
In the agreement with the literature review, HBc capsid has two isomorphs with T=3 
(180 subunits) and T=4 (240 subunits), where the theoretical hydrodynamic radius of T=4 
is 17 nm (Crowther et al., 1994). From the TEM images of Fig. 3-2D, the HCV-HBc VLP 
had majority of T=4 capsid with diameter of 34 nm. The reasons of switching the assembly 
structure between particle of 180 subunits and particles of 240 subunits remained unclear. 
It is mentioned that the assembly of E. coli derived HBc VLP is similar to the assembly of 
the core of the wild-type virus, and the different in size is not caused by the interaction 
between the protein and the contents inside the capsid (Crowther et al., 1994). The study 
of Crowther et al., 1994 also hypothesised that the size differences wild-type virus caused 
by the packaging of the complete RNA pre-genome and the viral polymerase. The 
limitation of this characterisation experiment is lack of size distribution of HCV-HBc VLP 
and exact measurement of each capsid types in terms of hydrodynamic diameter and 
molecular weight. To improve the size distribution of VLP, using gel filtration as a 
polishing step will help to achieve a uniform HBc VLP and further analyses using dynamic 
light scattering and multi angle laser light scattering will help to provide a complete 
characterisation of the protein.  
Fractional factorial experimental design approach is a practical tool to 1) gain technical 
insight to boost the soluble production of HCV-HBc and 2) develop empirical equation for 
the prediction. It is feasible to manipulate the process factors to improve the solubility of 
expression in a systematic way as proved in this study. The statistical analysis such as 
ANOVA and residual plot are useful to validate the reliability of the experimental model. 
The order of significant process factors was as following: 1) cell density at induction,  
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2) post-induction rotation speed of shaker, 3) post-induction temperature and 4) their 
interaction.  
Although the statistical approach successfully extracted significant information from 
the experiments, because there were only two (2) levels, the significance of factors 
identified in this design are not sufficiently extensive to explain the mechanisms involved 
(Uhoraningoga et al., 2018). Following the identification of the significant parameters, 
further experiments need to be conducted with fewer factors and more levels. This resulting 
response surface model will better aid optimisation. Some potential mechanisms why these 
process factors are important to soluble expression of HCV-HBc are proposed. 
The first major factor is the cell density at induction. Before induction, cells consumed 
nutrients to produce more host cell protein (HCP) to support the cell proliferation, in which 
dissolved oxygen rate and temperature mainly controlled the growth rate. However, when 
IPTG was added, cells shifted from expression of HCP to expression of foreign 
recombinant protein, which later caused metabolic burden to the host cells, either nutrient 
or energy. Fig. 3-4A and Fig. 3-4B show that the solubility of HCV-HBc VLP expression 
was dependent on the cell density at induction, the lower cell density at induction was, the 
greater solubility of the expression was. Also, the volumetric yield enhanced from 41.2 to 
91.1 mg L-1 (culture media) when shifting the induction to low cell density. Therefore, cell 
density at induction and inducer concentration are linked together in terms of dose 
dependent. 
The rotation speed of the shaker is a dominating factor in the expression of soluble 
HCV-HBc VLP. The cell population at late induction (OD600 at 2.0) was greater than those 
at early induction (OD600 at 0.8) so the needs of oxygen was also greater. Low rotation 
speed (120 rpm) did not provide enough oxygen to the culture. Limited oxygen level had a 
negative impact, suggesting that oxygen limitation induced stress on the culture. The results 
and explanation highlight the importance of oxygen level in bacterial growth and soluble 
protein expression, it also indicates the limitation of shake-flask cultivation (Losen et al., 
2004), such as low oxygen transfer rate and poor heat transfer. It is found that E. coli shifts 
its own metabolic pathway, switching between aerobic growth and anaerobic growth, 
depending on the level of oxygen in the culture. This behaviour consequently affects the 
tricarboxylic acid cycle (TCA) and expresses multiple genes to adapt to the availability of 
oxygen (von Wulffen et al., 2016). In aerobic conditions E. coli uses oxygen as the terminal 
electron acceptor, oxidizing pyruvate via the TCA cycle to produce adenosine triphosphate 
(ATP). ATP not only provides energy for protein translation (Konz et al., 1998), it is also 
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reported to be involved in virus-like particle assembly in case of Human immunodeficiency 
virus type 1 (HIV-1) VLP (Tritel and Resh, 2001). It is used by heat shock protein, Hsp70, 
in the presence of co-chaperones to stabilize native protein folding (Xu, 2018). Because 
oxygen is limited E. coli uses inorganic compounds as electron receptors instead of using 
oxygen. This altered electron transport chain leads to a decrease in ATP production in cells 
(Shalel-Levanon et al., 2005).  
In this research even though induction at 30 oC favoured the expression of the soluble 
virus-like particle, the biomass achieved was less than those induction at 37 oC. Higher 
temperatures can achieve higher biomass but potentially increasing the inclusion body 
formation. It is reported aggregation reaction is temperature-dependent because it is related 
to hydrophobic interaction (van Dijk et al., 2015). The solubility of HCV-HBc expression 
enhanced approximately 2.5-fold when culture was cultivated at 30 oC instead of 40 oC. In 
particular, when induced at pH 6.2 and 0.2 mM of IPTG, volumetric yield increased from 
33.4 to 77.1 mg L-1, and volumetric yield increased from 38.4 to 91.1 mg L-1 when induced 
at pH 7.2 and 0.8 mM of IPTG (Fig. 3-4A). These observations align with the argument, 
highlighting the importance of temperature during expression.  
In conventional induction, 1 mM of IPTG is required for induction. In this study 
 0.2 mM of IPTG was sufficient to express HCV-HBc VLP. It agrees with Muhlmann et al. 
(2017) that low IPTG concentrations (0.05 – 0.1 mM) are beneficial for the soluble 
expression. The pH level was adjusted with K2HPO4 2M and KH2PO4 0.5M. Media 
supplemented with MgCl2 is reported to prevent ribosome degradation (Nierhaus, 2014). 
However, DoE did not show that Mg2+ concentration was a significant factor. To adjust to 
desired pH, the amount of K2HPO4 used at the time induction was estimated at about 
80 - 100 mM, and KH2PO4 was about 5 - 10 mM. Fig 3-6D indicates there was an 
interaction between IPTG concentration and K+ ion on the soluble expression of HCV- 
HBc in shake-flask fermentation but the effect of this interaction was not significant as is 
listed in Table 3-3.  
Because the theoretical structure of HCV epitope in use is α-helices, protein synthesis 
and protein folding are more complicated. This necessitates the slow folding rate to ensure 
the native folding. The requirement of a high rotation speed (250 rpm) and low temperature 
(30 oC) following induction for soluble expression of HBc-based VLP is partially explained 
by these arguments. Protein expression rate, protein folding, and biomass are 
interconnected by post-induction process factors.  
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In comparison to HBc VLP, both volumetric yield and cellular yield of HBc-VLP were 
greater than HCV-HBc VLP under same optimal condition (experiment no. 21 in  
Table 3-2), indicating that the insertion of epitope has significant influence on the soluble 
expression of HBc in E. coli. However, how a particular structure, i.e., α-helix, influences 
on the formation of HBc VLP remains unknown. It is reported in the study of Vogel et al., 
2005 that the interaction between the insert epitope and core protein is potentially lead to 
misfolding of the protein monomer. Although the study focused on the insertion at MIR, it 
had suggested some possible reasons behind this phenomenon. A complicated and bulky, 
such as HCV epitope, may prevent the central helices of the HBc protein fold into 
juxtaposition. Moreover, Vogel et al., 2005 mentioned that the constraints from 1) the 
spatial proximity of the insertion site, and 2) the display of high-density of foreign epitope 
on the capsid surface, leading to the change in capsid stability, are also significant factors. 
Therefore, epitope that has unstable structure and bulky will significantly affect the capsid 
assembly, eventually decreasing the soluble expression of HBc VLP.  
It is clear that statistical approach extrapolates more information from experimental 
responses, compared with the one-variable-at-time approach. A boost of 4.8-fold in 
volumetric soluble yield is the evidence of the applicability of statistical approach to 
recombinant protein expression. 
This novel approach should be applied for other recombinant protein bioprocessing 
because of its predication on underlying interaction between process factors. An advantage 
of this approach is that the design of experiment is formed based on the aims of the study, 





3.5 Chapter summary and conclusions 
 
Based on experimental results and analyses in this chapter, the following important factors 
emerge: 
 
1. A HCV vaccine candidate has been produced in E. coli. It was found that HCV-HBc 
VLP tends to be expressed as inclusion bodies. The collected peak fraction in clarified 
crude lysate from chromatography at a retention time of 23.8 min has been examined 
by TEM to reveal that HCV-HBc protein folds into correct VLP spherical structure. 
 
2. In comparison to HBc VLP without carrying foreign epitope, HCV-HBc VLP 
expressed less soluble yield. It is hypothesised that HCV epitope has influence the 
HBc VLP formation, potentially increasing the protein misfolding. 
 
3. FFD is an effective statistical tool to investigate process factors that impact the 
expression of recombinant protein. This approach is novel because it has been used for 
other recombinant protein but not for HBc platform. Analyses show that the greatest 
yield of HCV-HBc has been recorded at 89.7 mg g-1 DCW. The influence of process 
factors could be ranked as: 1) cell density at induction, 2) post-induction rotation speed 
of shaker, and 3) post-induction temperature.  
 
4.  These new findings provide the design space to improve soluble production of HBc 
VLP in microbial system. 
 
Despite its advance, the novel statistical approach developed in this chapter has some 
drawbacks, namely, the expression and analysis heavily rely on equipment performance, 
especially limitations in shake-flask cultivation. Additionally, design of experiment does 
not explain the mechanisms involved. 
In the next chapter, Chapter 4, a novel statistical approach for boosting the soluble 
production of HBc VLP carrying simple structure epitope EBNA1 is developed. After 
recognizing the limitation in the experiment design and analytical methods in Chapter 3, 
the design of experiment for EBNA1-HBc starts with fractional factorial design for 
screening of factors, then optimising using response surface methodology in which, instead 
of evaluating from densitometry of SDS-PAGE, native agarose gel electrophoresis is an 
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A critical review of soluble intracellular E. coli-derived recombinant protein and 
application of statistical approach have been presented in Chapter 2. In addition, fractional 
factorial design has been applied to boost the soluble expression of HCV-HBc as is 
presented in Chapter 3, to show that it is a useful tool to optimise process factors. Moreover, 
it was found that HCV-HBc is easy to aggregate in both soluble and insoluble form. 
In this chapter, EBNA1-HBc is developed as vaccine candidate against Epstein-Barr 
virus infection and statistical approach is applied for the first time to increase the soluble 
yield of HBc VLP carrying non-structural epitope EBNA1. EBNA1 has a role in 
suppressing reactivation in latent infection and involve in lytic gene expression and DNA 
amplification in lytic infection (Sivachandran et al., 2012). 
To boost the soluble production of target protein and overcome the limitation in 
experiment design and analytical method in Chapter 3, alternative analytical methods and 
design of experiment are developed. After recognising that two (level) for each factor in 
fractional factorial design (FFD) does not include the curvature for continuous factor, the 
statistical approach used in this chapter includes FFD and response surface model (RSM). 
First, the process factors are screened using fractional factorial design (FFD). Three (3) of 
the process factors that have significant impacts on the soluble expression of EBNA1-HBc 
are identified and then their levels are optimised using RSM. The optimal combination is 
achieved from point prediction feature from RSM cultivations at the optimal condition are 
conducted to validate the optimal point. 
In addition, analytical method was further development, taking the advantages from 
HBc-VLP size, native agarose gel electrophoresis (NAGE) is an effective method to 
separate HBc-capsid out of cell lysate (Yoon et al., 2012). The fully assembled HBc VLP 
and soluble aggregates can be quantified using gel densitometry from NAGE. It is also 
noticed that thermal stability of chimeric HBc-VLP enables the possibility to use heat 
precipitation to remove host cell protein (HCP) as initial step of protein separation (Ng et 
al., 2006; Li et al., 2018). This pre-treatment step provides high-quality sample molecular 
characterisation by for High-performance Size-exclusion chromatography (HPSEC) 
(Yang et al., 2015).  
It is hoped that insight gained from this chapter might demonstrate the advance of 
statistical approach in sequential order from FFD to RSM to boost the soluble production 
of EBNA1-HBc in E. coli. These findings could thereby benefit the high-throughput 
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fermentation process factor screening and later on to apply for the scale-up in recombinant 
protein bioprocessing.  
 
4.2  Material and methods 
 
4.2.1 Expression strain 
 
The epitope used this chapter is different from the epitope used in Chapter 3. The epitope 
of EBNA1 (EBNA1: HPVGEADYFEY) was inserted at N-terminus of HBc  
(HBc: 183 amino acid) to form EBNA1-HBc. The plasmid pET-30a (+) (Invitrogen ®, 
USA) was used to form pET-30a (+)/HCV-HBc, carrying the gene of EBNA1-HBc protein 
under control of T7 promoter with lac operon. 
Via heat-shock transformation the plasmid was transformed into E. coli by using One 
Shot™ BL21 (DE3) chemically competent E. coli (Invitrogen©, USA). Cells were cultured 
on Luria Bertani (LB) agar plate. Cells were stored at minus 20 oC as the working cell.  
All reagents were analytical grade (AR) unless otherwise stated. 
 
4.2.2  Fractional factorial design for factor screening 
 
Preliminary experimental design was used to point out the significant variables that affected 
the soluble production of EBNA1-HBc VLP. To obtain main effects of process factor and 
two-factor interaction, a resolution V of fractional factorial design (FFD) was prepared by 
Design-Expert software (version 11, Stat-Ease©, Minnesota, USA) (Wu and Hamada, 
2009). The design included 32 expression condition, made up from six (6) design factors 
with two (2) designated levels as low (-1) and high (+1) level. 
Table 4-1 shows a fractional factorial design that was used to boost the soluble 
expression of EBNA1-HBc. The six (6) factors included (A) post-induction temperature 
(30 oC and 40 oC), (B) dissolved oxygen rate in terms of post-induction rotation speed of 
the shaker (110 and 250 rpm), (C) pH of the culture at induction point (6.2 and 7.2), (D) 
IPTG concentration (0.05 and 0.5 mM) (Invitrogen©, USA), (E) optical cell density at 
induction point (OD600 of 0.8 and 2.0), and (F) the presence of Mg
2+ (0 and 10 mM). The 
pH of the culture was adjusted with K2HPO4 2M (Chem-supply, Australia) and KH2PO4 
0.5M (Chem-supply, Australia). 
The main response was set as the cellular yield of soluble VLP per dry cell weight 
(mg g-1), in relation to the biomass per litre of culture media (g L-1) and the volumetric yield 
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of target protein per litre of culture media (mg L-1). Data analysis was performed by Design-
Expert. The response was kept as normal (no transformation required by the Box-Cox 
method) (Box and Cox, 1964). The significance of each factor was determined by the half-
normal probability plot and computed with the analysis of variance (ANOVA) as featured 
in Design-Expert. 
 
4.2.3  Response surface model for factor optimisation 
 
Response surface model (RSM) was used to improve the soluble production of EBNA1-
HBc in E. coli. To investigate three independent factors with five levels, a 23 factorial 
central composite rotary design (CCD) was used. Table 4-2 presents the experimental 
matrix, which includes 20 experiments and six (6) of them are centre points. The 
experimental matrix was created by Design-Expert software.  
Variables and their levels were chosen followed the screening experiment results. They 
are (A*) post-induction dissolved oxygen rate in relation to rotation speed of the shaker 
(170, 190, 220, 250, and 270 rpm), (B*) post-induction temperature (28, 30, 33, 36, and 38 
oC), and (C*) the optical density of cell population at induction of OD600 (0.6, 0.8, 1.1, 1.4, 
and 1.6). The response of the RSM matrix was set as the cellular yield, which is described 
as the amount of soluble HBc VLP per dry cell weight (mg g-1). 
The IPTG concentration is fixed at 0.5 mM for every experiment. Design-Expert 
software features point optimisation, which was employed to optimise the level of each 
factors for maximum response. The combination of optimised parameters was 
experimentally tested to validate the model accuracy in triplicate (n=3). 
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Table 4-1: Fractional factorial design matrix for factor screening of soluble expression of 
EBNA1-HBc VLP. 
 















(-1): 30 (-1): 120 (-1): 6.2 (-1): 0.05 (-1): 0.8 (-1): 0 
(+1): 40 (+1): 250 (+1): 7.2 (+1): 0.5 (+1): 2.0 (+1): 10 
oC rpm  mM OD600 mM 
1 30 110 6.2 0.5 2.0 0 
2 30 250 6.2 0.05 2.0 0 
3 30 250 6.2 0.05 0.8 10 
4 40 110 7.2 0.05 0.8 0 
5 30 250 7.2 0.5 0.8 10 
6 40 110 7.2 0.5 0.8 10 
7 40 250 7.2 0.05 0.8 10 
8 40 110 7.2 0.5 2.0 0 
9 30 250 7.2 0.5 2.0 0 
10 40 250 6.2 0.05 0.8 0 
11 30 110 7.2 0.5 2.0 10 
12 40 250 7.2 0.05 2.0 0 
13 40 110 6.2 0.5 2.0 10 
14 40 250 6.2 0.5 2.0 0 
15 40 110 6.2 0.5 0.8 0 
16 40 250 7.2 0.5 2.0 10 
17 40 110 6.2 0.05 2.0 0 
18 40 250 6.2 0.5 0.8 10 
19 30 250 7.2 0.05 0.8 0 
20 30 250 6.2 0.5 2.0 10 
21 40 110 7.2 0.05 2.0 10 
22 30 110 7.2 0.5 0.8 0 
23 30 110 6.2 0.05 2.0 10 
24 30 110 6.2 0.5 0.8 10 
25 30 110 6.2 0.05 0.8 0 
26 30 110 7.2 0.05 2.0 0 
27 40 250 6.2 0.05 2.0 10 
28 30 250 7.2 0.05 2.0 10 
29 30 250 6.2 0.5 0.8 0 
30 40 250 7.2 0.5 0.8 0 
31 40 110 6.2 0.05 0.8 10 
32 30 110 7.2 0.05 0.8 10 
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Table 4-2: Response surface model – central composite design for factor optimisation of 
soluble expression of EBNA1-HBc VLP. 
 







Cell density at induction 
(-1.68): 170 









 (-1.68): 0.6 




rpm oC OD600 
1 -1 -1 1 
2 0 0 0 
3 1 -1 -1 
4 -1 -1 -1 
5 1 1 -1 
6 0 0 -1.68 
7 -1 1 -1 
8 0 0 0 
9 0 0 0 
10 0 1.68 0 
11 1 -1 1 
12 0 0 0 
13 0 0 0 
14 0 0 1.68 
15 -1.68 0 0 
16 1 1 1 
17 -1 1 1 
18 1.68 0 0 
19 0 -1.68 0 
20 0 0 0 
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4.2.4  Expression of EBNA1-HBc VLP 
 
The E. coli transformed with the recombinant plasmids were cultured in 50 mL of sterilized 
LB media (10 g L-1 tryptone (Oxoid, USA), 5 g L-1 yeast extract (Oxoid, USA), 10g L-1 
NaCl (Chem-supply, Australia), supplemented with 50 µg mL-1 kanamycin sulfate 
(Invitrogen©, USA), at 37 oC and 200 rpm (round per minute) for 16 h.  
The overnight culture was added into 200 mL of fresh sterilized LB media volume 
with 50 µg mL-1 kanamycin sulfate, in the 500-mL flask, at a ratio of 1 v/v % 
(seeding/culture volume), then was cultivated at 37 oC and 200 rpm. Optical cell density 
(OD600) was measured by UV-1600PC Spectrometer (VWR International©, USA) at 
wavelength 600 nm. 
In terms of factor screening, the expression of EBNA1-HBc was conducted following 
FFD matrix, as is shown in Table 4-1. Experiments were conducted in randomised sequence 
to avoid bias. The MgCl2 (Chem-supply, Australia) was supplied to the culture at the 
beginning of the cultivation according to the FFD. When the cell density reached the 
designated value of OD600, the fermentation process factors were adjusted to specific 
experiment number in Table 4-1. K2HPO4 2 M (Chem-supply, Australia) and KH2PO4  
0.5 M (Chem-supply, Australia) were used to adjust the pH of the culture at induction. 
IPTG (Invitrogen©, USA) was added to the culture to express the EBNA1-HBc. 
Temperature and rotation speed of the shaker were also adjusted. The expression was 
continued for the next six (6) h. 
In terms of factor optimisation, the expression of EBNA1-HBc was followed RSM 
matrix. Experiments were performed in randomised sequence to avoid bias. When the cell 
density reached the designated value of OD600, the temperature and rotation speed of shaker 
were adjusted to specific experiment number in Table 4-2. IPTG of 0.5 mM was supplied 
to the culture to begin expression. 
The final cell density (OD600) was measured to determine the final biomass 
concentration. It is established that one (1) litre of culture media at OD600 of 1.0 equals to 
0.4 g of dry cell weight (DCW). Cells were harvested by centrifugation (3700 rpm, 20 oC, 
30 min) and were washed with deionized water. The cell pellet was stored at minus 20 oC 
for further analyses.  
Cells were suspended in lysis buffer and were disruption as is described in section 
3.2.3. The supernatant fraction was identified as clarified crude lysate.  
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Protein concentration was determined by Bradford assay (Bradford, 1976), using 
bovine serum albumin (Sigma-Aldrich, USA) as protein standard.  
 
4.2.5 NAGE and SDS-PAGE  
 
Native agarose gel electrophoresis was used to separate small and large capsid of HBc-
based VLP (Yoon et al., 2012), which was used to evaluate the soluble expression level of 
EBNA1-HBc VLP for both preliminary and optimisation study. 
Samples were mixed with NAGE-loading buffer at ratio 4:1 (v/v) and incubated at  
25 oC for 20 min before running. A 1 w/v % agarose (Sigma-Aldrich, USA) was prepared 
in 1X TAE buffer (Thermo Fisher Scientific, USA). Agarose gel was run with Owl™ 
EasyCast™ B2 Mini Gel Electrophoresis Systems (Bio-rad©, USA). Wells were loaded 
with 45 to 50 µg of clarified crude lysate of each condition. Ferritin nano-particle 
(approximately 500 kDa) with designated mass from 15 to 55 µg, was used as the marker. 
Protein was resolved at 80 V for 6 h at 4 oC in 1X TAE buffer. The procedure for staining, 
de-staining, gel image capture and densitometry analysis was followed the procedure of 
SDS-PAGE. 
SDS-PAGE (Polyacrylamide 12 w/v %) was used to determine the purity of EBNA1-
HBc in protein sample. The procedure for sample preparation, electrophoresis, staining, 
de-staining, gel image capture and densitometry analysis are described in section 3.2.4. In 
terms of determination of VLP in HPSEC collected peak, 12 w/v % reducing SDS-PAGE 
with silver staining was conducted using SilverQuest™ Silver Staining Kit (Invitrogen©, 
USA). 
The component of TAE buffer, NAGE-loading buffer, SDS- loading buffer, SDS-
running buffer, staining buffer and staining buffer was listed in Appendix B. 
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4.2.6 Host cell protein removal by heat precipitation 
 
To avoid the complicated nature of clarified crude lysate, removal of impurities, i.e. 
unstable thermal host cell protein, is essential. Similar to study of Li et al. (2018), the 
clarified crude lysate was heated on heat block for 30 min at 40, 50, 60, 65, 70, and 75, oC, 
respectively. The treated lysate was cool down to the 25 oC and centrifuged (12000 rpm, 
10 oC, 30 min). The purity (%) and recovery yield (%) of EBNA1-HBc are determined as 
Equation (4-1) and Equation (4-2), respectively. 
 
Purity (%) = 
The amount of EBNA1−HBC in sample 
The amount of total protein in sample
 ×  100 %  (Eq. 4-1) 
 
Recovery yield (%) =  
The amount of EBNA1−HBC in supernantant after heat treatment 
The amount of EBNA1−HBc in clarified crude lysate
 × 100 %
 (Eq. 4-2) 
4.2.7  High-performance size-exclusion chromatography  
 
HPSEC has been used to quantify HBc-based VLP particles (Yang et al., 2015). HPSEC 
was performed on the Prominence HPLC system (Shimadzu, Japan), equipped with TSK-
G5000 GWXL (300 × 7.8 mm, I.D., pore size 100 nm), (Tosoh Bioscience, Germany) and 
column-guard, with UV monitoring at wavelength 260 nm and 280 nm. 
Purified EBNA HBc-VLPs with known concentration was injected into HPSEC to 
develop a calibration curve. For each measurement, 50 µL of heat-treated clarified crude 
lysate was resolved at flowrate 0.5 mL min-1, the mobile phase was phosphate buffer (50 
mM, pH 7.4) (Chem-supply, Australia). Peak integration was analysed by LabSolution© 
(Shimadzu, Japan). Protein fractions were analysed by SDS-PAGE and silver-staining. 
HBc-based VLP was quantified by comparing the peak area between standard curves and 






4.3.1  Quantification of EBNA-HBc particles by NAGE 
 
Conventionally, the expression level of target protein is determined by SDS-PAGE. 
Sodium dodecyl sulfate breaks not only the fully assembled capsid but also soluble 
aggregates into monomer. Native agarose gel electrophoresis can separate the VLP capsid 
and soluble aggregates out of the impurities in the clarified crude lysate based on the size 
and overall charge of the particles without compromising the structure. 
Fig. 4-1 demonstrates the quantification of EBNA1-HBc VLP using NAGE. Fig. 4-1A 
presents the position of ferritin as reference and EBNA1-HBc capsid is fractionated by 
NAGE, according to the position of VLP standard. In this study, ferritin was used as 





Fig. 4-1: Quantification of HBc-VLP by NAGE; (A) Lane 1, 2, and 3 are ferritin with 
known mass. Lane 4 is purified HBc-VLP standard. Lane 5 6 7 are clarified crude lysate 
with known protein mass on 0.8 % (w/v) native agarose gel; (B) The calibration curve 
between band intensity and ferritin mass. 
 
It is feasible to plot the intensity of ferritin versus their loading mass as a standard 
curve, as is presented in Fig. 4-1B. The mass of VLP of each condition was quantified to 
determine the expression level based on their densitometry. For example, the EBNA1-HBc 
VLP band’s intensity in lane 5, lane 6 and lane 7 correspond with 21.3 µg, 17.7 µg and 13.8 
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µg of EBNA1-HBc VLP in clarified crude lysate, respectively. All the quantification of 
EBNA1-HBc VLP in clarified crude lysate for screening experiment and optimisation 
experiment is determined using NAGE. 
 
4.3.2 Factor screening by fractional factorial design 
 
The focus of the preliminary experiment is to narrow down the number of significant 
process factors that influence the soluble production of EBNA1-HBc. Table 4-3 
summarizes the fractional factorial design matrix, including six (6) factors, to determine 
the the yield of product per unit biomass, also known as, cellular yield (mg g-1 DCW), 
which was set as response 3. 
The response was experimentally estimated based on the densitometry from NAGE, 
as is summarised in Table 4-3, the range of cellular yield of soluble EBNA1-HBc VLP 
varies from 42 to 163 mg g-1 DCW. The greatest yield is 163 mg g-1 DCW, which is 
achieved at 30 oC, 250 rpm, pH 6.2, induced at OD600 of 0.8 with 0.5 mM of IPTG without 
Mg2+ (experiment no. 29). 
It is noticed that cultivation induced at OD600 of 2.0 produces a less soluble yield of 
EBNA1-HBc VLP (experiment no. 20), in comparison to culture induced at OD600 of 0.8 
(experiment no. 29). 
Fig. 4-2A presents the half-normal plot, which indicated the significant process factors 
and two-factor interaction (2FI). They are listed as A (Post-induction temperature), B (post-
induction rotation speed of shaker), C (pH), E (cell density at induction), AB (post-
induction temperature – rotation speed of shaker), BD (post-induction rotation speed of 
shaker and cell density at induction), CD (pH and IPTG concentration). Their p-values, 
which were achieved from the analysis of variance (ANOVA), were less than 0.05. Factor 
D (IPTG concentration) was added into the model to support the hierarchy. To validate the 
reliability of the model, Fig. 4-2B presents the normal probability plot of the external 
studentised residuals showing the error were normally distributed and insignificant. 
The value of R² = 0.74 demonstrated how the equation fits the dataset, implying that 
74 % of the variations in the soluble production of EBNA1-HBc can be explained by the 
model. The Adjusted R² = 0.65 is in reasonable agreement with Predicted R² = 0.50, less 
than 0.2 difference, and the Adequate Precision = 9.45. This finding indicates the model is 
applicable for navigating the design space.  
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 oC rpm  mM OD600 mM g L
-1 mg L-1 mg g-1 
1 30 110 6.2 0.5 2.0 0 1.0 97.2 97.7 
2 30 250 6.2 0.05 2.0 0 1.3 149.9 111.4 
3 30 250 6.2 0.05 0.8 10 1.1 127.3 113.2 
4 40 110 7.2 0.05 0.8 0 0.7 42.2 58.9 
5 30 250 7.2 0.5 0.8 10 1.1 96.6 85.9 
6 40 110 7.2 0.5 0.8 10 0.6 42.1 65.3 
7 40 250 7.2 0.05 0.8 10 1.0 136.9 135.6 
8 40 110 7.2 0.5 2.0 0 1.0 61.1 60.7 
9 30 250 7.2 0.5 2.0 0 1.5 102.5 68.3 
10 40 250 6.2 0.05 0.8 0 1.1 175.4 154.3 
11 30 110 7.2 0.5 2.0 10 1.0 84.7 79.1 
12 40 250 7.2 0.05 2.0 0 1.2 149.1 118.8 
13 40 110 6.2 0.5 2.0 10 1.0 62.7 58.1 
14 40 250 6.2 0.5 2.0 0 1.2 149.0 124.2 
15 40 110 6.2 0.5 0.8 0 0.7 62.3 92.6 
16 40 250 7.2 0.5 2.0 10 1.3 112.2 88.6 
17 40 110 6.2 0.05 2.0 0 1.2 48.3 42 
18 40 250 6.2 0.5 0.8 10 0.9 98.9 111.5 
19 30 250 7.2 0.05 0.8 0 1.1 142.9 129.8 
20 30 250 6.2 0.5 2.0 10 1.4 194.9 137.5 
21 40 110 7.2 0.05 2.0 10 1.0 47.5 47.1 
22 30 110 7.2 0.5 0.8 0 0.8 100.8 125.4 
23 30 110 6.2 0.05 2.0 10 1.0 52.3 52.3 
24 30 110 6.2 0.5 0.8 10 0.7 109.8 149.2 
25 30 110 6.2 0.05 0.8 0 0.7 61.1 84.3 
26 30 110 7.2 0.05 2.0 0 1.0 104.0 104.0 
27 40 250 6.2 0.05 2.0 10 1.2 128.0 104.3 
28 30 250 7.2 0.05 2.0 10 1.4 168.0 117.3 
29 30 250 6.2 0.5 0.8 0 1.1 179.7 163.4 
30 40 250 7.2 0.5 0.8 0 0.9 58.1 61.7 
31 40 110 6.2 0.05 0.8 10 0.8 74.4 94.9 




Fig. 4-2: Fractional factorial design analysis and model diagnosis for soluble production of 
EBNA1-HBc VLP; (A) The half-normal plot of standardized effect and (B) the normal (%) 
probability plot of externally studentised residual for the model. 
 
Equation (4-3) predicts the yield of EBNA1-HBc VLP (mg g-1) in preliminary study 
by fitting the experiment data to first-order polynomial equation (Eq. 2-1), where β is 
estimated from the experiment data, and X is the design factors: 
 
Yield EBNA1-HBc (mg g
-1) = +97.95 -9.30*A +15.53*B -7.14*C -0.5073*D -9.96*E 
 +8.18*AB –9.09*BD -10.94*CD (Eq. 4-3) 
 
Fig. 4-3 summaries the interaction between AB, BD, and CD, even though IPTG by 
itself is not a significant factor, the interaction between IPTG concentration with pH, and 
the interaction between IPTG concentration with rotation speed influence the final yield.  
With the addition of IPTG 0.05 mM, there was a huge boost in yield (70 mg g-1 to  
120 mg g-1) when shaker speed was set at 120 and 250 rpm, meanwhile, with IPTG 0.5 
mM, the difference in yield between two shaker speed was not significant. Regarding pH 
level at induction, the difference in yield when the culture was induced with IPTG 0.05 
mM was not significant in both pH 6.2 or pH 7.2, however, there was a remarkable negative 
impact in yield when the induction was conducted at pH 7.2 with IPTG of 0.5 mM, in 




Fig. 4-3: The interaction of process parameter on soluble production of EBNA1-HBc VLP; 
(A) the effect of shaker speed and temperature; (B) the effect of shaker speed and IPTG 
concentration; (C) the effect of IPTG concentration and pH level at induction;  
(+1) means high level and (-1) means low level in coded value. 
 
The influence of post-induction temperature was not significant when the level of  
post-induction shaker speed was high (250 rpm) but in case of low post-induction shaker 
speed (120 rpm), high temperature (40 oC) had a negative impact on the yield. Moreover, 
the negative sign of term E (cell density at induction) in Eq. 4-3 indicated there was a 
negative effect when culture was induced at mid-exponential phase (OD600 of 2.0).  
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4.3.3 Optimisation by response surface methodology 
 
The outcome of the preliminary study revealed the significant factors that affecting the 
soluble production of EBNA1-HBC VLP. They included: 1) post induction shaker speed, 
2) post-induction temperature and 3) cell density at induction. Soluble production of 
recombinant protein includes many biological pathways to support the cell viability and 
expression of foreign protein. Response surface model – central composite design  
(RSM-CCD) was applied for this complicated process. The design matrix included 20 
experiments that consists of 8 cubic points, 6 axial points and 6 central points.  
Table 4-4 presents the design of experiment for optimisation purpose where the 
response were set as the cellular yield of soluble EBNA1-HBc VLP (mg g-1 DCW ) and A*, 
B*, C* were coded terms for the 3 variables, the post induction shaker speed, the post-
induction temperature, and cell density at induction, respectively. The response was 
experimentally estimated based on the densitometry from NAGE.  
Table 4-5 presents the ANOVA results of the quadratic model of soluble production 
of EBNA1-HBc. To evaluate whether a coefficient is significant or not, P value is 
determined. With a P < 0.05, the model terms are evaluated as significant. Particularly, all 
the linear terms A* and C*, the interaction of A*B* (post-induction temperature and shaker 
speed) and quadratic terms A*2, B*2, and C*2 (higher order of process factors) have 
significant effects on the soluble production of the VLP. Factor B* was not a significant 
factor but was added to the model to support the hierarchy.  
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Table 4-4: Response surface model – central composite design matrix for optimisation of 










Actual value Actual value Predicted value 
Exp. 
no.  














rpm oC OD600 g L-1 mg L-1 mg g-1 mg g-1 
1 190 30 1.4 1.06 113.5 106.8 115.7 
2 220 33 1.1 0.95 193.5 203.6 207.2 
3 250 30 0.8 1.05 168.3 160.8 172.2 
4 190 30 0.8 1.03 115.9 112.2 100.3 
5 250 36 0.8 1.52 236.4 155.5 151.7 
6 220 33 0.6 1.32 203.5 154.2 155.4 
7 190 36 0.8 1.24 154.9 125.2 127.0 
8 220 33 1.1 0.73 147.7 202.3 207.2 
9 220 33 1.1 0.97 205.7 212.0 207.2 
10 220 38 1.1 1.70 244.7 143.9 147.1 
11 250 30 1.4 1.30 250.5 192.7 187.7 
12 220 33 1.1 0.93 185.8 199.8 207.2 
13 220 33 1.1 1.13 244.7 216.5 207.2 
14 220 33 1.6 1.30 236.0 181.7 181.4 
15 170 33 1.1 1.39 121.3 87.5 93.6 
16 250 36 1.4 1.75 283.0 161.6 167.2 
17 190 36 1.4 1.28 193.7 151.9 142.4 
18 270 33 1.1 1.30 234.0 180.0 174.9 
19 220 28 1.1 1.53 221.3 144.2 141.9 
20 220 33 1.1 0.93 192.7 208.4 207.2 
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F-value p-value  
Model 26410.93 7 3772.99 56.1 < 0.0001 Significant 
A (Rotation speed, rpm) 7977.2 1 7977.2 118.62 < 0.0001 Significant 
B (Temperature, oC) 32.9 1 32.9 0.4892 0.4976 Not significant 
C (Induction point, OD600) 815.76 1 815.76 12.13 0.0045 Significant 
AB 1116.28 1 1116.28 16.6 0.0015 Significant 
A² 9590.94 1 9590.94 142.62 < 0.0001 Significant 
B² 7074.33 1 7074.33 105.2 < 0.0001 Significant 
C² 2707.25 1 2707.25 40.26 < 0.0001 Significant 
Residual 807 12 67.25    
Lack of Fit 596.12 7 85.16 2.02 0.2283 Not significant 
R2 = 0.97; adjusted R2 = 0.95; predicted R2 = 0.91; Adequate precision = 21.91; df: degree of freedom  
 
From ANOVA analysis, the fit statistics provided the good fit of the selected model 
where R2 = 0.97 and adjusted R2 = 0.95. With the difference less than 0.2, the predicted  
R2 = 0.913 is in reasonable agreement with the adjusted R2. Adequate precision was 
calculated to measure the signal to noise ratio, with the value of 21.90, the signal is larger 
than 4, showing the signal is adequate for predictive purpose (Myers et al., 2016). With  
R2 = 0.97, the empirical model can explain 97 % of the variation in the soluble expression 
of EBNA-HBc in shake-flask fermentation. 
ANOVA analysis calculated the F-value of model is 56.10 and F-value of Lack of Fit 
is 2.02, implied that the model is significant and the lack of fit is not significant relative to 
the pure error. These calculated statistic figures shown that the model predicts the mean 
value well. 
As a major tool for evaluating the adequacy of the adopted model, Fig. 4-4 illustrates 
the normal probability plot of the external studentised residuals, demonstrating the errors 
are normally distributed and insignificant. 
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Fig. 4-4: Normal (%) probability plot of externally studentised residuals for the soluble 
production of EBNA1-HBc VLP in RSM model. 
 
In coded forms, Equation 4-4 presents the empirical model that illustrated the 
response created the following regression equation (Eq. 2-2), where the positive and 
negative effects of the variables on the response are presented as plus (+) and (-) symbols. 
Eq. 4-4 was used to calculate the predicted value as is presented in Table 4-4. 
 
Yield EBNA1-HBc (mg g
-1) = +207.17 +24.17*(A*) +1.55*(B*) +7.73*(C*) -11.8*(A*B*) 
-25.80*(A*²) - 22.16*(B*²) -13.71*(C*²) (Eq. 4-4) 
 
As is presented in Table 4-4, after conducting various combinations of fermentation 
process parameters, the cellular yield of EBNA1-HBc VLP increases from 87.5 to 217.0 
mg g-1. The lowest yield (87.5 mg g-1) was recorded at experiment 15, in this case, post-
induction rotation speed was 170 rpm, post-induction temperature was 33 oC and the cell 
density at induction point (OD600) was 1.1, suggesting that insufficient dissolved oxygen 
level after induction has negative impact on the soluble production of EBNA1-HBc VLP.  
The highest yield, 217.0 mg g-1, was observed at one of the central points, the 
expression condition includes post-induction rotation speed at 230 rpm, post-induction 
temperature at 33 oC and the cell density at OD600 of 1.1. The central point data yielded a 
good agreement between six replicated, from 199.8.4 to 217.0 mg g-1, showing that in 
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shake-flask fermentation, 1) EBNA1-HBc VLP favours the soluble production at 33 oC and 
2) the increase of oxygen level by increasing the rotation speed after induction is necessary.  
Moreover, from the empirical model, there is a good agreement between the predicted 
and actual values for EBNA1-HBc-VLP yield, showing the model is reliable to predict the 
soluble yield of EBNA1-HBc in shake-flask fermentation. 
There is a negative sign of A*B* model term in Equation 4-4, it is assumed there is a 
negative effect of the interaction between those process factors. Fig. 4-5 presents the 
contour plot of EBNA1-HBc VLP soluble production at three (3) different induction points 
(0.8, 1.1 and 1.4 of OD600). The soluble production of HBc VLP increases as the post-
induction temperature rises until reaching their central point. For post-induction rotation 
speed of shaker, the production reaches its peak at point of 0.5 (235 rpm). Induction at early 
exponential phase (OD600 of 0.8) had lower soluble yield, from 120 to 191 mg g
-1. Cultures 




Fig. 4-5: Contour plots of the impact of two-factor interaction on the soluble production of 
EBNA1-HBc at three different induction points; (A) at coded value of minus 1, OD600 of 
0.8; (B) at the central point (0), OD600 of 1.1; and (C) at coded value of 1, OD600 of 1.4. 
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4.3.4 Point optimisation feature and experimental validation 
 
The potential direction for maximizing soluble production of EBNA1-HBc VLP was 
evaluated by Design-Expert software package. By using “point optimisation” technique, 
the optimal expression condition was obtained.  
Fig. 4-6 illustrates contour of the desirability and soluble yield of EBNA1-HBc VLP. 
The mean value is predicted at 214.1 mg g-1 when culture is induced at the cell density at 
OD600 of 1.2, post-induction rotation speed of the shaker of 235 rpm, 0.5 mM of IPTG, and 
post-induction temperature at 33 oC. 
The predicted value is given in the range of 201.5 to 226.6 mg g-1. To validate the 
accuracy of the model, experiments were conducted in triplicate (n=3) using the optimal 
combination of factors. The soluble production was recorded at the mean value of 210.5 
mg g-1, and volumetric yield of 272 mg L-1, showing there is a good agreement between 




Fig. 4-6: Point optimisation achieved from RSM. The contour plot of (A) the desirability 
and (B) the soluble yield of EBNA1-HBc at optimal prediction point where A*=0.490 (235 
rpm), B*= -0.096 (33OC) and C*=0.281 (OD600 of 1.2) and IPTG of 0.5 mM.  
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4.3.5 Quantification of HBc-based VLP using heat precipitation & HPSEC 
 
Heat precipitation is a relatively cheap and simple method to extract the HBc-capsid out of 
the clarified crude lysate.  
The study of Ng et al. (2006) provides the range of temperature treatment that would 
not affect the structure of HBc-VLP. Fig. 4-7 presents the results of host cell protein 
removal by thermal treatment, including the purity of the EBNA1-HBc after treatment  
(Fig. 4-7A), and the recovery percentage of EBNA1-HBc before and after heat treatment 
(Fig. 4-7B) from SDS-PAGE result (Fig. 4-7C). The purity and recovery percentage of 
EBNA1-HBc were calculated based on Eq. 4-1 and Eq. 4-2, respectively. 
As is shown in Fig. 4-7A, the purity of VLP after treatment increased from 23 % to 
65.5 % as the sample was treated at 40 oC and 70 oC. There was no significant difference 




Fig. 4-7: Host cell protein removal by thermal treatment at different temperature, 
particularly, 40, 50, 60, 65, 70, and 75, oC; (A) the purity of VLP in the clarified crude 
lysate after heat treated; (B) recovery percentage of HBc-VLP before and after heat 
treatment; (C) SDS-PAGE result of heated samples. 
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The EBNA1-HBc recovery percentage varied from 97.4 % to 83.1 % as the samples 
were heat-treated from 40 to 75 oC. At 40, 50, 60, and 65, oC, the recovery rates were higher 
than 95 %. When treated at 70 oC, the recovery rate was 91.5 %, as is presented in  
Fig. 4-7B. However, the recovery percentage decreased to 83.1 % when sample was treated 
at 75 oC. Based on the recovery percentage and purity, results pointed out the most effective 
temperature was 70 oC. 
Fig. 4-8 presents the quantification of VLP when treated by heat using the NAGE and 
HPSEC. Fig. 4-8A shows the densitometry of VLP after gel separation, the intensity of lane 
4 (heat treated samples at 70 oC) is approximately equal to the intensity of lane 1 (clarified 
crude lysate). Moreover, lanes of heated sample have better resolution, these lanes have 
less noise from protein than lane 1.  
Preliminary results from HPSEC shown the retention time of purified soluble EBNA1-
HBc by TSK-5000 GWXL at flow rate 0.5 mL min
-1 is 15 min. Fig. 4-8B illustrates the 
difference between the chromatograms of before and after heat-treated at 70 oC at 
wavelength 280 nm. Both of them were resolved in TSK-5000 GWXL at elution rate of 0.5 
mL min-1. The peak at 15 min before and after heat treatment were similar, demonstrating 
the HBc-VLP was reserved after thermal treatment. The composition of heat-treated sample 
was further investigated by collecting the peak fractions of different retention time (minute 
of 13, 15, 21, 23, and 24). The collected fractions were analysed by SDS-PAGE with silver 
staining, as is presented in Fig. 4-8C. From SDS-PAGE, EBNA1-HBc capsid were located 
at the retention time of 15 min. This evidence supported the result of HPSEC in Fig. 4-8B.  
Fig. 4-8D presents the chromatogram of sample treated at 70 oC at two (2) wavelengths 
(260nm and 280nm). At the retention time of 15 min, the ratio of wavelength 260nm 
intensity over wavelength 280nm intensity (260/280 nm) is 1.7, showing there was a 
complex formation of protein and nuclear acid (Glasel, 1995). Sominskaya et al., 2013 
reported that during self-assembly process of HBc capsid, encapsulation of host cell nucleic 
acid occurs simultaneously. To confirm the structure of EBNA1-HBc VLP in peak 15, 
TEM image was captured, as is shown in Fig. 4-8E, there was a mixture of T=4 and T=3 
VLP with diameter of 34 and 32 nm.  
At the retention time of 21 min of treated lysate, the ratios of 260/280 nm are larger 
than 2.0, showing the components of this peak mostly was nuclear acid. The shoulder peak 
at 22.5 of treated lysate suggested that there were small size impurities, in agreement to the 
result of SDS-PAGE, as is shown in Lane 6, Fig. 4-7C. It is noticed that there was a shift 
of peak 22.5 of clarified crude lysate to peak 21 after treatment by heat. This shifting is 
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predicted to be caused by the aggregation of host cell protein when heated. Although 
clarification by centrifugation has removed most of the insoluble precipitate, there 
remained some of small soluble aggregates of host cell protein at peak 21 of treated lysate. 
The applicability of heat precipitation coupled with HPSEC could provide an 
alternative approach to quantify HBc VLP in crude lysate. To confirm the accuracy of this 
approach, peak area of different purified HBc-VLP masses was measured to develop the 
calibration curve in Fig. 4-8F. The mass of EBNA1-HBc VLP from clarified crude lysate 




Fig. 4-8: Quantification of EBNA1-HBc VLP using heat precipitation and HPSEC; (A) the 
quantity of HBc-VLP in lysate before and after treated at 60, 65, and 70, oC, by NAGE; (B) 
the chromatograms of clarified crude lysate before and after heat treated at 70 oC, resolving 
in TSK-5000 GWXL at elution rate of 0.5 mL min
-1; (C) SDS-PAGE with silver staining of 
the collected fractions at different retention time (minute of 13, 15, 21, 23, and 24) of 70 
oC treated lysate, resolved by SEC; (D) the chromatogram of clarified crude lysate after 
treated at 70 oC; (E) the TEM image of soluble EBNA1-HBc VLP in peak 15; (F) the 
calibration curve of standard HBc-VLP. 
 
As there was interference from nuclear acid, the mass quantified by HPSEC was higher 
than the mass quantified by NAGE. Fig. 4-9 illustrates the difference in VLP mass 
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quantified by two (2) methods from the set of 20 experiments in RSM-CCD. The 
experiment data were fitted in linear trend to generate a linear equation with R2 = 0.84. This 
correlation could support the development of this analytical method to quantify the amount 




Fig. 4-9: The correlation of VLP mass quantified by NAGE and HPSEC from 20 
experiments in RSM-CCD design. 
 
In addition, Table 4-6 demonstrates the advantages and disadvantages of both methods. 
Importantly, NAGE requires an internal protein marker for every gel. This marker can be 
HBc-VLP itself or protein in appropriate size, such as ferritin, so they will not be flush out 
of the agarose gel. The limit of detection of NAGE also a constraint of this methods. The 
sample collected during fermentation and volume of lysis buffer should be considered to 
match the limit of detection of NAGE. On the contrary, HPSEC can detect small quantity 
of VLP in small culture media sample, enabling an approach to monitor the expression and 
assembly of VLP during cell culture process. If the drawback in nucleic acid contamination 









1 Sample preparation Not required 
Heat treatment improves resolution 
Heat treatment is required to 
improve the integrity of the 
column 
2 Standard curves Internal calibration curve is required 
for every analysis 
Standard curve is developed only 
once. 
3 Number of samples 
per analysis 
Standard gel has 10 wells 
• 4 wells for internal makers 
• 6 wells for samples 
One sample of a time 
4 Process types Manual Automatic system  
5 Process time Seven (7) h per gel, including: 
• Running gel 
• Staining and de-staining 





Manual by densitometry software Peak integration in built-in 
software  
7 Limit of detection 5 µg to 70 µg per well Depends on the standard curves 






The demand of producing large quantity of soluble and native folding of recombinant 
protein is high in pharmaceutical industry. Since the study of Clark et al. (1987),  
HBc platform has been intensively studied to be used as epitope carrier, presenting the 
antigen from different pathogen and diseases (Roose et al., 2013).  
Using E. coli as expression system brings many benefits to the production process, 
however, the low-level of soluble expression of target product remains as challenge. 
Without optimised operation condition, recombinant protein has tendency to express in 
inclusion bodies. HBc-based VLP carrying EBNA1 had been successfully expressed in  
E. coli in this study. Based on the results, shake-flask fermentation and design of 
experiment provide the means to determine the effects of the investigated process 
parameters and their interaction on the soluble production of EBNA1-HBc VLP. 
Noticeably, the effects of the interaction between post-induction shaker speed and 
post-induction temperature in both screening and optimisation experiment is consistent. In 
case of oxygen limitation (shaker speed of 120 rpm), the influence of temperature shows 
its significant impact on soluble yield of HBc-VLP (65 mg g-1 at 40 oC and 100 mg g-1 at 
30 oC); low temperature expression increased the soluble production (Fig. 4-3A). It is 
reasonable since soluble expression of recombinant protein in E. coli favoured low 
temperature (less than 37 oC), taking the advantages from the lower specific growth rate, 
the increase in chaperone expression and activity (Ferrer et al., 2003), and lower protein 
synthesis and folding rate. When the oxygen level was increased (shaker speed in range of 
190 to 250 rpm), induction at OD600 of 0.8, the influence of temperature has minimal effect 
on soluble yield (160 to 180 mg g-1) as can be seen in Fig. 4-5A.  
The result from Fig. 4-3C suggests that IPTG and pH level has strong interaction on 
the soluble expression. At low dose of inducer, IPTG of 0.05 mM, the yield of soluble 
expression at pH 7.2 is higher than the expression at pH 6.2. IPTG of 0.05 mM is enough 
to induce the expression of EBNA-HBc-VLP in E. coli, but in terms of high cell density 
culture in bioreactors, the level of IPTG should be proportional to higher cell level. This is 
the reason why IPTG of 0.5 mM was chosen for later optimisation. Cells induced with 
IPTG of 0.5 mM favoured the expression at pH 6.2, suggesting that acidic environment 
was beneficial to soluble expression of HBc-VLP. 
The interaction between post-induction rotation speed of shaker and IPTG 
concentration highlights the demand of oxygen availability when E. coli express the foreign 
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protein. In E. coli, most of the major chaperone systems use the cycles of ATP binding and 
hydrolysis to stabilize non-native proteins, unfold misfolded proteins and provide the 
optimal condition for protein folding (Saibil, 2013). The level of ATP production was 
depended on the intracellular oxygen level. Moreover, oxygen also has influence of the 
gene expression by affecting the oxidative status of many enzyme (Knoz et al., 2008). Even 
with small dose of inducer (0.05 mM of IPTG), E. coli was able to produce a good yield of 
soluble EBNA1-HBc VLP when expressed at 250 rpm. It could be explained by the 
influence of strong promoter, T7 RNA polymerase (Studier and Moffatt, 1986). 
Table 4-7 summaries the yield obtained from different approach, namely: 1) before 
optimisation, 2) fractional factorial design, 3) RSM before point optimisation and  
4) RSM after point optimisation. By using “point optimisation” from Design Expert 
software, the soluble expression yield has increased 2-fold in volumetric yield and 1.7-fold 
in specific yield. Although fraction factorial design only improved the specific yield (mg 
g-1 DCW) by 1.3 x times, it is suitable to investigate both categorical variables (strain and 
plasmid) and continuous variables (temperature, inducer concentration, etc.). Meanwhile, 
RSM is more suitable for continuous variables.  
Comparing the soluble yields of WT HBc and EBNA1-HBc under the same cultivation 
condition suggests that the insertion of non-structural epitope to N-terminus of HBc protein 
did not affect the soluble production of chimeric HBc-based VLP. However, this hypothesis 
needs to be confirmed with major immunogenic region and C-terminus. 
In comparison to study of Yap et al, 2009, truncated HBc-based VLP carrying His-tag 
and β-galactosidase at N-terminal, was expressed in different temperature, 27, 30, and 37, 
oC. The yield from their study was reported at 70 – 75 mg L-1 with the solubility is greater 
than 90 % when culture was induced at 0.6-0.8 of OD600 with 0.5 mM IPTG for 
 16-18 h at 30 oC. These process parameters were similar to our operational process factor 
range, suggesting early induction and low temperature has beneficial impact on the soluble 
production of HBc-VLP. EBNA1-HBc VLP volumetric yield (bulk production) after point 
optimisation was approximately 4 x times, compared to Yap et al, 2009. 
In addition, the thermal stability of EBNA1-HBc was noticed during analysis. The 
quantification of EBNA1-HBc VLP in crude lysate using heat precipitation and HPSEC 
was conducted. The results highlight the efficiency of thermal treatment when clarified 
crude lysate containing HBc-VLP was heated at 70 oC to remove host cell protein as is 
presented in Fig. 4-7. This method prevents the chance of column blocking and provides a 
clean feed into the HPSEC system.  
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Table 4-7: The comparison in soluble yields of EBNA1-HBc-VLP in different steps. 
 
Methods Vol. yield Yield Expression condition 
 mg L-1 mg g-1 Temp oC/RPM/OD600/IPTG mM 
Before optimisation 154.9 125.2 36/190/0.8/0.5 
Fractional factorial 179.7 163.4 30/250/0.8/0.5 – Exp. no. 29 Table 4-3 
RSM before P.O(a) 147.7 - 244.7 199.8 - 216.5 33/220/1.1/0.5 – Centre points 
RSM after P.O 272.0 210.5 33/235/1.2/0.5 
a P.O: Point optimisation features from RSM in Design-Expert 
 
Within the same sample, the mass of VLP quantified by HPSEC was greater than those 
quantified by NAGE, which can be explained by the interference of nucleic acid in HPSEC 
measurement. This interference can be explained by the encapsulation of host cell nucleic 
acid when full-length HBc protein is used (Sominskaya et al., 2013). In particular,  
C-terminal of full-length HBc contains arginine-rich domain (Porterfield et al., 2010). 
Moreover, according to Li et al., 2018 study, when the clarified crude lysate is heated at  
70 oC, there is a chance that the pore of HBc capsid has been expanded, entrapping host 
cell nucleic acid and protein inside the capsid. 
To overcome this drawback, DNAse I was used to minimise nucleic acid 
contamination (data not shown), but EBNA1-HBc became unstable immediately, 
suggesting the interactions between protein-nucleic acid contributed to capsid stability 
(Birnbaum and Nassal, 1990). A further investigation to remove nucleic acid and stabilize 
DNA-free targeting protein after removal of nucleic acid is critical in future research. Some 
purification approaches have been suggested by Li et al., 2018 and Zhang et al., 2021, 
including 1) using two-step heat treatment followed by hydrophobic interaction 
chromatography and 2) using ammonium sulfate precipitation to recover HBc VLP, 
followed by the disassembly-purification-reassembly process to obtain nucleic acid free 
HBc particles. 
In addition, it is found that EBNA1-HBc VLP in clarified crude lysate can stand the 
temperature of 70 oC for 30 min but for purified EBNA1-HBc in 20 mM Tris-HCl buffer 
at pH 7.4. This phenomenon shows that component of lysis buffer has impacts on the 
thermal stability of EBNA1-HBc because it contains Triton X-100. It is reported by 
Alqueres et al. (2011) that Triton X-100 enhances the thermostability of target protein. 
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There are some limits of the current study, including the lack of media optimisation, 
and the disadvantages of RSM. First, LB media does not contain carbon source, growth and 
protein expression utilise mostly on nitrogen source. A media screening before cultivation 
in fermenter is essential. Second, even though RSM shows the effect of these investigated 
process parameters on the soluble production of EBNA1-HBc VLP but it only tells what 
happened, not the mechanism behind these observations. Knowing what happen is a key to 
further research to explain the underlying cause. 
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4.5 Chapter summary and conclusions 
 
Based on experimental results and discussion of this chapter, the following important 
factors emerge: 
 
1. An EBV vaccine candidate has been produced in E. coli. NAGE is an effective means 
to quantify EBNA1-HBc VLP from clarified crude lysate.  
 
2. Six (6) process factors were investigated in two level fractional factorial design (FFD). 
The significant process factors screened from FFD, including post-induction 
temperature, post-induction rotation speed of shaker and cell density at induction, were 
optimised using response surface methodology – central composite design. After 
conducting 20 experiments and confirmed “point prediction” optimisation, the greatest 
yield of EBNA1-HBc was 210.5 mg g-1 DCW at 33 oC, 235 rpm, OD600 of 1.2, and 
IPTG of 0.5 mM. 
 
3. It was found that thermal stability of EBNA1-HBc is suitable for the removal of host 
cell protein by heat precipitation. With the applicability of thermal treatment, size 
exclusion chromatography is able to quantify the amount of EBNA1-HBc VLP in 
clarified crude lysate. These new findings provide research direction to use HPSEC in 
high throughput screening to meet the demand for industrial production.  
 
It is evident from this chapter that the expression folding state and productivity of 
EBNA1-HBc can be improved by optimisation of fermentation process factors. The 
sequential order of using FFD and RSM provides a mean to boost the production of  
HBc-based VLP in E. coli. 
In the next chapter, Chapter 5, a media screening is performed and the optimal 
combination of process factors operated in laboratory-scale fermenter will be presented to 
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A review of batch and fed-batch cultivation for soluble intracellular E. coli-derived 
recombinant protein and feeding strategy has been presented in Chapter 2. Regarding 
EBNA1-HBc, the productivity has been optimised using fractional factorial design and 
response surface methodology as outlined in Chapter 4. The optimal combination of post-
induction process factors for shake-flask cultivation is 235 rpm, 33 oC, and OD600 of 1.2 
with 0.5 mM of IPTG. 
Luria-Bertani broth (LB) is a common peptide media in which E. coli can grow to high 
cell density of up to OD600 of 7 (Sezonov et al., 2007). The presence of yeast extract not 
only provides a nitrogenous source for building block synthesis in cell, but also reduces 
acetic acid secretion during bacterial growth (Tripathi et al., 2009). Because of the 
applicability of fermenter, cells are cultivated under a well-controlled condition, it is 
feasible to reach to high cell density culture (HCDC) (OD600 > 20). Therefore LB media is 
not suitable for HCDC. Finding an alternative media is crucial for fermenter scale 
cultivation. Additionally, cultivation time is a vital factor in HCDC because of plasmid loss 
(Nugent et al., 1983). Consequently, the cultivation loses the capability to produce 
recombine protein. Moreover, the extended culture period of batch culture leads to nutrient 
limitation, in which cells inhibit the synthesis of products but promote the production of 
protease, an enzyme that catalyses proteolysis (Rozkov and Enfors, 2004). It is 
hypothesized that when the culture reaches to high cell density, the limitation in nutrient or 
accumulation of by-products disrupts protein production (Eiteman and Altman, 2006).  
It was also found that the cell density at induction point has significant impact on 
soluble production of EBNA1-HBc in shake-flask fermentation in Chapter 4. However, 
because of the significant differences in cell density between shake-flask and fermenter-
scale, the influence of cell density in fermenter should be further investigated. In addition 
the feeding strategies proved to have significant impact on the production of recombinant 
protein (de Andrade et al., 2018). It is essential to determine these impacts on the soluble 
production of EBNA1-HBc. 
The aim of Chapter 5 is to gain quantitative insight into batch and fed-batch cultivation. 
The following investigation are included: 1) the optimal combination of post-induction 
fermentation process factors achieved from Chapter 4 was applied to different culture 
media before scaling-up to a 14-L fermenter; 2) in laboratory-bench scale fermenter, batch 
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cultivations at different induction points were conducted; and 3) two (2) fed-batch 
cultivations with DO-stat feeding and constant feeding were operated. 
A justification is that this provides the technical insights to improve soluble production 
of E. coli-derived HBc VLP. With promising results, it will be practical to boost production 
of recombinant protein in general and HBc VLP in particular by optimisation of process 
factors. This approach increases the chance of the vaccine candidate reaching pilot-scale 
production (100 L) and further commercialisation. 
 
5.2 Material and methods 
 
5.2.1  Expression strain 
 
The expression strain that was used in this study was the same strain used in the 
optimisation of shake-flask fermentation in Chapter 4. Briefly, the recombinant E. coli 
BL21 (DE3) (Invitrogen©, USA) harbouring an IPTG inducible pET30a (+)/EBNA1-HBc 
plasmid is used for the expression of a 23 kDa EBNA1-HBc VLP. 
All reagents were analytical grade (AR) unless otherwise stated. 
 
5.2.2  Media screening 
 
E. coli transformed with the recombinant plasmids from glycerol stock was cultured in 50 
mL of sterilized LB media, containing tryptone (Oxoid, USA), yeast extract (Oxoid, USA), 
and NaCl (Chem-supply, Australia) with the composition listed in Table 1. The media were 
supplemented with 50 µg mL-1 kanamycin sulfate (Invitrogen©, USA), at 37 oC and 
200 rpm (round per minute) for 16 h. Four (4) different media were prepared according to  
Table 5-1, including LB, TB, SB and 2xYT.  
The overnight culture was added into 200 mL of different fresh sterilized media with 
50 µg mL-1 kanamycin sulfate, in a 500-mL flask, at a ratio of 1 v/v % (seeding/culture 
volume), and cultivated at 37 oC and 200 rpm. Cell density of the culture (OD600) was 
measured offline using UV-1600PC Spectrometer (VWR International©, USA). When the 
cell density reached OD600 of 1.2, the expression condition was adjusted to 32 
oC and  
230 rpm, and IPTG (Invitrogen ®, USA) added to a final concentration of 0.5 mM. The 
expression was continued for the next six (6) or nine (9) h. The cell culture samples were 
centrifuged at 12000 rpm, 20 oC, 10 min, washed with deionized water then stored at minus 
20 oC.  
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Table 5-1: Media composition for screening experiment. 
 
Media 
Ingredient and concentration 
Tryptone Yeast extract NaCl K2HPO4 KH2PO4 Glycerol 
g L-1 g L-1 g L-1 mM mM g L-1 
TB - Terrific Broth 12 24 - 72 17 5 
SB - Super Broth 30 20 5 - - - 
LB - Luria-Bertani 10 5 10 - - - 
2YT - 2x yeast extract 
& tryptone 
16 10 5 - - - 
 
5.2.3 Batch cultivations 
 
To determine the impact of induction point in batch fermentation, five (5) L of Terrific 
Broth media was used with the composition as is listed in Table 5-1. Yeast extract, tryptone 
and glycerol (Chem-supply, Australia) were dissolved and sterilised at 121 oC for 50 min. 
K2HPO4 and KH2PO4 (Chem-supply, Australia) were sterilised separately from the other 
three (3) component at 121 oC for 50 min. Following cooling to 37 oC, all of the media 
component was transferred to the 14-L fermenter and was supplemented with kanamycin 
sulfate at the final concentration of 50 µg mL-1 plus 0.01 % (v/v) of Antifoam 204 (Sigma-
Aldrich, USA). The inoculum was prepared as described in section 5.2.2, i.e. seeding from 
the glycerol stock to 50 mL culture then 200 mL culture. When the optical density of 200 
mL culture reached the OD600 of 4.5 to 5.0. The culture was used to inoculate five (5) L of 
sterilized TB media in stainless steel dished-bottom of 14-L water-jacketed vessel (57.4 cm 
height x 29.3 cm outer diameter) with BioFlo© 320 bioprocess control station (New 
Brunswick Scientific Co., Inc., NBS). To avoid evaporation on the head plate of the 
fermenter, an air-outlet condenser was used. For mixing and air dispersion, two six-bladed 
(2.11 cm height x 8.43 cm outer diameter) Rushton type impellers, stirred by top-mounted 
motor, were used.  
All the cultures were conducted in biphasic of temperature, 37 oC for growth phase and 
32 oC for induction phase. The electrode of pH and Dissolved Oxygen (DO) sensor (Mettler 
Toledo, USA) were used to monitor the pH and DO level of the culture. To maintain pH of 
6.8, liquid ammonia NH4OH 7 M (Chem-supply, Australia) and phosphoric acid H3PO4  
4 M (Chem-supply, Australia) were added. Instrument grade compressed air was filtered 
with 0.2 µm Polytetrafluoroethylene (PTFE) membrane (Pall Corporation, USA), and was 
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sparged into the fermenter below the impeller using an L-type sparger. The dissolved 
oxygen level was maintained at 30 % by adjusting the agitation speed (300 to 800 rpm) and 
aeration rate (0.2 to 1 VVM – the volume of air per volume of liquid per minute) in cascade 
mode. The initial optical density of the fermenter culture was kept at 0.15 to 0.2 of OD600 
to ensure consistency between cultivations. During cultivation parameters including optical 
cell density, temperature, pH, dissolved oxygen level, aeration, and agitation were 
observed. 
EBNA1-HBc expression was induced by IPTG of 0.5 mM at three (3) different cell 
densities, OD600 of 5, 10 and 20. The post-induction temperature was changed from 37 to 
32 oC. Samples for protein expression analyses were harvested 30 min before induction and 
for every 1 h for the next 6 h post-induction. Optical cell density of each sample was 
measured to determine dry cell weight using spectrometer. The cell culture samples were 
centrifuged at 12000 rpm, 20 oC, 10 min, washed with deionized water then stored at  
minus 20 oC.  
 
5.2.4 Fed-batch cultivations 
 
Initially cultures were conducted in batch mode. The procedure is described in  
section 5.2.3. Before switching to fed-batch, dissolved oxygen was used as an indicator for 
the depletion of carbon source. A pulse rises in DO value indicated the depletion of carbon 
source and feeding is initiated. The supplementary media contained 400 g L-1 glycerol,  
120 g L-1 tryptone and 240 g L-1 yeast extract, was sterilized at 121 oC for 20 min before 
adding kanamycin sulfate. Two (2) feeding strategies, namely, constant volume feeding 
(non-feedback control) and DO-stat feeding (feedback control), were employed.  
To achieve comparable results, the feed amount should be equal between two (2) 
feeding methods, DO-stat based feeding strategy was conducted first. With DO-stat 
feeding, the agitation speed was increased gradually from 400 to 700 rpm then fixed at 700 
rpm. The aeration was set at 0.5 VVM throughout the cultivation. After the pulse rose in 
DO value, every time the DO value increased over 50 %, a dose of 2 to 3 mL of 
supplementary media was injected to maintain the DO value at 30 %. The mass of the 
feeding bottle was weighted every 30 min using an electronic weighing balance to 
determine the amount of feeding solution added to the culture. 
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With constant feeding, the DO was maintained at 30 % by cascade mode of agitation 
speed (300 to 800 rpm) and aeration rate (0.2 to 1 VVM). The feed rate (mL min-1) was 
calculated based on the amount of feed used in DO-stat and 6 h post-induction time.  
Cultures were induced with IPTG at final concentration of 0.5 mM at OD600 of 20, then 
continued for six (6) h at 32 oC. During induction phase, samples of 25 mL culture media 
were collected every 1 h for protein analysis. Samples were centrifuged 12000 rpm, 20 oC, 
10 min, washed with deionized water then the cell pellet was stored at minus 20 oC.  
 
5.2.5 Cell disruption and protein concentration assay 
 
Ultra-sonication was used to extract the intracellular protein. Cell disruption was followed 
as is described in section 3.2.3. Protein concentration was determined by Bradford assay 
(Bradford, 1976). Bovine serum albumin (Sigma-Aldrich, USA) was used protein standard. 
All measurements of protein concentration were performed in duplicate. 
 
5.2.6 NAGE and SDS-PAGE 
 
Native agarose gel electrophoresis was used to separate capsid of HBc-based VLP from 
crude lysate. The detail procedure is followed as is described in section 4.2.5. The purity 
of HBc-based VLP were estimated on SDS-PAGE gel (Polyacrylamide 12 w/v %). A 
detailed SDS-PAGE procedure has been also mentioned in section 3.2.4. The component 
of TAE buffer, NAGE-loading buffer, SDS- loading buffer, SDS-PAGE running buffer, 
staining buffer and staining buffer was listed in Appendix B. 
 
5.2.7 Protein purification by ammonium sulphate precipitation 
 
The clarified crude lysate was precipitated with solid NH4(SO4)2 (Chem-supply, Australia) 
at the final concentration of 1 M at 25 oC for 30 min. The protein precipitate was collected 
using centrifugation (9000 rpm, 20 oC, 15 min) and the supernatant was discarded. Protein 
pellet was solubilised in buffer containing 20 mM Glycine-NaOH (Chem-supply, 
Australia), 4 M Urea (Chem-supply, Australia) and pH 9.0 for 12 h at 4 oC. The solution 
containing the target protein was dialyzed against 20 mM Tris-HCl buffer at pH 7.4 for 




5.2.8 Transmission electron microscopy  
 
To confirm VLP structure of purified EBNA1-HBc after dialysis, purified EBNA1-HBc 
was diluted in 20 mM Tris-HCl, pH 7.4 to the concentration of 0.3 mg mL-1. The carbon-
Formvar coated copper grids was glow discharged for 15 s using Solarus Plasma Cleaning 
System (Gatan, Inc). 5 μl of protein sample at concentration was deposited on the grid for 
2 min and touched dry by blotting paper. The grid was negatively stained with 5 μl of 2 % 
(v/v) uranyl acetate aqueous solution for 2 min then blotted dry. The grids were examined 
using Fei Tecnai G2 Spirit TEM (FEI™, Japan), followed the instructions of Adelaide 




5.3.1  Media screening for EBNA1-HBc VLP production 
 
After obtained the optimal combination of process parameters from response surface model 
in previous chapter, two (2) post-induction time and four (4) different media compositions, 
as is listed in Table 5-1, were screened to boost the soluble expression of EBNA1-HBc 
VLP in shake-flask cultivation. Fig. 5-1 presents the soluble production of target protein in 
four (4) media between two (2) post-induction time in terms of growth curve, volumetric 
yield and cellular yield. 
Fig. 5-1A demonstrates the growth curves of E. coli in LB, TB, SB and 2YT. The final 
cell density achieved in LB media was the lowest (OD600 of 3.4 for 6 h and OD600 of 4.5 
for 9 h). Meanwhile other media were able to support E. coli culture to higher final cell 
density, particularly, in TB, OD600 of 4.5 and OD600 of 6.3; and in SB, OD600 of 4.5 and 
OD600 of 6.7, regarding the post-induction period of 6 h and 9 h, respectively.  
Fig. 5-1B presents the estimation of EBNA1-HBc VLP in clarified crude lysate. 
Ferritin nanoparticle (approximately 500 kDa) with designated mass was used as internal 
maker as is shown in lane 1 to lane 4. Moreover, the amount of EBNA1-HBc after 6 h and 
after 9 h expression is shown in lane 5 to 8 and Lane 9 to 12, respectively. The sequential 
order from left to right is yield in LB, TB, SB and 2YT. The EBNA1-HBc VLP were 
separated from soluble aggregates and impurities. 
Fig. 5-1C demonstrates the volumetric yield of soluble protein by different culture 
media at 6 h and 9 h post-induction time. Yield achieved from LB media was the lowest 
(250 mg L-1 and 276 mg L-1 of culture media), in comparison with those achieved from 
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other media. For the expression of 6 h, TB, SB and 2YT obtained a similar volumetric yield 
in range of 365 to 375 mg L-1, however, in case of expression of 9 h, the volumetric yield 
acquired from 2YT media decreased from 375 to 304 mg L-1 and those yield acquired from 
TB and SB increased slightly to the range of 392 to 398 mg L-1. Fig. 5-1D illustrates the 
cellular yield (mg g-1), which was evaluated by the ratio between volumetric yields and 
biomass as DCW. Overall, the average cellular yield obtained after 6 h expression  
(191 mg g-1) was higher those after 9 h expression (156 mg g-1). It is found that the cellular 
yields obtained from four (4) different media were approximately equal regardless the  
post-induction time. The cellular yields of 6 h induction varies from 181 to 203 mg g-1, and 




Fig. 5-1: Growth curves of E. coli and soluble yields of EBNA1-HBc in four media and 
two post-induction time. (A) The growth curves in LB (▲), SB (●), 2YT (♦) and TB (■); 
(B) the quantification of EBNA1-HBc in clarified crude lysate by NAGE. Lane 1 to 4, 
ferritin as internal marker. Lane 5 to 8, amount of EBNA1-HBc after 6 h expression; Lane 
9 to 12, amount of EBNA1-HBc after 9 h expression. Sequential order from left to right: 
LB, TB, SB and 2YT; (C) The volumetric yields and (D) the cellular yields of EBNA-HBc 
expressed in LB, TB, SB and 2YT from left to right. 
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From these data revealed in Fig. 5-1, TB and SB were more effective than 2YT and 
LB, suggesting that the nutrient richness of medium and induction period have apparent 
effects on the volumetric yield of soluble and correct folded of EBNA1-HBc VLP in  
E. coli. Between TB and SB, in our study, only TB media composition has glycerol, which 
is an important carbon source to the survival of E. coli (Kram and Finkel, 2015), for this 
reason, further experiments in fermenter were conducted in TB media with 6 h  
post-induction time. 
 
5.3.2 Purification using ammonium sulphate precipitation 
 
The molecular weight of fully assembled VLP is significantly larger than other host cell 
protein, providing a pathway to high recovery rate by primary purification method, 
ammonium sulphate precipitation (Freivalds et al., 2011). Protein sample harvested from 
fermenter-scale cultivation was incubated with 1M ammonium sulphate at 25 oC for  
30 min. It is feasible to collect 90 % of EBNA1-HBc VLP in protein precipitate with the 
purity of 80 %. After solubilised the precipitate in 4 M urea and dialyzed against Tris-HCl 
buffer, the overall recovery was 78 % with purity of 95 %. These measurements were 
acquired from densitometry of SDS-PAGE image, as is presented in Fig. 5-2A.  
EBNA1-HBc was located at at 23 kDa. 
Moreover, TEM is used to confirm the correct HBc VLP structure after dialysis, as is 
presented in Fig. 5-2B. EBNA1-HBc folded into two classes based on their triangular 
number, T=3 (diameter of 32 nm) and T=4 (diameter of 35 nm), consists of 180 monomers 
and 240 monomers, respectively. The evidence shows that E. coli-derived EBNA1-HBc 






Fig. 5-2: The purification of EBNA1-HBc using ammonium sulphate precipitation. (A) 
Purity of EBNA1-HBc determined by SDS-PAGE. Lanes 1, 2 and 3 are the total cell 
protein, clarified crude lysate and inclusion bodies, respectively. Lanes 4 and 5 are 
ammonium sulphate supernatant and ammonium sulphate precipitate, Lanes 6 and 7 are 
sample after solubilisation in urea and after dialysis; (B) TEM image of correct HBc VLP 
structure after dialysis. 
 
5.3.3 Influence of cell density at induction in batch cultivation 
 
Samples taken from specific culture were lysed and purified using ammonium sulphate 
precipitation. The yield of EBNA1-HBc reported here has high purity level (> 95 %) as 
stated in section 5.3.2. It is established that the dry cell weight is equal to 0.4 g L-1 OD-1. 
Fig. 5-3 illustrates the expression of EBNA1-HBc when induced at three (3) different 
cell density, including OD600 of 5, 10 and 20. Overall, the results emphasized the cell 
density at induction has direct influence on the volumetric yield of EBNA1-HBc in E. coli. 
It is found that induction at early exponential phase (OD600 of 5) achieved highest 
volumetric yield and cellular yield, 1300 mg L-1 and 136 mg g-1, respectively. The higher 
cell density at induction was, the lower the yields was. The lowest yield obtained were from 
the cultivation induced at OD600 of 20, as 418 mg L
-1 and 26 mg g-1.  
The temperature of the culture was adjusted from 37 oC to 32 oC at the time of 
induction. From Fig. 5-3A, 5-3B and 5-3C, after induced by IPTG, cells were continued to 
grow at lower growth rate for first 2 h, then were suppressed from hour 2 to hour 5. It is 
suggested that IPTG lost its suppression property from hour 5 to hour 6 observed by the 
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increment of biomass, as is presented in Fig. 5-3A and Fig. 5-3C. Besides that, the soluble 
protein reached their maximum volumetric yield after 4 h of post-induction.  
To estimate the ratio between soluble and total EBNA1-HBc expressed, cell samples 
harvested at the end of the cultivation were lysed. The crude lysate was further centrifuged 
to separate 1) soluble intracellular protein and 2) inclusion bodies. Both fractions were 
analysed using 12 % reducing SDS-PAGE. From Fig. 5-3D, lane 1, 3 and 5 showed a high-
intensity band at 23 kDa. By scanning the densitometry of these bands against those in lane 
2, 4, and 6, it is estimated that the ratio of soluble/total EBNA1-HBc expressed in fermenter 





Fig. 5-3: Expression of EBNA1-HBc in E. coli induced at three different cell density. 
Optical cell density (OD600) (●), biomass (g L
-1) (▲), and volumetric yield (mg L-1) (■). 
(A) Culture induced at OD600 of 5; (B) Culture induced at OD600 of 10; (C) Culture induced 
at OD600 of 20. (D) Expression forms (product folding state) confirmed by SDS-PAGE. 
Lanes 1-2, Lane 3-4, and Lane 5-6, soluble and insoluble fraction of final sample from 
culture that was induced at OD600 of 5, 10, and 20, respectively. Lanes 7-8, Lanes 9-10, 
soluble and insoluble fraction of final sample from culture that was induced at OD600 of 20 
with constant feeding and DO-stat feeding, respectively.  
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5.3.4 Influence of feeding strategy in fed-batch cultivation 
 
Batch cultivation has limitation as the amount of nutrient is fixed during the operation. 
It is feasible that cells have utilized all the essential nutrient to generate biomass, leading 
to poor productivity. To overcome this drawback, fed-batch cultivation was employed to 
supply more nutrient for EBNA1-HBc production.  
Fig. 5-4 presents the cultivation and expression of EBNA1-HBc in fed-batch mode. 
For accurate comparison between two strategies, DO-stat based feeding was conducted first 
to measure the amount of supplementary media, which was approximately 250 mL. 
Therefore, 250 mL of supplementary media was supplied at constant feeding rate of 0.7 
mL min-1 for six (6) h of induction time. 
As are illustrated in Fig. 5-4B and Fig. 5-4D, the feeding profiles were similar to each 
other. Since the DO level of constant feeding strategy was controlled in cascade mode by 
adjusting agitation and aeration rate, the DO level of culture was consistent at 30 %, 
however, the DO level of culture using DO-stat feeding strategy was more fluctuated 
because it was controlled by the addition of feed solution. Overall, Fig. 5-4A and  
Fig. 5-4C demonstrates the continuous production of EBNA-HBc over 6 h. Both volumetric 
and cellular yields of these two fed-batch fermentations were higher than those yield in 
batch mode. It is remarkable that constant feeding strategy was able to boost the volumetric 
yield from approximately 400 mg L-1 to 1800 mg L-1, an increase of 4.3-fold, meanwhile, 
DO-stat based feeding strategy only increased the productivity by 1.7-fold, as compared in 
Table 5-2.  
Besides that, the final cell density achieved from constant feeding was higher than 
those achieved from DO-stat feeding by 2 g L-1. Another noteworthy point is the results 
from SDS-PAGE, as is presented in Lane 7 to 10 of Fig. 5-3D. Most of the target protein 
(> 95 %) was expressed as soluble form in both cases of feeding strategy shown in lane 7 





Fig. 5-4: Cultivation and expression of EBNA1-HBc in E. coli induced at OD600 of 20 with 
DO-stat feeding and constant feeding. (A) and (C) Biomass and productivity from constant 
feeding and DO-stat feeding, respectively; Optical cell density (OD600) (●), biomass 
(g L-1) (▲), volumetric yield (mg L-1) (■); (B) and (D) Dissolved oxygen level and amount 
of feed using the constant feeding and DO-stat feeding strategy, respectively; Dissolved 
oxygen level (%) (-) and total amount of feed (mL) (o). 
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Type of cultivation Batch Batch Batch Fed-batch Fed-batch 




Time of culture (h) 8.5 9 10 9.5 10.5 
Final cell density (OD600) 23.7 29.8 40.4 39.8 45.2 
Final biomass conc. (DCW g L-1) 9.5 11.9 16.2 15.9 18.1 
Soluble/Total EBNA1-HBc (%) >90 >90 >90 >95 >95 
Before-induction 
specific growth rate (h-1) 
     
 
Pre-induction phase 1.3 1.3 1.1 1.3 1.1 
 
At the time of induction 1.3 1.1 0.7 1.1 0.7 
Post-induction 
specific growth rate (h-1) 
     
 
Post-induction (hour 0 to hour 2) 0.58 0.5 0.17 0.27 0.27 
 
Post-induction (hour 2 to hour 6) 0.1 0.04 0.07 0.07 0.04 
 
Overall (6 h) 0.25 0.16 0.1 0.1 0.12 
Volumetric yield (mg L-1) 1290 666 418 700 1800 
Cellular yield YP/X (mg g-1) 136 56 26 44 99 
Volumetric production rate 
(mg L-1 h-1) 
151.8 74 41.8 73.7 171.4 
Cellular production rate 
(mg g-1 h-1) 
16 6.2 2.6 4.6 9.4 
Soluble protein expression level (%) 31.3 21.3 8.9 15 32.1 
Volumetric yield increase (fold) 3.1 1.6 1.0 1.7 4.3 
Cellular yield increase (fold) 5.2 2.2 1.0 1.7 3.8 
EBNA1-HBc protein mass (g) in 
volume of culture (L) 
6.8 g in 
5.2 L 
3.4 g in 
5.2 L 
2.1 g in 
5.2 L 
3.8 g in 
5.45 L 





5.3.5 Media cost per protein analysis 
 
To evaluate the process economics, the direct production cost was broken down to the cost 
of raw materials (antibiotic, inducer and media composition), and utilities (Cardoso et al., 
2020). Here, the production cost was focused on the cost of media per protein.  
As is presented in Table 5-3, media cost per protein (AU$ per gram of protein) was 
evaluated for five (5) cultivation based on the amount of media ingredient, inducer and 
antibiotic used. In batch cultivation, media cost per protein was $10.8, $22.1, and $35.9 in 
cultivations that induced at OD600 of 5, 10 and 20, respectively. The estimation show that 
induction at early exponential phase (OD600 of 5) was most cost-effective in terms of media 
cost. It reduced the media cost per protein by 70 %, compared with those in the cultivation 
that induced at (OD600 of 20). In fed-batch cultivation, the media expense per protein was 
$25.0 and $9.7 for DO-stat feeding strategy and constant feeding strategy, showing that 
constant feeding strategy has significant benefits in media cost per protein. Details of media 
ingredient cost per unit (AUD$ per g) can be found in Appendix C – Table C-1. 
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Table 5-3: Media cost per protein analysis. 
 
  Cultivation 1 Cultivation 2 Cultivation 3 Cultivation 4 Cultivation 5 
























Volume L 5.2  5.2  5.2  5.2 0.25  5.2 0.25  
              
Glycerol g L-1 5 0.9 5.0 0.9 5.0 0.9 5.0 400.0 4.2 5.0 400.0 4.2 
Yeast extract g L
-1 24 20.5 24.0 20.5 24.0 20.5 24.0 240.0 30.3 24.0 240.0 30.3 
Tryptone g L
-1 12 14.9 12.0 14.9 12.0 14.9 12.0 120.0 22.0 12.0 120.0 22.0 
K2HPO4 
g L-1 
12.5 7.9 12.5 7.9 12.5 7.9 12.5 0.0 7.9 12.5 0.0 7.9 
KH2PO4 g L








0.12 24.6 0.12 24.6 0.12 24.6 0.12 0.0 24.6 0.12 0.0 24.6 
H3PO4 
(21 % w/v) mL 27 0.3 40.0 0.4 45.0 0.4 74.0 0.7 36.2 0.3 
NH4OH 
(12.5% w/v) mL 10 0.2 115.0 1.8 123.0 1.9 72.0 1.1 78.3 1.2 
Total cost AUD$  73.4  75.1  75.3   95.2   95.0 
              
Induction 
point  
OD600 of 5 OD600 of 10 OD600 of 20 OD600 of 20 OD600 of 20 
Type of 
cultivation  
Batch Batch Batch 
Fed-batch  
with DO-stat feeding 
Fed-batch  
with constant feeding 
EBNA1-HBc 
protein mass  









Hepatitis B core is one of the most attractive platforms to display foreign epitope of interest 
(Roose et al., 2013). It has been a challenge to produce high yield of soluble HBc VLP as HBc 
VLP tends to be expressed as inclusion bodies (Suffian et al., 2017). Results from Chapter 4 
revealed that it is feasible to improve both solubility and yield of E. coli-derived EBNA1-HBc 
by optimisation of the process factors. As the cell density in fermenter cultivation is 
significantly greater than cell density in shake flask cultivation, the influence of cell density at 
induction point should be determined. In addition to process factors, media optimisation plays 
a vital role in recombinant production as well. 
Screening of the growth media is an effective method to boost the cell density and 
production of recombinant protein (Islam et al., 2007). Four (4) complex media, including LB, 
TB, SB and 2YT, were used to evaluate the expression of EBNA1-HBc in 6 h and 9 h of post-
induction time. From Fig. 5-1, the volumetric yield achieved from LB was lower than other 
yields achieved from other media, this could be explained by the nutrient availability and 
biomass. Since the cellular yields achieved from these media were approximately equal, the 
increase in volumetric yield came from the higher biomass. TB was able to increase the 
volumetric yield 1.45-fold, in comparison to yield in LB media. Among four media, only TB 
has carbon source. Liu et al. (2005) reported that the growth rate of E. coli on glycerol during 
exponential phase without any recombinant gene is 0.54 h-1, less than growth rate on glucose, 
which is 0.97 h-1. It is reported that E. coli does not produce significant amount of acetate when 
culturing on glycerol (Lee, 1996) and slow utilization of glycerol in E. coli is found to reduce 
the accumulations of acetate (Martinez-Gomez et al., 2012). These studies support the 
argument that glycerol is beneficial for EBNA1-HBc production. 
In Chapter 4, heat precipitation and NAGE has been used to evaluate the soluble 
expression level of different expression condition. The purpose of using heat precipitation is to 
provide a clean feed for HPSEC to determine the expression level. However, as stated in 
Chapter 4 – Discussion, the interference of nucleic acid makes the measurement less accurate. 
Because of the significant difference in quantity, it will be impractical to use heat to remove 
host cell protein in terms of cost and efficiency. Another key factor is the limit of detection in 
NAGE, sample needs to be diluted so the protein concentration of sample is in range of 
detection, increasing the deviation in measurement. Therefore, an alternative primary recovery 
step in purification process is necessary to prepare high quality sample for further 
determination of soluble protein expression level in fermenter scale cultivation. Ammonium 
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sulphate precipitation and urea resuspension is proved to maintain the structure of the 
assembled VLP with the high protein recovery yield and purity (Zhang et al., 2020). It is 
established based on the complete disassembly of HBc VLP particle into assembly unit while 
maintaining the primary conformation of the assembly subunit (Zhang et al., 2020). The 
application of ammonium sulphate precipitation and urea resuspension for EBNA1-HBc VLP 
achieved the protein recovery yield of 78 % with purity of 95 %. This method provides an 
accurate means to determine the soluble expression of EBNA1-HBc. 
It is established that biphasic cultivation strategy can be used to optimise the protein 
expression (Kaisermayer et al., 2016), culture was cultured at 37 oC to gain optimal biomass 
before culturing at 32 oC for protein expression. After conducted three (3) batch cultivation 
with different induction points, it is found that most of the target protein was expressed as 
soluble form, as is presented in Fig. 5-3D. Cell density at induction point has been proved to 
have significant impact on the soluble expression of EBNA1-HBc (Fig. 5-3A, 5-3B and 5-3C). 
These findings were consistent to the results that achieved in shake-flask fermentation. The 
higher cell density at induction point is, the lower yield is. The reason behind this could come 
from the nutrient availability and accumulation of by-product, such as acetate (Lee, 1996; Choi 
et al., 2006). Because recombinant protein synthesis demands a large amount of resource in 
both energy and nutrient, when culture enters the later stage of exponential phase, amino acid 
starvation is often occurred during the expression, making it hard for cells to utilise the 
remaining nutrient for protein production (Tripathi et al., 2009).  
As is presented in Table 5-2, the volumetric yield of culture induced at OD600 of 5 is 
1.6-fold and 3.1-fold, compared to culture that induced at OD600 of 10 and 20, respectively. 
Moreover, shake-flask cultivation when culture is induced at 33 oC, OD600 of 1.2 with 0.5 mM 
of IPTG achieves the optimal volumetric and cellular yield. For comparison between  
shake-flask cultivation and batch cultivation in fermenter, the volumetric yield increased from 
272 to 1300 mg L-1 (4.8-fold) and cellular yield decreased from 210 to 136 mg g-1. It has been 
observed that HCDC often achieves less cellular yield than protein expression in shake-flask 
(Jeong and Lee, 1999). Even though these reported yields here are bulk production, it is 
significantly higher than other study in terms of E. coli derived-HBc expression. Despite of the 
different in nature of epitope and insertion site of HBc, in the study of Zhang et al. (2020), the 
yield of purified HBc183-MAGE is recorded at 43 mg L-1. Moreover, in the study of Yap et al. 
(2009), HBc is attached to His-tag and octapeptide of β-galactosidase at N-terminus, to form 
His-HBcAg and His-β-HBcAG, which had volumetric yield of 20 mg L-1 and 70 mg L-1, 
respectively. 
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It is suggested that the nutrient was not enough for protein production when culture reached 
to OD600 of 20. To overcome this limitation, fed-batch mode is used to supply the essential 
nutrient. However, feeding strategy and the choice of carbon source are important to boost the 
production rate since overfeeding can lead to the accumulation of acetate or high flux of carbon 
through glycolysis (Holms, 1986). As glycerol has been proved to be more effective than 
glucose-based cultivation (Pflug et al., 2007), supplementary media consists of glycerol, yeast 
extract and tryptone is introduced to the cultures induced at OD600 of 20 based on constant 
feeding and DO-stat feeding. The advantages of DO-stat feeding strategy include the ability to 
scale up, particularly for aerobic cultivation, since the configuration of process parameters did 
not change much to maintain dissolved oxygen level, compare to other feeding approaches 
where process parameters were controlled in cascade mode (Farrell et al., 2015). DO-stat 
feeding has shown its effectiveness in production of soluble β-galactosidase by de Andrade et 
al. (2019).  
It is observed that the growth curves, feeding amount and feeding profile were similar for 
the two feeding strategies, which questions why the yield obtained from constant feeding at  
0.7 mL min-1 was 2.6-fold higher than the yield obtained from DO-stat feeding strategy. This 
negative effect can be explained by the carbon limitation between feeding pulses as the pump 
control is set as “on” and “off”. Kaleta et al. (2013) reports that carbon source is required to 
produce protein and direct the ATP generation. Carbon limitation leads to the change in the 
metabolism pathway of E. coli, eventually decreasing the productivity. This result suggests that 
DO-stat feeding strategy is not an effective method for EBNA1-HBc production if the pump 
system is set as on/off mechanism. This strategy can be used to boost the biomass to high cell 
density culture but not for protein production. Even though DO-stat feeding is not suitable for 
EBNA1-HBc production, the feeding profiles and amount of feed are useful to develop an 
alternative feeding approach, constant feeding. By this approach, the carbon source is supply 
continuously at a rate that prevents overflow metabolism. 
It is remarkable that production rate achieved in gram-per-litter scale. However, in 
comparison between batch induced at OD600 of 5 and fed-batch induced at OD600 of 20 with 
constant feeding, the volumetric yield only increased from 1300 to 1800 mg L-1. It raises the 
question in production cost. As is shown in Table 5-3, EBNA1-HBc cost per media (AU$ per 
gram of protein) was evaluated for batch induced at OD600 of 5 and the fed-batch induced at 
OD600 of 20 with constant feeding, which is $10.8 and $9.7, respectively. By using fed-batch 
mode, EBNA1-HBc cost per media was less than 10 %. 
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While the constant feeding has been shown to be effective to produce EBNA1-HBc in 
E. coli. The induction at higher cell density (OD600 of 40 to 100) should be determined in future 
development to have a complete induction profile for expression of HBc VLP in E. coli. 
 
5.5 Chapter summary and conclusions 
 
The following important factors emerge from this chapter: 
 
1. TB and SB media were more advanced, compare with other complex media such as LB 
and 2YT media. TB media is the most advantageous media for soluble production of 
EBNA1-HBc in 6 h.  
 
2. EBNA1-HBc VLP was expressed as soluble intracellular protein in both batch and  
fed-batch operation. The solubility of the expression is > 90 %. The effect of cell density 
at induction is consistent between shake-flask and fermenter-scale cultivation. The 
productivity of the operation decreases as the cell culture is induced at higher cell density.  
 
3. At OD600 of 20, the cultivation is hypothesised to be in carbon limitation. In comparison 
with batch cultivations induced at OD600 of 20, fed-batch cultivation with DO-stat feeding 
improves the volumetric yield 1.7-fold and fed-batch cultivation with constant feeding 
boosts the volumetric yield to 4.3-fold. The greatest yield achieved was 1800 mg L-1. 
 
4. In terms of media cost per protein (AUD$ per gram of protein), fed-batch cultivation with 
constant feeding saves 10 %, compared with batch cultivation induced at OD600 of 5. 
 
In the next chapter Chapter 6, the conclusions arising from this research and the future 
developments that can be made to boost the soluble production of E. coli-derived HBc VLP 















The main aim of this research is to apply statistical approach to determine the effects of 
process factors, eventually boosting the soluble production of chimeric HBc-VLP in microbial 
system. It includes the screening and optimisation of two (2) protein models in small-scale 
fermentation: 1) HBc-VLP carrying epitope HCV, and 2) HBc-VLP carrying epitope EBNA1. 
Cultivation in fermenter-scale was also optimised based on the findings from small-scale 
(shake-flask cultivation). 
The key findings of this thesis are: 
 
1. A statistical approach offers a platform to identify the most important factors and 
interactions. Results permit optimisation. This approach is more advanced than one-
variable-at-a time (OFAT) methods. The results achieved from statistical approach can be 
applied into fermenter-scale cultivation and to recombinant protein bioprocessing. 
 
2. Soluble production of HCV- HBc was improved using fractional factorial design (FFD). 
The results from FFD ranked the most important process factors in order: 1) cell density 
at induction, 2) post-induction rotation speed of shaker, and; 3) post-induction 
temperature. The greatest soluble volumetric and cellular yields achieved from FFD were 
84.4 mg L-1 of culture media and 89.7 mg g-1 DCW. It was about 65 to 70, % of total  
HCV-HBc expressed. This outcome was obtained from expression conditions of 0.8  
mM of IPTG, 30 oC, 250 rpm and induction point at OD600 of 0.8. The pH and presence of 
Mg2+ ion did not show statistically significant impacts on soluble production of HCV-HBc. 
 
3. Fractional factorial design was performed to identify significant process factors. 
Response surface methodology (RSM) with central composite design (CCD) was 
conducted to optimise the soluble production of EBNA1-HBc. The important process 
factors were identified, they are 1) cell density at induction, 2) post-induction rotation 
speed of shaker, and; 3) post-induction temperature. From the “point optimisation” 
feature of RSM, the optimal combination of post-induction process factors are 33 oC,  
235 rpm, and induction point of OD600 of 1.2 with 0.5 mM of IPTG. The yields were 
measured at 272.0 mg L-1 of culture media and 210.5 mg g-1 DCW. 
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4. Terrific Broth was found to be the most advantageous media for soluble production of 
EBNA1-HBc in E. coli. Induction time of 6 h had greater soluble yield than induction 
time of 9 h. 
 
5. Because of the differences in cell density, to confirm the effects of process factors and 
their optimal combination, fermenter-scale cultivations were conducted. Findings 
demonstrate that the influence of cell density at induction on soluble production of 
EBNA1-HBc in batch operation is consistent between shake-flask and fermenter-scale. 
The soluble yields decreased as the culture was induced at greater cell density. Induction 
at OD600 of 5 achieved greatest soluble yield, 1290 mg L
-1 of culture media. 
 
6. Two (2) fed-batch operations were conducted following DO-stat-based feeding and 
constant feeding in which it was observed that DO-stat feeding improved volumetric 
soluble production of culture induced at OD600 of 20 1.7 x times, whilst constant feeding 
boosted the volumetric productivity 4.3 x times. It achieved gram-per-litre production 
scale, particularly 1800 mg L-1 of culture media However, the reason why DO-stat is not 
effective as constant feeding is not presently understood. It is hypothesised that carbon 
limitation between feeding pulses affects the metabolism pathway of how cells utilize 
their energy and convert it into biomass or metabolic product. Further investigation is 
required to confirm this hypothesis; however, this is beyond the scope of the present 
research. 
 
7. Significantly most of the EBNA1-HBc in fermenter-scale cultivation is expressed as 
soluble intracellular protein. The solubility of expression is significantly high, greater 
than 90 %. 
 
8. Fed-batch cultivation with constant feeding saved 10 % in media cost compared with 
batch cultivation that induced at OD600 of 5. 
 
9.  It was found that clarified crude lysate containing EBNA1-HBc can be treated with heat 
at 70 oC to remove host cell protein (impurities). Heat precipitation and size exclusion 
chromatography offer an alternative approach to quantitatively measure the fully 
assembled HBc-VLP in clarified crude lysate. 
 
10.  Although full-length HBc-VLP is a versatile vaccine scaffold, the choice of epitope 
should be carefully considered to achieve productive soluble expression. Considering the 
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insertion at N-terminal of the HBc protein, it is shown that EBNA1-HBc had greater yield 
than HCV-HBc in terms of soluble expression. In comparison with HBc carrier (without 
epitope), HCV-HBc VLP has less soluble yield than HBc VLP in the same expression 
condition. It is hypothesised that the structure of epitope has influence on the formation 
of HBc VLP in E. coli because HCV epitope has a long amino acid sequence (44 aa) and 
α-helix structure and EBNA1 epitope has 11 aa and random coils. However, there is 
insufficient data to conclude this hypothesis, the investigation should be expanded to the 
insertion at MIR region and C-terminal. 
 
It is concluded that the statistical approach offers an advanced platform to optimise process 
factors in microbial expression system in small scale fermentation. FFD coupled with RSM is 
generalizable to a range of recombinant protein bioprocesses, not just only HBc-VLP. It could 
provide a new process design tool to boost the production of vaccine candidate at both synthesis 
and analysis stages. 
Findings from this research work promote the use of microbial system to synthesise HBc 
vaccine candidate. These are going to aid a detailed understanding of fermentation process 
factors that contribute to the soluble production of HBc-VLP.  
This research work is original. Results obtained from this research work will be beneficial 
to recombinant protein bioprocessing industry. 
 
6.1.1 Limitation of this work 
 
There are present limitations of this research that need to be determined in future work, namely 
1) quantitative variation of complex media between batches, 2) an explanation of cell metabolic 
activity to answer why particular setting is the optimal combination of factors, and; 3) the 




6.2 Recommendations for future research 
 
Importantly, the success of this research shows that this novel statistical approach can be 
applied to boost the soluble production of recombinant protein. It is recommended that 
statistical approach should be used to enhance the quality of design by the International 
Conference on Harmonization (ICH) (2009) for pharmaceutical development. 
Because the soluble production of EBNA1-HBc has been significantly improved, it is 
essential to investigate the expression of HBc-VLP at greater cell density (OD600 of 40 to 100) 
to complete the induction profile. Instead of using yeast extract, a combination  
glucose–glycerol mixture and glutamate could minimise the variation in yeast extract and 
improve protein production (Chiang et al., 2020). A study on how carbon limitation affects 
protein production in DO-stat feeding is needed in future development. 
Based on the experimental results, the native structure of inserted epitope influences the 
soluble expression yield of HBc VLP, particularly, epitope that has secondary structure (HCV) 
achieved less yield than simple epitope (EBNA1). Because the influence of epitope on the 
formation of HBc VLP in E. coli is not well-studied, it is recommended to use Molecular 
Dynamic simulation software to identify how the folding of epitope influence on HBc VLP 
formation. 
It is suggested that the empirical equation from RSM has potential to be coupled with 
process simulation software e.g. SuperPro Designer (Intelligen, Inc) to produce a more 
powerful design and assessment tool for the biopharmaceutical industries. 
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APPENDIX A – A definition of some important terms used in this research  
 
Virus-like particle Virus-like particle is a multi-protein complex, which 
assembles into native structure of viral capsid without viral 
genome; VLP forms a high-density of repetitive surface 
structure (spikes) (Fuenmayor et al., 2017). 
 
Hepatitis B core protein The structural of Hepatitis B virus monomeric protein, 
consists of 183 to 185 amino acids, based on the subtypes, 




The production of biological pharmaceutical product or 
specific protein i.e. vaccine, insulin. A manipulated gene is 
constructed and transferred into an expression host cell. 
Cultivation of transformed cell is conducted to obtain the 




The recombinant proteins are expressed and folded in correct 
structure in cytoplasm. After cell disruption, the target 
protein is detected in soluble cytoplasmic fraction (Sorensen 




Newly synthesised protein folding intermediates fails to 
achieve the native folding, they will be degraded or form into 
small proto-aggregates (soluble aggregates) (Schrodel, and 
de Marco, 2005) 
 
Inclusion bodies The protein of interest is expressed as insoluble aggregates 
because of mis-folding. These aggregates are often 
biologically inactive (Markossian and Kurganov, 2004). 
 
Cell lysis/  
cell disruption 
An operation in which cell pellet is suspended in lysis buffer. 
Cells is lysed using ultra sonication or high-pressure 
homogeniser. Crude lysate is obtained after operation. 
 
Crude lysate A protein solution that is obtained after cell disruption 
process. It contains cell debris, soluble host cell protein, 
soluble target protein, soluble aggregates and inclusion 
bodies. 
 
Clarification An operation that is used to separate soluble protein, 
inclusion bodies and cell debris by centrifugation. 
 
Clarified crude lysate The supernatant fraction of protein sample achieved from 
clarification. It contains soluble host cell protein, soluble 






The upstream process of recombinant protein production. It 
includes two steps: 1) generation of biomass and 2) 





Process factors that belong to cultivation i.e. temperature, 
pH, dissolved oxygen level, etc. 
 
Induction Cells carry the plasmid of interest to synthesise target protein. 
The step of adding inducer i.e. IPTG or lactose to activate the 
expression. 
 
Feeding strategy The operation that is used to supply extra nutrient to the 
culture, switching from batch mode to fed-batch mode. It 
includes pH-stat, DO-stat, constant feeding, linear, etc. 
 
Optical cell density A unit that corresponds to the cell population. Optical cell 
density is measured by spectrometer at wavelength 600 nm. 
It is used as a correlation to dry cell mass. It is found in this 
study that biomass concentration equal to 0.4 times optical 
density. 
 
One factor at a time 
(OFAT) 
A conventional research method, also known as, one variable 
at a time. A set of experiment is conducted by changing the 
levels of a factor while other factors and their level are 
unchanged (Frey et al., 2013). 
 
Statistical approach A novel method that is used to screening and optimisation of 
process variables. This approach is based on exploration of 
the relationships between variables (categorical and 
continuous) and experimental response to identify the factors 
that significantly influenced the response and predict the 





A design that is used for screening purpose. It is considered 
as a subset of factorial design, usually half or quarter of the 
full factorial design. It is suitable when the variable larger 
than five (5). It can fit the experimental data to first-order 




A design that is used for optimisation purpose. The objective 
can be single or multiple responses. It is often used for 
continuous factors and there are two main types, central 
composite design and Box–Behnken design. (Montgomery, 
2012) 
 
Point optimisation A feature from response surface model in which the optimal 
combination of process factors is obtained using desirability 
function or graphical method. 
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APPENDIX B – Buffer composition in-use for Chapters 3, 4 and 5 
 
Cell lysis buffer A buffer that is prepared for cell disruption operation. Cell pellet 
is suspended in this lysis at desired ratio. 
Composition: 
i. 20 mM of Tris base 
ii. 3 mM of EDTA 
iii. 0.1 % (v/v) Triton X-100 





A buffer that is used as mobile phase for size exclusion 
chromatography, particularly, TSK-G5000 GWXL column. 
i. For HCV-HBc: 50 mM phosphate buffer at pH 7.4 





A buffer that is mixed with protein sample at ratio 4:1. The 
prepared sample is heated on heat block before place in gel. 
Composition: 
i. 0.25 M Tris-base 
ii. 0.25 % (w/v) Bromophenol blue 
iii. 0.5 M dithiothreitol (DTT) 
iv. 50 % (v/v) Glycerol 
v. 10 % (v/v) sodium dodecyl sulfate (SDS) 





A buffer that is used as electrophoresis buffer. Buffer is diluted to 
1X when needed. 
Composition in 1000 mL of water: 
i. 30.0 g of Tris base 
ii. 144.0 g of glycine 
iii. 10.0 g of SDS 




A solution that is used to dye the gel after gel electrophoresis. Gel 
is often stained for 30 min. 
Composition: 
i. 0.1 % (w/v) Coomassie blue R350 
ii. 20 % (v/v) methanol 




A solution that is used to remove dye from the gel. After  
de-staining, protein band on the gel will appear while the other 
area of the gel is transparent. 
Composition in 1000 mL of water: 
i. 10 % (v/v) acetic acid 
ii. 10 % (v/v) ethanol 
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TAE (10X) A buffer that is used in native agarose gel electrophoresis (NAGE). 
TAE stands for Tris – Acetate – EDTA. Solution is diluted to 1X 
when needed 
Composition in 1000 mL of TAE 10X: 
i. 48.5 g of Tris base 
ii. 11.4 mL glacial acetic acid 





A buffer that is mixed with protein sample at ratio 4:1. The 
prepared sample is placed at 25 oC for 20 min before it is placed 
in gel. 
Composition: 
i. 0.25 M Tris-base 
ii. 0.5 % (w/v) Bromophenol blue 
iii. 50 % (v/v) Glycerol 




A buffer that is used to solubilise the protein precipitate from 
ammonium sulfate precipitation. 
Composition: 
i. 20 mM Glycine-NaOH 
ii. 4 M Urea 
iii. pH 9.0, adjusted by NaOH 
 
Dialysis buffer A buffer that is used for buffer exchange. 
Composition: 
i. 20 mM of Tris base 




APPENDIX C – Supporting data 
 
Fig. C-1 presents the calibration curve that was used in protein concentration assay. Bovine 
serum albumin with the concentration of 0.1, 0.25, 0.5, 0.75, mg mL-1, was used to plot the 
curve. Linear trend was fitted to generate the equation: y = 1.13x + 0.11, with R2 = 0.99; where 
y is the protein concentration (mg mL-1), and x is the absorbance from spectrometer (AU). In 
case of the measured absorbance is out of range, protein sample is diluted. 
 
 




Fig C-2 presents the calibration curve that is used to convert optical cell density to dry cell 
concentration. Sample that had optical cell density of 5 was diluted into samples that had OD600 
of 1, 1.5, 2.5, 3.5 and 4.5. These sample was heated for 24 h at 60 OC to remove water. The dry 
cell was weighted on analytical scale. Linear trend was fitted to generate the equation:  
y = 0.40x, with R2 = 0.99; where y is the dry cell concentration (g L-1), and x is the optical cell 


































Optical cell density at wavelength 600 nm (OD600)
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The price of media ingredient, IPTG inducer, and antibiotic are listed in Table C-1. Price was 
obtained from supplier websites (last accessed on Oct. 30, 2020, 10.00 h), they are: 
1.  Chem Supply Australia: https://www.chemsupply.com.au 
2. Oxoid Thermo Fisher: https://www.thermofisher.com 
3. Gibco Thermo Fisher: https://www.thermofisher.com 
4. Invitrogen Thermo Fisher: https://www.thermofisher.com. 
 
Price of each items are converted to AUD$ per g or AUD$ per mL-1 to calculate the media 
expense in Table 5-3. The expense of media (AUD$) and media cost per protein (AUD$ g-1) 
are calculated following Equation C-1 and Equation C-2. 
 
The expense of media (AUDS) = (XO × YO + X additional × Y additional) × Z  (Eq. C-1) 
where Xo is the initial medium volume (L), X additional is the additional medium volume (L), 
YO is the initial media ingredient concentration (g L
-1), Y additional (g L
-1) is the additional media 
ingredient concentration (g L-1), and Z  is the cost per unit (AUD$ g-1). 
 
The media cost of protein (AUD$ g-1) = 
The expense of media (AUD$)
Protein mass (g)
 (Eq. C-2) 
 
Table C-1: Media ingredients price. 
 
  Supplier AUD$ g-1 
Glycerol Chem Supply 0.033 
Yeast extract Oxoid Thermo Fisher 0.164 
Tryptone Oxoid Thermo Fisher 0.238 
K2HPO4 Chem Supply 0.122 
KH2PO4 Chem Supply 0.092 
Kanamycin sulfate Gibco Thermo Fisher 11.96 
IPTG Invitrogen Thermo Fisher 39.80 
  Supplier AUD$ mL-1 
H3PO4 (21 % w/v) Chem Supply 0.0093 
NH4OH (12.5 % w/v) Chem Supply 0.0154 
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